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Abstract 
Pancreatic polypeptide (PP) is a peptide hormone released post prandially 
from the endocrine F cells of the pancreas. Acute administration of PP to 
mice reduces both body weight and food intake, and an IV infusion of PP to 
healthy weight humans reduces food intake over 24 hours. However, the 
short half life of PP limits its utility as an obesity treatment. This thesis 
investigates the development of pancreatic polypeptide (PP) analogues, and 
their possible role as a novel obesity treatment. I hypothesised that specific 
amino acid substitutions in the PP molecule would increase, enzymatic 
resistance and affinity for the Y4 receptor, and would thus result in 
analogues of PP with improved biological function.  
I investigated the substitution of amino acids on the breakdown of PP 
analogues using reverse phase HPLC and MALDI-TOF MS. Receptor 
binding assays and food intake studies in fasted male C57/BL6 mice were 
used to investigate the effect of amino acid substitutions on receptor binding 
affinity and on the anorectic effects in vivo. Finally, long term chronic food 
intake studies using different models of obesity were used to investigate the 
long term effects of PP analogue XPP.  
The PP analogue XPP was shown to be more enzymatically resistant than 
PP, with improved binding to the hY4 receptor and greater acute inhibition of 
food intake when investigated in vivo. When administered chronically in two 
models of obesity, XPP was shown to reduce body weight in specific models 
at specific time points. These experiments demonstrated the potential of XPP 
as an obesity treatment. The development of PP analogues may thus 
provide a useful and novel treatment for obesity. 
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1.1Energy Homeostasis 
Homeostasis is a term used to describe the process by which organisms 
maintain a constant internal environment despite variations in external 
conditions. A stable internal environment is required to enable the optimal 
functioning of the body system. Energy homeostasis is maintained by the 
balancing of energy intake (gained from food and drink) and energy output 
(physiological processes such as muscle contraction).  
Body weight remains constant in most human adults despite small daily 
deviations from an ideal/set point (Jequier and Tappy, 1999). A period of 
fasting may result in a short term increase in food intake (hyperphagia); this 
increase in food intake should result in the recovery of lost body weight and 
ultimately enable body weight to return to baseline levels. This mechanism 
enables body weight to remain relatively constant over a period of months or 
years despite occasional mismatches in energy intake and expenditure 
(Jequier and Tappy, 1999).  When energy intake is greater than energy 
expended, the excess is stored in the form of fat.  
1.2 Obesity  
Obesity is a medical condition in which excess body fat has accumulated to 
the extent that it may have an adverse effect on health, leading to reduced 
life expectancy and/or increased health problems  (Walter et al., 2009). An 
adult with a body mass index (BMI) of greater than 30kg/m2 is classified as 
obese. This is calculated by dividing body weight measured in kilo grams (kg) 
by the square of the person‟s height in metres (m). BMI is subdivided into 
underweight (≤18.5 kg/m2), healthy (18.5-25 kg/m2), overweight (25-29.9 
kg/m2), obese (30-34.9 kg/m2), severely obese (35-40.5 kg/m2), morbidly 
obese (40-44.9 kg/m2) and super obese (≥45kg/m2) (World Health 
Organisation, 2006).  
Currently, the mean BMI for an adult in the UK is 27kg/m2, which is above 
the healthy range (Butland B, 2007). In 2006, 40% of men in the UK in the 
25-34 years age group were overweight, and a further 22% classed as obese. 
In the same age group, 29% of women were overweight and 17% obese (Ali 
A, 2008). NHS predictions suggest that the number of people who are either 
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overweight or obese is likely to continue to rise, including 60% of men and 50% 
of women by 2050 (World Health Organisation, 2006; Butland B, 2007). 
Obesity has both a social and an economic cost; the Commons Select 
Health Committee estimates that treatment of obesity alone cost £991 million 
per year up to 2001 and in 2002 it was £1,124 million; 2.3 and 2.6 percent of 
the total NHS expenditure for the respective year (Butland B, 2007).  
Long term obesity is associated with health problems and premature 
mortality (Flegal et al., 2005). The co-morbidities associated with obesity 
include hypertension, Type II diabetes mellitus (T2DM), cardiovascular 
diseases, osteoarthritis, cancer of the colon, prostate, kidney and gall 
bladder, stroke, and breathing problems such as sleep apnoea (Butland B, 
2007; Fontaine et al., 2003; Krauss et al., 1998; Kopelman, 2000).  
The cause of obesity is currently thought to be a combination of genetic and 
environmental factors. The theory of a genetic predisposition to obesity was 
first described in 1962 by JV Neel. Neel‟s thrifty gene hypothesis suggests 
that during times of plenty it is advantageous to accumulate fat, as this will 
aid survival in times of famine. Those people that survive the times of famine 
were then able to pass on these thrifty genes to the next generation (Neel, 
1962). An alternative hypothesis proposes that there has been a genetic drift 
towards obesity (Ali A, 2008; Stender et al., 2007; Speakman, 2008).  
Genetic drift is described by Speakman as a process by which a gene which 
is not under selection but uses a lower and an upper intervention limit to 
regulate a system loses either the upper or lower intervention limit, and 
therefore a system drift occurs. There is debate over the importance of 
genetics in obesity and related conditions. Twin adoption studies 
demonstrate, genetic factors powerfully influence the development and 
extent of weight gain (Bouchard et al., 1990). Specific mutations that result in 
obesity have been identified, including mutations in leptin or the leptin 
receptor, and mutations in melanocortin 4 receptors (Santoro et al., 2009). 
However, the increase in the prevalence of obesity is too rapid to be 
explained purely by genetic change. It is likely that genes influence body 
weight in relation to the environmental context.  
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Outside of these putative genetic drives, environmental factors including the 
decline of manual labour and the rise in abundance of appetising highly 
calorific foods have certainly contributed to the rise in obesity levels. 
Understanding the systems regulating energy homeostasis will aid the 
development of newer, more effective treatments for obesity and obesity 
related conditions. 
Increased energy intake has played an important role in the increase in 
obesity levels in recent years. An individual‟s body weight is usually tightly 
controlled by a number of systems including the neuroendocrine system and 
signals from adipose tissue (Berthoud, 2002; Bray, 1980; Farooqi and 
O'Rahilly, 2009). Day to day there may be small differences between calories 
ingested and energy expended. Over the space of a year or more, energy 
expenditure and calories ingested usually remain constant and in balance 
(Jequier and Tappy, 1999). It is hypothesised that in recent years the change 
in western diets has unbalanced the body‟s regulatory mechanisms  
(McCrady and Levine, 2009).  
A western diet as a whole is very energy dense, with a large proportion of 
daily calories consumed consisting of carbohydrates and fats (Cordain et al., 
2005). Hunter gather societies are thought to have a traditional, low fat, high 
carbohydrate diet, but are subject to high levels of obesity when their 
traditional diet is replaced by a more western style of food. A well 
documented example is the Pima Indians, who have higher levels of obesity 
and diabetes when exposed to a western diet and lifestyle, but low levels of 
obesity and diabetes when following a more traditional lifestyle and diet 
(Ravussin et al., 1994; Schulz et al., 2006; Weyer et al., 2001). In the 
western world, despite more information on food labelling regarding fat 
content and health implications, obesity levels have continued to rise.  In 
recent years a greater proportion of food consumed is made outside the 
home, with increased consumption of convenience and fast food. A typically 
high fat menu from a fast food restaurant  contains 1100KJ/100g (energy in 
kilojoules per 100grams consumed), which is considerably higher than 
average UK diet of 670KJ/100g (Stender et al., 2007). This increase in the 
number of meals being consumed outside the home, and their high calorie 
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and fat content is thought to contribute to rising obesity levels (Rosenheck, 
2008). 
Reduced activity or lack of exercise is also associated with weight gain and 
obesity. From the mid 1900‟s the proportion of the population undertaking a 
job requiring manual labour declined and the number of sedentary, desk 
based jobs increased (McCrady and Levine, 2009; Gregory et al., 2007). 
This shift has been suggested to promote weight gain, as energy intake is no 
longer being balanced by energy output (McCrady and Levine, 2009). A 
recent NHS health survey suggested that men spend 8.0 hours per week 
taking part in some kind of physical activity and women 5.4 hours per week 
(Ali A, 2008). These figures are lower than a decade previously where a 
greater proportion of the population undertook a job which involved physical 
activity (McCrady and Levine, 2009; Gregory et al., 2007).  
1.3 Current Strategies For The Treatment of Obesity 
Obesity has been shown to decrease life expectancy by approximately seven 
years in a number of studies (Allison et al., 1999; Fontaine et al., 2003; 
Fontaine et al., 2003; Jia and Lubetkin, 2009; Peto et al., 2010; Stewart et al., 
2009; Walter et al., 2009). As discussed previously in section 1.2, the social 
and economic cost of obesity is great. It is therefore advantageous to 
encourage weight loss in overweight and obese patients. The first strategy is 
to modify diet and lifestyle. Reducing calories ingested and increasing 
calories expended promotes weight loss. It has been shown, however, that 
there is limited compliance with very low calorie or low fat diets (Bray, 2008; 
Pirozzo et al., 2003), and there is often weight regain approximately 18 
months after completion of the diet (Pirozzo et al., 2003). If diet and lifestyle 
modifications are ineffective, the next step is usually some form of medical 
treatment to aid weight loss. Medical treatments for the treatment of obesity 
are discussed in section 1.3.1. The last resort for long term weight loss is a 
surgical route, usually either gastric banding or gastric bypass. National 
Institute for Health and Clinical Excellence (Nice) guidelines suggest that 
obesity surgery should only be carried out if all appropriate non-surgical 
measures have failed to be effective over 6 months and if the patient has a 
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BMI >40kg/m2, or >35kg/m2 in conjunction with serious co morbidities such 
as T2DM (National Institute for Health and Clinical Excellence (NICE), 2006). 
1.3.1 Medical treatment  
At present there is only one drug treatment approved to treat obesity in the 
UK: Orlistat Xenical (Roche pharmaceuticals, Switzerland) is the prescription 
only form of Orlisat (120mg three times a day). Xenical is made by Roche 
pharmaceuticals, Switzerland, and can be prescribed at a dose of 120mg 
three times a day for patients with a BMI ≥30kg/m2,  or a BMI ≥27kg/m2 in 
conjunction with other risk factors.  Orlistat is also available as the over the 
counter treatment Alli (GSK, USA), as a 60mg dose to be taken three times a 
day.  Alli is only sold to patients with a BMI of over 28kg/m2.  
Orlistat was derived from a bacterial lipase inhibitor. Inhibition of pancreatic 
lipase impairs triglyceride breakdown (Davidson et al., 1999). Orlistat 
treatment in conjunction with a calorie controlled diet results in a weight loss 
of 2.8-3.2kg greater than placebo controls over the period of a year 
(Davidson et al., 1999; Sjostrom et al., 1998; Hill et al., 1999; Leung et al., 
2003). However, a study has shown that those patients who received Orlistat 
for a year and then received placebo control while maintaining the calorie 
controlled diet for another year, regained the weight lost in the initial period 
(Sjostrom et al., 1998). While those patients maintained on orlistat for the 
second year gained less weight than those receiving placebo, they failed to 
lose any further weight (Sjostrom et al., 1998). Inhibiting fat digestion and 
absorption results in excess faecal fat loss. Other side effects include oily 
spotting, faecal urgency and increased defecation (Guerciolini, 1997; Leung 
et al., 2003). There is also an associated decrease in absorption of fat 
soluble vitamins, including vitamins E and β-carotene (Davidson et al., 1999), 
though levels rarely fall outside of the normal limits (Bray and Tartaglia, 
2000). Orlistat has limited efficacy, and therefore limited weight loss occurs 
(Padwal and Majumdar, 2007; Avenell et al., 2004; Neovius and Narbro, 
2008). As mentioned above, once treatment with Orlistat is ceased, weight is 
often regained, (Svendsen et al., 2008; Sjostrom et al., 1998).  
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The anti-obesity drug Sibutramine was until recently sold under the trade 
name Reductil (Abbott laboratories). Sibutramine is a member of the 
monoamine reuptake inhibitor class of drugs, which inhibits food intake 
predominately by inhibiting the reuptake of norepinephrine and serotonin, but 
also by inhibiting the reuptake of dopamine, into nerve terminals. In year-long 
randomized trials comparing Sibutramine with placebo, subjects in the 
Sibutramine group lost 9.3% of their initial baseline body weight (30mg dose) 
whereas those in the placebo groups lost only 1.9% (Bray et al., 1999).  In 
January of 2010, the European Medicines agency recommended its 
suspension from sale due to concerns over the increased incidence of 
cardiovascular events in patients taking Sibutramine (Williams, 2010).  
Orlistat is the only treatment currently available for the treatment of obesity. 
However, the amount of weight lost and the tendency of patients to regain 
weight after treatment is ceased means that it is not a very cost effective 
option. At present a number of treatments are being developed to treat 
obesity. Most of these proposed treatments are centrally acting drugs which 
interact with appetite regulation and hedonic central nervous system 
pathways. Examples include Lorcaserin (Arena Pharmaceuticals), a 5- HT2c 
receptor agonist, and Qnexa (Vivus), a combination of the amphetamine-like 
drug phentermine and the epilepsy drug topiramate.  A phase 3 trial of the 
drug Qnexa showed a 14kg weight reduction at 1 year (Vivus 
Pharmaceuticals, 2009).  Drugs which act via central pathways often act on 
systems that do not exclusively regulate appetite, which increases the 
potential for side effects and adverse reactions. This was demonstrated 
when rimonabant, a cannabinoid receptor antagonist used as an obesity 
treatment, was removed from the market due to problems with depression 
and anxiety (Doggrell, 2008). Currently there is discussion about the use of 
T2DM treatments such as Exenatide, which also results in weight loss, as 
possible treatments for obese patients without T2DM (Nayak et al., 2010). 
Exendatide is an analogue of the gut hormone glucagon-like peptide 1 (GLP-
1), and other gut hormones, including oxyntomodulin, peptide YY, and 
pancreatic polypeptide, have also been proposed as possible treatments for 
obesity (Field et al., 2008; Neary and Batterham, 2009; Field et al., 2009). 
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Modifying the physiological satiety system to mimic the post prandial state 
may help reduce food intake and therefore cause weight loss. 
1.3.2 Surgical treatment  
The most successful long term treatment for obesity is bariatric surgery 
(Martins et al., 2010). There are a number of different surgical options 
depending on the level of obesity, co-morbidities, patient preference and the 
weight loss required.  Laparoscopic adjustable gastric banding (LAGB) is 
often used for moderate/ less severe cases of obesity, whereas the Roux–
en-Y gastric bypass (RYGB) is used for cases in which greater weight loss is 
required. LAGB is achieved by placing an adjustable band circling the 
proximal stomach; the gastric restriction is then controlled by inflating the 
band via a subcutaneous port. The RYGB procedure is more complex and 
has a greater risk of complications. It is also difficult to reverse, whereas the 
LAGB can be readily adjusted or removed. The RYGB involves dividing the 
stomach and creating a small gastric pouch which is attached to the distal 
limb of the jejunum. This bypasses most of the stomach, the duodenum and 
some of the jejunum. Both the RYGB and the LAGB result in significant 
weight loss up to 5 years post surgery.  
A meta-analysis comparing LAGB and RYGB showed that at 1,2,3,4 and 5 
years post surgery RYGB patients achieved the greatest loss of excess 
weight at all time points (Christou and Efthimiou, 2009). RYGB results in the 
loss of up to 70% excess weight at 1 year, whereas LAGB can result in the 
loss of up to 49% excess weight (Christou and Efthimiou, 2009; Garb et al., 
2009). At the 1 year time point, drug treatments on average achieve a 2-3 kg 
(approximately 8%) weight loss compared to placebo controls (Hill et al., 
1999; Rubio et al., 2007). In studies comparing weight loss via drug 
treatment or surgical treatment, at the sixth month check up point, both 
groups had lost approximately 13% of their total excess weight. The drug 
treatment group subsequently maintained their weight loss, whereas those 
patients in the surgical group continued to lose weight.  At the two year 
check up, patients who had undergone surgery had lost 20kg, compared with 
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6kg in the drug treatment group (Palazuelos-Genis et al., 2008; Schaeffer et 
al., 2008).  
The RYGB was originally designed to reduce body weight by the 
malabsorption of nutrients. However, this appears not to be the cause of 
weight loss in RYGB patients, as following surgery the gut adapts and 
malabsorption abates  (Brolin et al., 2002). The cause of weight loss after 
bypass surgery remains unclear. Bariatric surgery increases circulating 
levels of the anorexigenic gut hormones GLP-1, insulin and peptide YY, and 
decreases levels of the orexigenic gastric hormone ghrelin (Morinigo et al., 
2004; Korner et al., 2005). Changes in taste have also been reported 
following RYGB, which may also contribute to weight loss (Tichansky et al., 
2006). Recently a rat model of RYGB has suggested that there may also be 
an increase in energy expenditure following RYGB surgery, though it is  
unknown whether RYGB alters energy expenditure in humans (Bueter et al., 
2009).   
Bariatric surgery is currently the most effective treatment for obesity. 
However, surgical intervention is not without risk. Bariatric surgery has until 
recently been performed as an open surgery, which carried with it high risks 
of infection. With laparoscopic techniques now more widespread, the 
reduced risks still include anaesthesia complications and post surgical 
complications such as malnutrition/malabsorption (Gong et al., 2008). 
Surgery related death can occur in up to 2% of bariatric surgery operations 
(Adams et al., 2007). In addition, given the size of the obesity problem, it is 
not economically possible to use bariatric surgery to treat all cases (Avenell 
et al., 2004; Bessesen, 2008). 
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1.4 The Hypothalamus 
The hypothalamus is a central nervous system (CNS) region important in the 
regulation of energy homeostasis. It is situated above the pituitary gland and 
on either side of the third ventricle. The hypothalamus is traditionally 
sectioned into three zones longitudinally: the periventricular, medial and 
lateral zones, and into four sections along the rostro-caudal axis: preoptic, 
anterior, tuberal and mammillary (Berthoud, 2002; Simerly, 1995). Over forty 
separate nuclei make up the hypothalamus, and these can be further sub-
divided into subnuclei (Figure 1.1) (Berthoud, 2002). Hypothalamic nuclei 
exhibit a wide variety of functions, including controlling pituitary hormone 
secretion, reproduction and body temperature. Nuclei with a role in energy 
homeostasis will be discussed in sections 1.4.1 to 1.4.4.  
The hypothalamus has a large number of afferent and efferent projections 
which allow it to co-ordinate a wide range of physiological activities, including 
energy homeostasis. Experiments performed in the 1950‟s were the first 
significant evidence that the hypothalamus regulates energy balance (Anand 
and Brobeck JR, 1951). Lesioning studies demonstrated that destruction of 
the ventromedial hypothalamus (VMN) causes hyperphagia in mice, rats, 
dogs, monkeys and humans (Bernardis et al., 1975; Lindholm et al., 1975; 
Anand and Brobeck JR, 1951). Conversely, destruction of the lateral 
hypothalamus (LH) reduces body weight and food intake (Bernardis and 
Bellinger, 1993; Bernardis et al., 1975; Anand and Brobeck JR, 1951). 
Electrical stimulation of the LH causes an increase in body weight and body 
fat in rats (Stellar and Heard, 1976). Early lesioning experiments resulted in 
the development of the „dual centre hypothesis‟, which proposed that the 
VMN acts as a satiety centre and the LH as a feeding centre.  The dual 
centre hypothesis has subsequently been considered over simplified. Recent 
models of feeding behaviour incorporate the two centre theory, but focus on 
neural networks spread across multiple hypothalamic nuclei, which send and 
receive signals of energy balance, often via specific neuropeptides (Elias et 
al., 1998). 
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Figure 1.1 A three-dimensional view of the major rat hypothalamic nuclei. 
(AHA), anterior hypothalamic area; (ARC), arcuate nucleus; (AV3V), 
anteroventral area of third ventricle; (CI), capsula interna; (DP), dorsal 
parvocellular subnucleus of paraventricular nucleus (PVN); (DMN), 
dorsomedial nucleus; (F), fornix; (LHA), lateral hypothalamic area; (LM), 
lateral magnocellular subnucleus of paraventricular nucleus; (LPOA), lateral 
preoptic area; (ME), median eminence; (MP), medial parvocellular (PVN); 
(MPO), medial preoptic area; (OT), optic tract; (SCh), suprachiasmatic 
nucleus; (SON), supraoptic nucleus; (SI), substantia inomminata; (ST), 
subthalamic nucleus; (VMN), ventromedial nucleus; (VP), ventral 
parvocellular subnucleus of paraventricular nucleus. Adapted from (Berthoud, 
2002). 
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1.4.1 The Arcuate Nucleus (ARC) 
The ARC is located on either side of the third ventricle at the base of the 
hypothalamus. The median eminence,  a circumventricular organ with an 
incomplete blood brain barrier (Broadwell and Brightman, 1976), is adjacent 
to the ARC and is hypothesised to facilitate circulating factors reaching 
receptors located on ARC neurons. The position of the ARC next to the third 
ventricle also enables nutrients and hormones to diffuse from the 
cerebrospinal fluid into the ARC. In addition, the ARC receives neuronal 
inputs from other hypothalamic nuclei and the brainstem  regarding feeding 
and satiety (Ricardo and Koh, 1978). The ARC is therefore in a position to 
integrate signals of nutritional status from the periphery and from other CNS 
regions to co-ordinate energy homeostasis (Figure 1.2). 
Within the ARC, two distinct populations of neurones regulate energy 
balance (Cone et al., 2001). One population co-expresses neuropeptide Y 
(NPY) and agouti related peptide (AgRP), and the other co-expresses pro-
opiomelanocortin (POMC) and cocaine and amphetamine-regulated 
transcript (CART). NPY/AgRP neurones are considered to be orexigenic, 
and project to regions including the paraventricular nucleus (PVN), the lateral 
hypothalamic area (LHA) and the dorsomedial hypothalamus (DMH), as well 
as to other neurons within the ARC (Kalra et al., 1999). POMC/CART 
neurones are anorexigenic and project to similar regions, and also to the 
perifornical area. These two groups of neurons act antagonistically: 
activation of NPY/AgRP neurons inhibits POMC/CART neurons, and 
conversely, POMC/AgRP neurons inhibit NPY/AgRP neurons (Wynne et al., 
2005b; Roseberry et al., 2004; Hentges et al., 2004; Cowley et al., 2001). 
ARC neurones also project to extra hypothalamic brain regions, including the 
forebrain, brainstem and the ventral raphe nuclei, where they are thought to 
act to mediate energy homeostasis (Broberger and Hokfelt, 2001).  
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Figure 1.2 A schematic diagram of the neuronal populations within the ARC 
of the hypothalamus. One subpopulation of neurons releases NPY and 
AgRP, whilst the other subpopulation of neurons releases CART peptide and 
alpha melanocyte stimulating hormone (α-MSH), a product of POMC 
cleavage. Neurons from the ARC project to other brain regions and 
hypothalamic nuclei to co-ordinate energy homeostasis. Adapted from 
(Wynne et al., 2005b). 
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1.4.2 The Paraventricular Nucleus 
The PVN is an essential area of the hypothalamus in the regulation energy 
homeostasis (Elmquist et al., 1997; Turton et al., 1996), and plays a key role 
in the integration of signals from the ARC, brainstem and cortex (Sawchenko 
and Swanson, 1983). A number of neuropeptides associated with the 
regulation of food intake and energy expenditure are expressed in the PVN. 
Destruction of the PVN in rodents leads to hyperphagia and weight gain 
(Aravich and Sclafani, 1983; Leibowitz et al., 1981). Unlike the ARC, the 
PVN is protected from the general circulation by the intact blood brain barrier. 
Injection of orexigenic factors, including NPY, AgRP and noradrenalin, into 
the PVN stimulates food intake (Leibowitz, 1978; Edwards et al., 1999; Kim 
et al., 2000), whilst injection of anorexigenic factors, including leptin and 
GLP-1, reduces food intake (McMahon and Wellman, 1998; Shih et al., 
2003). Neurons from the PVN project to the median eminence, where they 
release hypothalamic regulating factors including corticotrophin-releasing 
hormone (CRH), vasopressin and thyroid-releasing hormone (TRH) into the 
hypothalamic-pituitary portal system to regulate the secretion of pituitary 
hormones into the systemic circulation.  
1.4.3 The Dorsomedial Nucleus (DMN) 
The DMN is situated close to the ARC. The DMN receives projections from 
NPY neurons from the ARC and neurons from the DMN project to other 
areas of the hypothalamus involved in the regulation of food intake, including 
the PVN (Dalton et al., 1981). The destruction of the DMN results in 
hyperphagia and obesity, and injection of NPY or GABA into the DMN 
increases food intake (Kelly et al., 1979).  
1.4.4 The Ventromedial Hypothalamus (VMN) 
The VMN is part of the mid region of the hypothalamus adjacent to the ARC 
and also thought to play a role in energy homeostasis. Ablation of the VMN 
results in hyperphagia and obesity in rodents  (Bernardis and Border, 1975). 
The VMN receives projections from ARC NPY/AgRP neurons, and VMN 
neurons project to the hypothalamic DMN and the brainstem, which are 
involved in the regulation of food intake (Fu and van den Pol, 2008; Kalra et 
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al., 1999). The VMN has not been found to produce peptides with well 
characterised roles in the regulation of food intake, but it does contain 
receptors for both NPY and leptin. 
1.4.5 The Brainstem and Energy Homeostasis  
The brainstem is located in the posterior of the brain and is structurally 
continuous with the spinal cord. The brainstem comprises the medulla 
oblongata, pons, midbrain and the diencephalon. The brainstem relays 
information from the cerebellum to the periphery via the cranial/spinal nerves 
and vice versa. The brainstem regulates a number of essential functions, 
including breathing, consciousness, temperature regulation and acute 
nutritional status via the cranial nerves (Broberger and Hokfelt, 2001). 
Sensory afferent fibres within the vagus nerve activate neurons within the 
nucleus of the solitary tract (NTS), which is part of the dorsal vagal complex 
(DVC). These signals are then relayed to various parts of the brain, 
described in greater detail in section 1.4.5.1.  
1.4.5.1 Brainstem and Vagus Nerve 
The NTS is located in the caudal brainstem. The NTS receives and 
integrates inputs related to food intake from a number of peripheral systems 
via the vagus nerve including leptin and circulating gut hormones such as 
cholcystokinin-8 (CCK-8) (Yuan and Barber, 1993; Schick et al., 1990). The 
NTS lies in close proximity to the area postrema, which like the ARC has an 
incomplete blood brain barrier. Circulating hormones can therefore access 
receptors in the AP and NTS (Maolood and Meister, 2009). Lesions to the 
NTS and brainstem can alter feeding behaviour and reduce body weight 
(Hyde and Miselis, 1983; Miselis et al., 1984). The NTS may therefore be 
able to detect changes in circulating factors related to food intake. It has 
been proposed that the brainstem is involved in meal initiation and 
termination (Grill and Kaplan, 2002). 
Gut hormones including peptide YY (PYY3-36), PP, CCK, ghrelin and leptin 
can access the brain. A number of these gut hormones, including PP and 
PYY3-36, are thought to be unable to cross the blood brain barrier, but may act 
via the vagus nerve or directly on regions of the brainstem, thus bypassing 
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the blood brain barrier. The vagus nerve, also known as the tenth cranial 
nerve, extends from the brainstem alongside the internal jugular vein and 
into the chest and abdomen. Approximately 80-90% of vagus nerve fibres 
are afferent, conveying sensory information from the periphery to the brain. 
The vagus nerve plays an important role in the gut brain axis, and vagotomy 
studies suggest than an intact vagus nerve is essential for the actions of 
ghrelin, PP and PYY (Le Roux et al., 2005; Gaddipati et al., 2006; Koda et al., 
2005; Laskiewicz et al., 2003; Taylor et al., 1978). It has also been 
suggested that the brainstem can mediate the anorectic effects of gut 
hormones independent of the hypothalamus, as CCK reduces food intake in 
decerebrated rats, which lack neuronal communication between the 
brainstem and he hypothalamus (Grill and Smith, 1988; Wynne et al., 2004). 
1.4.5.2 Dorsal Vagal Complex  
Together, the area postrema (AP), the NTS and the dorsal motor nucleus 
comprise the DVC. The AP is located posterior to the fourth ventricle. It is 
thought to play a role in autonomic regulation of the CNS.  The AP has an 
incomplete blood brain barrier which has resulted in the DVC being 
characterised as a circumventricular organ (McKinley et al., 1990).  Due to its 
lack of blood brain barrier, the AP can detect both peripheral and central 
chemical mediators, as well as receiving autonomic innervation from the 
vagus nerve (Contreras et al., 1984; Wang et al., 1998; Schick et al., 1990; 
Wang et al., 2008). The AP has been shown to play a role in feeding and 
energy balance. Ablation of the AP attenuates PYY3-36 induced inhibition of 
food intake in rats, and inhibits basal secretion of PP (Deng et al., 2001). 
Receptors for a number of peripheral satiety factors have been identified in 
the AP, including the PP Y4 receptor and the GLP-1 receptor (Goke et al., 
1995; Trinh et al., 1996; Parker and Herzog, 1999).  
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1.5 Hypothalamic Neuropeptides 
1.5.1 Neuropeptide Y 
Neuropeptide Y (NPY) is a 36 amino acid peptide member of the „PP‟ fold 
family of peptides, which also contains PYY and PP. It was first isolated from 
porcine hypothalamic extracts in 1982 (Tatemoto et al., 1982). All members 
of the „PP-fold‟ family of peptides bind to Y receptors (Table 1.1). Each of 
these receptors (numbered 1 to 5) have different substrate affinities and 
brain expression patterns (Parker and Herzog, 1999). NPY has the highest 
affinity for the Y1 and Y5 receptors, and it is thought that these receptors 
mediate the orexigenic effects of NPY (Kanatani et al., 2000).  
NPY is the most potent known orexigen. Injection of NPY into the third 
ventricle powerfully increases food intake in rodents (Stanley et al., 1986), 
and injection of NPY into specific hypothalamic nuclei, including the PVN, 
also stimulates food intake (Stanley and Leibowitz, 1985). Repeated daily 
injections of NPY into the PVN results in hyperphagia and weight gain in 
rodents (Stanley et al, 1986). Despite these orexigenic effects, mice deficient 
in NPY have a normal body weight and adiposity (Thorsell and Heilig, 2002). 
However, down-regulation of NPY mRNA in the ARC of adult rats 
significantly reduces food intake and body weight, suggesting that the lack of 
phenotype for the NPY knockout mouse may be due to developmental 
compensation (Marsh et al., 1999; Gardiner et al., 2005). Ablation of 
NPY/AgRP neurons in adult mice has also been shown to cause anorexia 
(Luquet et al., 2005; Gropp et al., 2005; Bewick et al., 2005).  
   
The ARC contains the best characterised population of NPY-expressing 
neurons. These ARC NPY neurons also express AgRP (Hahn et al., 1998). 
The level of NPY expression in the ARC neurons is dependent on energy 
status: fasting increases NPY expression (Brady et al., 1990). ARC NPY 
neurons extend to other areas of the brain associated with energy status, 
including the PVN and DMN.  
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1.5.2 Melanocortin System 
The melanocortin system is comprised of the peptide products of POMC 
cleavage, and the endogenous melanocortin receptor antagonists, agouti 
and AgRP. POMC is a 241 amino acid precursor polypeptide which is 
cleaved by the prohormone convertase group of enzymes into molecules 
including adrenocorticotrophin (ACTH) and alpha-MSH. The POMC gene is 
expressed in the anterior pituitary, the skin, the immune system and the 
hypothalamus (Castro and Morrison, 1997). In the anterior pituitary, POMC is 
cleaved into ACTH. In the hypothalamus and the intermediate lobe of the 
pituitary, ACTH is further processed to generate alpha-MSH. ARC POMC 
expression is linked to energy status, with expression levels being reduced 
during periods of fasting (Swart et al., 2002). In humans, POMC mutations 
can cause early onset obesity, red hair and adrenal insufficiency, whereas in 
mice, a loss of a copy of the POMC gene makes mice more susceptible to 
diet induced obesity, as well as causing adrenal insufficiency and a 
distinctive agouti fur colour (Challis et al., 2004; Krude et al., 1998).  
There are five melanocortin receptors, named MC1R-MC5R.  It is thought 
that only the MC3R and the MC4R play a role in energy homeostasis. The 
main endogenous ligand of the MC3/MC4R is alpha-MSH. Alpha MSH is 
produced by cells within the ARC of the hypothalamus, and intra 
cerebroventricular (ICV) administration of alpha MSH inhibits food intake 
(Watson and Akil, 1979; Murphy et al., 1998). Both MC3R and MC4R are 
expressed in hypothalamic nuclei including the ARC and the PVN (Mountjoy 
et al., 1994). Mice lacking the MC4R are obese and hyperphagic (Mencarelli 
et al., 2008). MC3R null mice are not significantly overweight but do have 
increased fat mass compared to native litter mates (Butler et al., 2000). 
Injection of alpha MSH into the third ventricle inhibits food intake and 
chronically reduces body weight (Semjonous et al., 2009; Benoit et al., 2000). 
Conversely, AgRP and agouti peptide antagonise the MC3R and MC4R 
receptors. Agouti peptide is a competitive antagonist of alpha MSH at the 
MC1R and MC4R, but under normal circumstances is only found in the 
periphery (Lu et al., 1994). AgRP is expressed in the ARC of the 
hypothalamus, and is the endogenous antagonist for central MC3R and 
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MC4R. ARC AgRP expression increases during fasting (Swart et al., 2002). 
Administration of AgRP into the third ventricles of rats dose dependently 
increases in food intake (Rossi et al., 1998).  
1.5.3 Cocaine- and Amphetamine-Regulated Transcript 
CART is the third most abundant mRNA transcript within the hypothalamus 
(Kristensen et al., 1998; Elias et al., 2001). CART mRNA is expressed in the 
ARC, the PVN and the LHA (Elias et al., 1998; Hurd and Fagergren, 2000). 
Within the ARC, CART is co-expressed with POMC (Dhillo et al., 2002; Elias 
et al., 2001). CART is a putative neuropeptide; it is found in dense core 
vesicles of neuron dendrites, and its release is calcium dependent (Murphy 
et al., 2000; Smith et al., 1997). As yet, no receptor for CART has been 
identified, though data suggest it is linked to an inhibitory G-protein coupled 
receptor, activation of which leads to an intracellular increase in extracellular 
signal-regulated kinase (ERK) (Lakatos et al., 2005). Fasted and food 
restricted animals have reduced CART mRNA expression in the ARC 
(Sucajtys-Szulc et al., 2010; Kristensen et al., 1998). The CART peptide is 
processed into different fragments, with fragment 55-102 thought to be the 
active form, and hence being the most widely studied (Dey et al., 2003). 
Injection of CART (55-102) into the third cerebral ventricle inhibits food intake. 
ICV administration of a CART antiserum increases night time food intake 
(Kristensen et al., 1998). However, the injection of CART (55-102) into either 
the ARC or the VMN increases food intake (Abbott et al., 2001). The differing 
effects on food intake observed following administration of CART (55-102) 
into different regions suggests that different populations of CART neurons 
may play different roles in energy balance (Abbott et al., 2001). 
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Figure 1.3 Schematic diagram showing the sites of action of hormones that 
influence food intake. Red arrows and text denotes the pathways by which 
the anorexigenic gut hormones PYY3-36, OXM, CCK and PP act,  black those 
for the orexigenic gastric hormone ghrelin, and purple those for the adiposity 
signals leptin and insulin. Adapted from (Wynne et al., 2004). 
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1.6 Peripheral Signals Of Adiposity 
1.6.1 Leptin 
Leptin is a product of the ob gene which is predominately expressed in white 
adipose tissue (Figure 1.3) (Zhang et al., 1994). It is 146 amino acid 
hormone released into circulation in proportion to adipose tissue levels 
(Maffei et al., 1995). Leptin has a number of functions, including the 
regulation of energy homeostasis, immune function and fertility (Chehab et 
al., 1996). Leptin signals via the leptin receptor (ob-Rb), which is expressed 
in the ARC, VMH, DMH and LHA of the hypothalamus, and in other areas of 
the CNS such as the brainstem (Hayes et al., 2010). Leptin acts to maintain 
long term energy homeostasis and a set level of body adiposity (Elmquist et 
al., 1998). In the ARC, leptin receptors are located on both orexigenic 
NPY/AgRP neurons and anorexigenic POMC/CART neurons (Mercer et al., 
1996; Elmquist et al., 1997). An increase in white adipose tissue leads to an 
increase in circulating leptin levels, activating POMC/CART neurons and 
inhibiting NPY/AgRP neurons. A reduction in adiposity results in a decrease 
in circulating leptin levels, which disinhibits orexigenic NPY/AgRP neurons.  
Leptin also acts on leptin receptors in other hypothalamic nuclei. Circulating 
leptin levels can also reflect short term food intake. Food restriction/fasting 
can acutely suppress leptin levels. A diet of 35% of average daily calorie 
requirements for 4 days reduced circulating leptin levels by 40%, but this is 
rapidly reversed by refeeding (Maffei et al., 1995; Mars et al., 2006). 
Absence of leptin signalling results in hyperphagia and obesity in rodents 
and humans (Montague et al., 1997). However, these mutations are very 
rare in humans. A condition more commonly associated with abnormal leptin 
signalling in humans is leptin resistance (Bjorbaek, 2009; Munzberg, 2010; 
Maffei et al., 1995). Leptin resistance is associated with obesity and may be 
due to persistently high circulating levels of leptin causing receptor 
desensitisation (Scarpace and Zhang, 2009). Leptin was once considered a 
possible target for anti-obesity treatment, as administration of leptin to leptin-
deficient mice reduces food intake and body weight (Levin et al., 1996). It 
was subsequently found that obese subjects have higher circulating levels of 
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leptin and in many cases are leptin resistant (Segal et al., 1996). Exogenous 
administration of leptin to the obese is therefore ineffective as a weight loss 
drug.  
There are a number of rodent models of obesity with abnormal leptin 
signalling. The Ob/Ob mouse and the Db/Db mouse are the best 
characterised (Coleman, 1978; Ingalls et al., 1950). The Ob/Ob mouse lacks 
functional leptin, but has a functional leptin receptor. The lack of functioning 
leptin is due to a recessive mutation, first identified in a group of mice in 
Jackson laboratories in 1949 (Ingalls et al., 1950). Ob/Ob mice are 
hyperphagic and obese and develop severe insulin resistance at an early 
age (Lindstrom, 2007). The Db/Db mouse lacks a functional leptin receptor 
and is hyperphagic and obese, with poorly regulated blood glucose levels. It 
is thus also used as a model of obesity and diabetes. 
Leptin levels are closely related to fertility; very high and very low levels of 
leptin have been linked to reduced fertility levels in mouse models (Chehab 
et al., 1996). The Ob/Ob mouse model is infertile (Mounzih et al., 1997), as 
the absence of leptin reduces hypothalamo-pituitary-gonadal drive, 
preventing animals from going through puberty  or maintaining normal 
reproductive function (Goumenou et al., 2003). Interestingly, the infertility of 
the Ob/Ob mouse is rescued by cross breeding with either the Y2 or Y4 
receptor knockout mouse (Sainsbury et al., 2002).   
1.6.2 Insulin 
Insulin is a 51 amino acid peptide hormone, produced in the beta cells of the 
pancreatic islets of Langerhans.  Insulin regulates glucose homeostasis by 
stimulating glucose uptake and glycogen storage, and by suppressing 
gluconeogenesis. Circulating levels of insulin are positively correlated with 
long-term energy balance, and it has been suggested that insulin acts as a 
signal of adiposity (Bagdade et al., 1967). Circulating insulin levels inversely 
correlate with insulin sensitivity in the periphery: long term elevated 
circulating insulin levels are linked to insulin resistance and T2DM. Insulin is 
released rapidly after a meal to maintain glucose homeostasis via a tyrosine 
kinase signal transduction pathway. Insulin crosses the blood brain barrier 
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via a saturable receptor-mediated process in proportion to circulating levels 
(Krauss et al., 1998; Baura et al., 1993) and acts as an anorexigenic signal 
(Won et al., 2009). Administration of insulin into the third cerebral ventricle in 
rodents reduces food intake (Ikeda et al., 1986).  Insulin receptors have been 
found on POMC neurons in the ARC of the hypothalamus, and central 
administration of insulin to fasted rats increases POMC mRNA expression 
(Benoit et al., 2002). The anorexigenic effects of central insulin are blocked 
by administration of  a melanocortin receptor antagonist SHU 9119 (Benoit et 
al., 2002). This suggests that the central effects of insulin on appetite may be 
mediated via the melanocortin system. 
Due to the increase in numbers of patients with T2DM, and obesity, new 
treatments are being developed to help maintain better control over blood 
glucose levels (Bourne J, 2001). Exenatide is an anti-diabetic drug which 
acts as a GLP-1 receptor agonist to inhibit glucagon release and increase 
glucose dependent insulin release (Bosi et al., 2008; Davidson et al., 2008). 
It was developed in collaboration by Amylin pharmaceuticals and Eli Lilly 
(Nielsen and Baron, 2003). During phase III clinical trials, exendin-4 reduced 
significantly HBA1c and increased insulin release; it has also been shown to 
cause weight loss (Buse et al., 2004).  
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1.7 Peripheral Signals from the Gastrointestinal Tract 
1.7.1 Ghrelin 
Ghrelin is a 28 amino acid peptide produced in the fundus of the stomach by 
the chromogranin A immunoreactive X/A-like cells (Kojima et al., 1999). 
There are two major circulating forms of ghrelin: acetylated ghrelin and des-
acyl ghrelin (Hosoda et al., 2000).  Acetylated ghrelin is the active form of 
ghrelin; the addition of the acyl side chain, n-octanoic acid, to the third serine 
residue of ghrelin is essential for receptor binding and subsequent effects on 
food intake (Kojima et al., 1999). Ghrelin is an endogenous agonist for the 
growth hormone secretagogue receptor (GHSR) (Jarkovska et al., 2004), 
stimulation of which has long been known to cause the release of growth 
hormone (Kojima et al., 1999). The GHSR is highly expressed in the anterior 
pituitary, but also in the ARC and the VMN of the hypothalamus (Kojima and 
Kangawa, 2002). Circulating ghrelin levels rise before a meal and decrease 
post prandially (Nakazato et al., 2001). Central or peripheral administration of 
ghrelin dose dependently increases food intake (Lawrence et al., 2002; 
Kojima and Kangawa, 2002; Wren et al., 2001). Circulating ghrelin levels 
inversely correlate with long term energy stores. Anorexic individuals have 
high circulating levels which fall to normal levels on weight gain (Otto et al., 
2001).  Conversely, obese subjects have low plasma ghrelin levels which 
normalise after weight loss (Hansen et al., 2002). Unlike lean individuals, 
obese subjects may not experience the same rapid post prandial fall in 
circulating ghrelin, which may contribute to their obesity (English et al., 2002). 
Peripheral administration of ghrelin activates NPY/AgRP neurones in the 
ARC (Ruter et al., 2003; Nakazato et al., 2001) and has no effect on appetite 
in NPY/AgRP knockout mice (Chen et al., 2004), suggesting its orexigenic 
effects are mediated by this neuronal population.  
1.7.2 Cholecystokinin 
Cholecystokinin (CCK) is produced by mucosal endocrine I cells in the small 
intestine (Polak et al., 1975). There are a number of active forms of CCK 
which circulate in the blood stream, including CCK-58, CCK-33 and CCK-8 
(Reeve, Jr. et al., 1994; Zhou et al., 1985). Levels of circulating CCK rise 
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following nutrient intake, and levels remain high for a number of hours (Liddle 
et al., 1985).  CCK is also expressed in the brain, where it can act as a 
neurotransmitter, and is thought to play a role in a number of processes, 
including memory, anxiety and reward behaviour, as well as satiety (Crawley 
and Corwin, 1994).  
Peripheral administration of CCK to both humans and rodents inhibits food 
intake (Smith and Gibbs, 1975; Muurahainen et al., 1988). Peripheral CCK 
signals via the vagus nerve; peripheral administration of CCK increases c-fos 
expression in the rat brainstem and does not influence food intake in 
vagotomised rodents (Zittel et al., 1999). Peripheral CCK has a rapid but 
relatively short-lived effect on appetite in rodents (Moran, 2000; Thompson et 
al., 1975).  In animals, chronic administration of CKK reduces food intake, but 
there is a compensatory increase in meal frequency that means there is no 
effect on body weight (West et al., 1984; West et al., 1987). Chronic 
administration of a CCK antagonist results in weight gain in rodent models, 
but interestingly without an increase in food intake (McLaughlin et al., 1985; 
Meereis-Schwanke et al., 1998). 
It has been suggested that any effects on body weight observed following 
CCK administration may be due to the interaction of CCK with leptin, which 
enhances the satiating effect of CCK (Matson et al., 2000). 
1.7.3 Proglucagon- derived products 
The proglucagon gene was originally discovered by Bell et al in 1983. It 
undergoes tissue specific post translational processing in the intestine, 
pancreas and central nervous system (Bell et al., 1983).  In the L-cells of the 
small intestine, proglucagon is cleaved by prohormone convertase 1 and 2 
into glicentin, oxyntomodulin, GLP-1 and glucagon-like peptide 2 (GLP-2) 
(Tang-Christensen et al., 2001; Bonic and Mackin, 2003). In the alpha cells 
of the pancreas, proglucagon is cleaved by prohormone convertase 2 to 
produce glucagon (Dhanvantari et al., 1996; Patzelt and Schiltz, 1984).  
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1.7.3.1 Glucagon 
Glucagon is a 29 amino acid peptide released from the alpha cells of the 
pancreatic islets of Langerhans. Glucagon acts to counteract the actions of 
insulin on blood glucose levels, by increasing glucose synthesis, and the 
release of glucose from storage as glycogen (glycogenolysis). Levels of 
circulating glucagon are low post prandially, but rise on fasting. Glucagon 
binds to the glucagon receptor (GLU-R), which is a G-protein coupled 
receptor (GPCR) linked to the activation of cyclic AMP, an intracellular 
secondary messenger (Jelinek et al., 1993). High affinity glucagon binding 
sites have been identified in the liver, kidneys, brain, and adipose tissue 
(Moens et al., 1996). GLU-R receptors are also found on the beta cells of the 
pancreas, where their activation is linked to an increase in insulin release. 
This allows newly available circulating glucose to be taken up by insulin-
dependent tissues, such as liver and muscle. T2DM and the metabolic 
syndrome are thought to be partly due to the failure of post prandial glucagon 
suppression, together with insulin deficiency/insulin resistance (Spellman, 
2007; Unger and Orci, 1975). 
1.7.3.2 Glucagon-like Peptide 1 
GLP-1 is a 30 amino acid peptide derived from the proglucagon gene.  
Physiologically, GLP-1 stimulates glucose-dependent insulin secretion and 
inhibits glucagon secretion (Drucker, 2001).  GLP-1 has also been linked to 
the inhibition of gastric emptying and food intake (Nauck et al., 1997; 
Naslund et al., 1999). The L cells of the intestine release two bioactive forms 
of GLP-1 into the circulation (Herrmann et al., 1995; Orskov et al., 1993). 
GLP-1 (7-37) and GLP-1 (7-36 amide) are both released post prandially 
(Orskov et al., 1996). Exogenous GLP-1 (7-36) inhibits food intake when 
administered peripherally or centrally to rodents (Turton et al., 1996). Daily 
injections of GLP-1 into the third ventricle reduce body weight in rats 
(Meeran et al., 1999).  Intra venous (IV) infusion of GLP-1 to normal weight 
volunteers inhibits food intake (Verdich et al., 2001). Circulating GLP-1 levels 
are inversely correlated with body mass (Ranganath et al., 1996). GLP-1 
may play a role in energy expenditure, as a 4 hour infusion of GLP-1 reduced 
energy expenditure in normal-weight and obese volunteers (Flint et al., 2000).  
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The GLP-1 receptor is expressed in the hypothalamus and the brainstem 
(Goke et al., 1995; Uttenthal et al., 1992; Shimizu et al., 1987), where its 
expression is lower in fed rats than in fasted rats (Zhou et al., 2003).  GLP-1 
knockout mice show normal feeding behaviour, but are hyperglycaemic when 
fasted (Scrocchi et al., 1996). GLP-1 is a substrate for the degradative 
enzyme dipeptyl peptidase IV (DPPIV), which limits its circulating half life  to 
approximately 2 minutes (Orskov et al., 1993).  A number of treatments for 
diabetes have been developed recently using DPPIV resistant forms of GLP-
1 (Burcelin et al., 1999).   
1.7.3.3 Exendin-4 
Exendin-4 is a 39 amino acid peptide, which acts as a potent agonist for the 
GLP-1 receptor. It was originally found in the saliva of the Gila monster (Eng, 
1992), and has since been developed by Amylin Pharmaceuticals and Eli 
Lilly and Company as a treatment for T2DM type 2 diabetes under the trade 
name Exenatide (Nielsen and Baron, 2003).  Exendin-4 inhibits glucagon 
release, and increases insulin secretion in humans. Unlike T2DM treatments 
such as metformin, treatment with exendin-4 is also associated with weight 
loss.  HbA1c is a measure of glycated haemoglobin, commonly used as a 
measure of blood glucose levels over an extended period. After 3 years of 
treatment, patients receiving Exenatide lost an average of 5.3kg compared to 
placebo, and had a 1% reduction in their glycated haemoglobin (HbA1c) 
levels (Klonoff et al., 2008; Szayna et al., 2000). However, treatment with 
GLP-1 and exendin-4 is commonly associated with nausea (Buse et al., 2010; 
Astrup et al., 2009).   
1.7.3.4 Glucagon-like Peptide 2 
Glucagon-like peptide 2 (GLP-2) is a 33 amino acid peptide product of the 
proglucagon gene (Dhanvantari et al., 1996). It is secreted from the L cells of  
intestines, and like GLP-1 is a substrate for the degradative enzyme DPPIV 
(Drucker et al., 1997). GLP-2 acts via the GLP-2 receptor, which is 
expressed in both the small and the large intestine (Munroe et al., 1999). 
Unlike GLP-1 and other proglucagon products, GLP-2 does not reduce food 
intake in animals or humans following  peripheral administration (Schmidt et 
al., 2003). However, central administration to rodents has been reported to 
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reduce food intake (Tang-Christensen et al., 2001). This central anorectic 
effect may be due to GLP-2 activating central GLP-1 receptors (Lovshin et al., 
2001).  The main actions of GLP-2 include inhibiting gastric motility and 
gastric acid secretion, and promoting intestinal growth (Meier et al., 2006).  
1.7.3.5 Oxyntomodulin 
Oxyntomodulin is a 37 amino acid peptide comprised of the 29 amino acids 
of glucagon with the addition of 8 amino acids at the C terminus (Bataille et 
al., 1981). Oxyntomodulin is released post prandially from the intestinal L 
cells (Ghatei et al., 1983; Stanley et al., 2004). Like other members of the 
proglucagon family, oxyntomodulin inhibits gastric acid secretion and inhibits 
food intake in rodents and humans (Dakin et al., 2004). A specific 
oxyntomodulin receptor has not been identified, and it is thought that 
oxyntomodulin exerts its actions through the GLP-1 receptor.  Oxyntomodulin 
does not reduce food intake in mice which lack the GLP-1 receptor (Baggio 
et al., 2004). However, there is evidence that there may be a specific 
oxyntomodulin receptor. Both oxyntomodulin and GLP-1 reduce food intake 
with a similar magnitude when administered peripherally, but oxyntomodulin 
has a lower affinity for the GLP-1 receptor than GLP-1 (Dakin et al., 2001). In 
addition, the anorectic effects of peripherally administered oxyntomodulin are 
attenuated by administration of the potent GLP-1 receptor antagonist 
exendin (9-39) into the ARC, but those of peripherally administered GLP-1 
are not (Dakin et al., 2004). This provides further evidence that distinct 
receptors or receptor subtypes may mediate the effects of oxyntomodulin 
and GLP-1.  
In animal studies, oxyntomodulin acutely reduces food intake when 
administered peripherally and centrally (Dakin et al., 2004; Dakin et al., 
2001).  Peripheral administration of oxyntomodulin to humans via an IV 
infusion acutely reduces food intake compared to saline controls up to 12 
hours post infusion (Cohen et al., 2003).  Chronic daily IP administration of 
oxyntomodulin over 7 days reduces body weight gain in rats (Dakin et al., 
2004). Daily subcutaneous (SC) administration of a long lasting 
oxyntomodulin analogue has also been shown to reduced body weight gain 
in rodents (Liu et al., 2010). In humans, administration of 400nmol (SC) of 
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oxyntomodulin 30 minutes before each meal for a month to healthy over 
weight and obese patients significantly reduced body weight compared to 
saline control group (Wynne et al., 2005a). Thiakis Ltd has developed an 
oxyntomodulin analogue which is more degradation resistant than the native 
oxyntomodulin, for the treatment of obesity in humans (Cooke and Bloom, 
2006). This molecule is currently undergoing clinical trials. In overweight 
patients, acute combined oxyntomodulin and PYY3-36 infusion reduces food 
intake compared to saline control or infusion with either hormone alone (Field 
et al., 2010).  
Oxyntomodulin may also regulate energy expenditure. When administered 
daily via the third ventricle to rats it reduces body weight compared to ad 
libitum and pair fed controls (Dakin et al., 2002). In humans, pre-prandial SC 
administration of oxyntomodulin reduced food intake and increased activity 
related energy expenditure when examined by indirect calorimetry (Wynne et 
al., 2006).  
1.7.4 ‘PP-Fold’ Family of Peptides  
Peptide YY, NPY and PP are all members of the „PP fold‟ group of peptides. 
All  three show high levels of sequence homology (Ekblad and Sundler, 
2002). This group are named after the distinct fold in their tertiary structures, 
consisting of a “U” shaped extended polyridine helix and an alpha helix 
connected by a beta turn. (Figure 1.4 on page 58, shows the basic structure 
of PP). These two peptides have  NPY as a common ancestor (Blomqvist et 
al., 1992). PP is thought to have evolved following a chance duplication of 
the PYY gene (Larhammar, 1996a; Cerda-Reverter and Larhammar, 2000). 
PP fold peptides exert their effects via a group of G protein coupled receptor 
known as the Y receptors. Currently there are 5 known forms of the Y 
receptor: Y1, Y2, Y3, Y4 and Y5. Y3 receptors are only found in avian 
species. All Y receptors share limited sequence homology but similar 
pharmacology. Each receptor has a different affinity for each PP fold ligand, 
and different expression patterns within the brain and the periphery. Each of 
the different Y receptors can bind at least two of the PP fold peptides 
(Table1.1). 
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The expression of the Y receptors is mainly limited to the brain and the 
digestive tract, though the Y1 receptor is also found in blood vessels, and Y2 
in the heart (Table 1.1) (Dumont et al., 1998; Ferrier et al., 2002).  Within the 
hypothalamus, Y1 receptors are found predominately in the ARC, and Y2 
receptors in the PVN and the ARC,  (Parker and Herzog, 1999). The Y4 
receptor is highly expressed in the area postrema and the dorsal vagal 
complex of the brain stem (Parker and Herzog, 1999; McTigue et al., 1993) 
where there is limited expression of other Y receptors.   
1.7.4.1 Peptide YY  
PYY is a 36 amino acid peptide first isolated in 1982 from porcine intestinal 
extracts (Tatemoto, 1982). PYY is released from gastrointestinal L-cells post 
prandially in proportion to calories ingested (Adrian et al., 1985).  Levels rise 
approximately 18 minutes after ingestion of food and remain high for 2 hours 
(Adrian et al., 1987). PYY is cleaved by the enzyme DPPIV at the N-terminus 
to generate PYY3-36 , the major circulating form of PYY (Grandt et al., 1993).  
PYY3-36 is a selective agonist for the Y2 receptor, whereas PYY1-36 is an 
agonist for the Y1, Y2 and Y5 receptors. Intravenous infusion of PYY3-36 
acutely reduces food intake in humans. Healthy volunteers infused with 
physiological doses of PYY3-36 (to mimic post prandial circulating plasma 
levels), reduced their food intake at a buffet meal by 35% (Batterham et al., 
2002). However, supra-physiological doses of PYY3-36 are associated with 
nausea (Le Roux et al., 2008). 
In rodents, peripheral administration of PYY3-36 acutely inhibits food intake, 
and chronically reduces food intake and body weight (Vrang et al., 2006). 
However, the chronic effects of PYY3-36 are relatively short lived, with any 
effect on food intake being abolished after four days of SC or IP 
administration (Parkinson et al., 2008; Vrang et al., 2006). This may be an 
administration issue, as intermittent IV infusion (1 hour IV infusion at 
30pmol/kg/min every other hour) of PYY3-36 in obese rats has been shown to 
reduce body weight by 20% over 10 days (Chelikani et al., 2006).  
Nastech and Merck previously developed a nasally administered form of 
PYY3-36 to be taken before a meal. This treatment reached phase II clinical 
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trials, but there was a high dropout rate thought to be due to nausea caused 
by the super physiological plasma levels of PYY3-36 achieved. In the trial, 
within 26 minutes of administration, plasma PYY3-36 concentrations reached 
approximately 105pmol/L, twice the normal post prandial level (Gantz et al., 
2007; MDRNA, 9 A.D.).  
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Receptor Y1 Y2 
(Presynaptic) 
Y4 Y5 
Distribution Hypothalamus 
Dorsal root 
ganglia  
Amygdala  
Blood vessels 
Cortex 
 
Hypothalamus 
Dorsal root 
ganglia  
Hippocampus 
Intestine 
Heart 
Hypothalamus 
Amygdala 
Thalamus, 
Area postrema 
Brain stem 
Intestine 
Pancreas  
 
Hypothalamus 
Thalamus 
NTS 
Affinity NPY  
PYY 
 
 
NPY 
PYY 
PYY3-36 
PP 
NPY 
PYY  
NPY 
PYY 
NPY2-36 
NPY3-36 
 
 
Table 1.1 Y receptor distribution and ligand affinities for the PP-fold family 
(Ferrier et al., 2002; Jois et al., 2006; Parker and Herzog, 1999; Trinh et al., 
1996).  Affinities are listed highest to lowest. 
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1.7.4.2 Pancreatic Polypeptide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Pancreatic polypeptide (PP) is a 36 amino acid peptide with an amidated C 
terminus (Larhammar, 1996a), originally isolated in avian species and first 
described by Kimmel in 1975 (Kimmel et al., 1975). In humans, PP is found 
at highest concentrations within the pancreas (123pmol/ml), but is also found 
at lower levels in other areas of the digestive tract, including the stomach 
(Adrian et al., 1977; Adrian et al., 1976).  
PP is released post prandially from pancreatic endocrine F cells in proportion 
to the calories ingested. (Adrian et al., 1978; Adrian et al., 1976). PP has 
also been shown to be released in a diurnal rhythm, with levels reaching their 
highest at 3pm and returning to their lowest at 9am (Johns et al., 2006). The 
average fasted plasma circulating level of PP is approximately 30pmol/l, 
which rises to over 160pmol/l post prandially (Adrian et al., 1976). Meal 
composition also influences PP release; carbohydrates do not stimulate PP 
release as effectively as protein or fat (Feinle-Bisset et al., 2005).  
The post prandial release of PP from the pancreas is under vasovagal 
control (Schwartz, 1983). Vagal afferents from the GI tract synapse with 
neurons in the NTS and the AP of the brainstem, and are relayed to the DMN 
indicating the presence of food in the stomach and intestines. Vagal efferents 
from the DMN projecting to the pancreas signal to stimulate PP release 
(Berthoud et al., 1991).  PP and the Y4 receptors are involved in the control 
of gastric and pancreatic secretion. Infusion of exogenous PP has been 
shown to stimulate gastric acid secretion, and inhibit pancreatic secretion, as 
well as to decrease gastric motility (McTigue et al., 1993; Gettys et al., 1992; 
Okumura et al., 1994; McTigue and Rogers, 1995). Lesions to the AP have 
been shown to ablate the ability of exogenous PP to inhibit pancreatic 
secretions (Deng et al., 2001), and vagotomy prevents the post-prandial 
release of PP and its subsequent effects (Schwartz, 1983). 
As previously stated in section 1.7.4, PP has the highest affinity for the Y4 
receptor, and its effects on food intake are mediated via its activation of the 
Y4 receptor (Lin et al., 2009; Sainsbury et al., 2010; Asakawa et al., 1999). 
The Y4 receptor is linked to cyclic AMP via G protein Gq; increased Y4 
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receptor activation inhibits cyclic AMP production (Kojima et al., 2007; 
Hosoda et al., 2000; Dumont et al., 2005; Dumont et al., 1993). In smooth 
muscle cells, Y4 receptors activate the G protein Gq and stimulates inositol 
triphosphate (IP3) formation and IP3 dependent calcium release to allow 
muscle contraction (Misra et al., 2004).  
High basal levels of PP, usually caused by F cell endocrine tumours, have 
been associated with weight loss in a number of patients (Strodel et al., 1984; 
Adrian, 1986; Martella et al., 1997). Transgenic mice over-expressing the PP 
gene (resulting in circulating levels of PP twenty times higher than their wild 
type litter mates) ate significantly less compared to wild type litter mates and 
had lower body weights (Ueno et al., 1999). Administration of PP anti-serum 
to these animals returned food intake and body weight to levels similar to 
wild type animals (Ueno et al., 1999).  
Other studies investigating the role of PP in the regulation of appetite have 
found that patients suffering from the condition anorexia nervosa 
demonstrated an exaggerated PP response upon eating (Uhe et al., 1992; 
Fujimoto et al., 1997; Kinzig et al., 2007). Conversely, patients with Prader-
Willi Syndrome (PWS), a condition characterised by hyperphagia and obesity, 
decreased fat free mass, decreased energy expenditure and decreased 
bone density,  have higher than average fasting circulating levels of PP. 
However, they have a blunted PP response to feeding (Zipf et al., 1981; Zipf 
et al., 1983).   Infusion of PP (50pmol/kg/h) in PWS has been shown to 
reduce food intake in a free buffet meal by 12%, post infusion (Berntson, 
2003). PWS patients have other alterations in gut hormone profiles. 
Circulating PYY levels are also higher post prandially in PWS patients, and 
there is a greater rise in plasma PYY levels post prandially (Bizzarri et al., 
2010; Gimenez-Palop et al., 2007). Fasting ghrelin levels are higher in PWS 
patients, and the post prandial fall in ghrelin is more pronounced in PWS 
patients (Bizzarri et al., 2010; Gimenez-Palop et al., 2007).  
Infusion of 10pmol/kg/min of PP to healthy volunteers reduced food intake at 
a buffet meal by 21.8% compared to saline control, and reduced food intake 
at 24 hours by 25% (Batterham et al., 2003). A lower infusion rate of 
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5pmol/kg/min reduced acute food intake by 10.5% and had no effect on 24 
hour food intake (Jesudason et al., 2007). Both of these studies resulted in 
supra-physiological circulating levels of PP with no reported adverse effects, 
further suggesting indicating that PP may have potential as a treatment for 
obesity. This thesis describes experiments investigating the utility of PP and 
PP analogues in the regulation of food intake and the treatment of obesity.  
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Amino acids Tertiary structure 
1-8 Poly-proline helix 
9-14 Beta turn 
15-32 Amphipathic alpha helix 
 
Figure 1.4 A schematic diagram showing the basic structure of PP, with 
some side chains represented by spheres. Above is a table indicating the 
amino acids composing the structures which give PP its distinct tertiary 
shape. Adapted from (Gellman and Woolfson, 2002).  
 
C -Terminus 
N -Terminus 
Amino Acid 1 
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1.8 Hypothesis and Aims of Thesis 
Hypothesis: Rational modifications to the amino acid sequence of PP will 
result in a PP analogue more efficacious at inhibiting food intake and 
promoting weight loss than native PP.  
Aims: To determine: 
 The effect of specific changes to the structure of PP on 
its susceptibility to breakdown by specific enzymes and 
tissue preparations, and its binding affinity for the human 
Y4 receptor. 
 The effect of specific changes to the structure of PP on 
its in vivo longevity and efficacy at reducing food intake 
in rodents following acute peripheral administration.  
 The effects of chronic administration of a specific PP 
analogue (identified in experiments conducted to 
address aims 1 and 2 above) on food intake and body 
weight in rodent models of obesity. 
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Chapter 2 
 
The Breakdown Of PP 
And The Design Of 
Enzyme-Resistant 
Analogues 
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2.1 Introduction 
PP is a member of the „PP-Fold‟ family of peptides which includes NPY and 
PYY. These three polypeptides share a strong sequence homology 
(Larhammar, 1996a), with PP and PYY only differing by the 4 amino acids 
between amino acids 9 and 12.  As previously described in section 1.7.4.2, 
PP is a 36 amino acid peptide with an amidated C terminus (Larhammar, 
1996b) released post prandially from the pancreatic F cells (Adrian et al., 
1978; Adrian et al., 1976). When PP was administered to healthy adults via 
an IV infusion it significantly reduced food intake over 24 hours compared to 
a saline control (Batterham et al., 2003; Jesudason et al., 2007). This 
anorectic effect suggests that PP may have potential as an obesity treatment. 
However, PP is a relatively small peptide which is thus susceptible to a 
number of degradative enzymes and other mechanisms. PP consequently 
has a short circulating half life of around 7 minutes (Adrian et al., 1978). This 
short half life limits the utility of unmodified PP as an obesity treatment. 
Previous studies on other gut hormones including GLP-1, oxyntomodulin and 
PYY3-36 have shown that small regulatory peptides are susceptible to 
degradation by a number of membrane bound ectopeptidases and other 
membrane bound enzymes, limiting their circulating half life (Kenny, 1986b; 
Roques et al., 1993). As the PP family of peptides show strong sequence 
homology and are thought to be derived from a common ancestor, it is likely 
that the peptidases that breakdown other members of the PP-fold family will 
also degrade PP (Ekblad and Sundler, 2002; Blomqvist et al., 1992; 
Larhammar, 1996a; Larhammar, 1996b). Developing an analogue of PP 
which can better resist degradation by these enzymes may therefore improve 
the efficacy of PP at reducing food intake and, ultimately, at reducing body 
weight. 
Analogues of other gut hormones with improved bioactivity have previously 
been developed. Both the GLP-1 analogue liraglutide, and the oxyntomodulin 
analogue OXM 6421 have improved efficacy compared to their native 
hormones, and are now either used or being developed as treatments for 
T2DM and obesity (Liu et al., 2010; Degn et al., 2004; Astrup et al., 2009; 
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Green et al., 2003). Inhibitors of enzymes known to inactivate hormones 
have also been used and developed into treatments for T2DM. DPPIV 
inhibitors are currently on the market and licensed for the use in T2DM; 
examples include sitagliptin and vildagliptin (Davidson et al., 2008; Liu et al., 
2009).  These DPPIV inhibitors increase the circulating levels of GLP-1 to 
help lower blood glucose levels. 
2.1.1 Kidney Brush Border Membrane (KBB) 
The exact mechanisms of PP clearance are unknown. PYY is broken-down 
by a number of enzymes and peptidases located in the kidney (Medeiros and 
Turner, 1994a; Medeiros and Turner, 1994b; Mentlein et al., 1993a), and it is 
therefore likely that the kidneys are also a major site of PP clearance. The 
kidney is thought to play a major role in the degradation of a number of 
peptide hormones, including atrial natruretic peptide, bradykinnin, 
angiotensin and substance P (Stephenson and Kenny, 1987b; Stephenson 
and Kenny, 1987a; Kenny and Maroux, 1982; Vanneste et al., 1988). 
Enzymes including aminopeptidase N, aminopeptidase A, DPPIV, and 
neprilysin are all located within the kidney brush border membranes 
(Stephenson and Kenny, 1987b; Kenny and Stephenson, 1988; Vanneste et 
al., 1988; Hupe-Sodmann et al., 1995; Bertenshaw et al., 2001; Medeiros 
and Turner, 1995).  It has been suggested that the levels of certain enzymes 
within the kidney brush boarder are dependent upon nutritional status, with, 
for example, starvation increasing the levels of DPPIV in rats (Ihara et al., 
2000). This perhaps suggests a mechanism by which nutritional status 
regulates circulating gut peptide levels. The kidney brush borders could 
therefore be a key site for the breakdown of PP, and the reabsorption of 
amino acids, and  kidney brush border preparations may therefore be a 
useful tool to investigate the breakdown of PP and PP analogues (Kenny and 
Stephenson, 1988). 
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2.1.2 Dipeptyl Peptidase IV (DPPIV) 
DPPIV is a member of the serine family of peptidases (s9b) which acts to 
cleave the first two amino acids at the N-terminus of small to medium sized 
peptides (Mentlein et al., 1993b; Mentlein, 1999; Drucker et al., 1997). 
Human DPPIV is 766 amino acid glycoprotein. It has been suggested that 22 
of those amino acids, anchor it to the plasma membrane at the N-terminus 
(VLLG LLGAAALVTI ITVPVVLL), this is flanked by a short intracellular 
hydrophobic sequence of 6 amino acids (MKTPWK) (Mentlein, 1999). 
Previously, it has been suggested that for cleavage by DPPIV, a peptide 
must possess a proline or an alanine at position P1 of the amino acid chain, 
and a hydrophobic amino acid such as tyrosine at the P2 position (Bongers 
et al., 1992).  DPPIV has a number of substrates, including NPY, PYY and 
GLP-1 (Mentlein et al., 1993a; Mentlein et al., 1993b). PYY has been shown 
to be cleaved to by DPPIV to form PYY3-36, the predominant circulating form 
of PYY, and the form with the highest affinity for the Y2 receptor (Grandt et 
al., 1993).  
Recently, DPPIV inhibitors have been developed to increase the half life of 
GLP-1 to aid in the treatment of T2DM (Davidson et al., 2008). Sitagliptin and 
Vildagliptin are two DPPIV inhibitors approved for the treatment of T2DM. 
These two drugs act to inhibit the breakdown of GLP-1 by DPPIV, therefore 
increasing circulating GLP-1 levels and lowering elevated blood glucose 
levels. The long lasting GLP-1 analogue exenatide has been modified to 
prevent breakdown by DPPIV, therefore significantly increasing its plasma 
half life (Nielsen et al., 2004; Green et al., 2003). As DPPIV has been shown 
to cleave PYY, and NPY, it is also likely to cleave PP. However, this has not 
previously been investigated. 
2.1.3 Neprilysin (NEP) 
NEP is a 742 amino acid metallopeptidase enzyme with a zinc core. It is 
usually found bound to membranes, and is expressed throughout the body.  
NEP was originally discovered in purified kidney brush border (Gee et al., 
1985; Roques et al., 1993; Hupe-Sodmann et al., 1995), and particularly high 
concentrations are found in the kidneys, brain, and lungs. NEP has a wide 
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number of substrates, including GLP-1, Neurokinin A and B, Neurotensin, 
Oxytocin and Gastrin (Erdos and Skidgel, 1989). NEP cleaves peptide 
chains on the amino side of hydrophobic residues.  This has been 
demonstrated in GLP-1, in which a number of peptide bonds are cleaved by 
NEP. Interestingly, the Asp 27-Phe28 and the Trp 31-Leu 32 bonds of GLP-1 
were cleaved most readily (Hupe-Sodmann et al., 1995). It has been 
suggested that exendin-4, a long lasting analogue of GLP-1, is a poor 
substrate for NEP, which may also partly explain its extended half life (Hupe-
Sodmann et al., 1995a; Goke et al., 1993). This suggests that substituting 
amino acids susceptible to attack by peptidases may increase peptide 
hormone bioactivity. PYY and NPY have also been shown to be cleaved by 
NEP, suggesting that PP may also be processed by NEP (Medeiros and 
Turner, 1994a; Medeiros and Turner, 1994b; Medeiros and Turner, 1996).  
2.1.4 Meprin  
Meprin is another metalloproteinase highly expressed in the kidney brush 
border, and also found on intestinal epithelia and mesenteric leukocytes 
(Bond and Beynon, 1986; Bond et al., 1986). It has been suggested that 
meprin comprises approximately 5% of total brush border protein  (Bond and 
Beynon, 1986). Meprin peptidase is composed of two sub units which share 
50% homology at the amino acid level. These two distinct types of sub unit, 
are named alpha and beta subunits. Meprin beta is a homooligomer of beta 
sub units, and meprin alpha is heterooligomer of alpha and beta sub units or 
a homooligomer of alpha units (Bertenshaw et al., 2002; Becker et al., 2003). 
Meprin beta is the predominate form in the adult human intestine (Bond et al., 
1984). The meprins are similar in size and in substrate requirements to NEP. 
However, the NEP inhibitor phosphoramidon does not impair meprin beta 
activity (Bond et al., 1986; Takayama et al., 2008). Meprins are thought to 
have a wide range of substrates, including gastrin, angiotensin, collagen IV 
and fibronectin (Bertenshaw et al., 2001). Meprin alpha and meprin beta 
have different substrate requirements. The best known substrates for meprin 
beta are gastrin and chemokines (Bertenshaw et al., 2001), whereas the best 
known substrates for meprin alpha are the cytokines (Kruse et al., 2004).  It 
has been suggested that the meprins have a preference for hydrophobic 
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amino acids, and for peptide bonds flanked by neutral or hydrophobic amino 
acids (Butler et al., 1987).  
2.1.5 Enzyme Resistant Hormone Analogues 
A number of hormone analogues which are more resistant to enzymatic 
breakdown than the native forms have already been developed.  One 
example is desmopressin acetate (DDAVP) which is a longer lasting, more 
potent analogue of the hormone vasopressin commonly used in the 
treatment of diabetes insipidus (Robinson, 1976).  The GLP-1 analogue 
exendin-4 has a significantly increased half life compared to native GLP-1 
(Goke et al., 1993), which may be due to increased resistance to peptidases 
including NEP and DPPIV (Hupe-Sodmann et al., 1995a). The 
oxyntomodulin analogue OXM 6421 has a longer half life than native OXM 
following peripheral administration (Druce et al., 2009; Liu et al., 2010), 
which is probably due to amino acid changes at sites susceptible to cleavage 
by peptidases including NEP and DPPIV. The kisspeptin-10 analogue, [dY] 
Kiss-10 has also been shown to be more potent than native kisspeptin-10. 
Analogue [dY] Kiss-10 significantly stimulated total testosterone at 60 
minutes post peripheral injection in mice, when endogenous Kiss-10 did not 
(Curtis et al., 2010). Currently there are at least two analogues of PYY being 
developed as treatments for obesity (MDRNA, 9 A.D.; Vivus Pharmaceuticals, 
2009). Using analogues of hormones with greater enzyme resistance to treat 
disease has several advantages, including specificity, which should limit side 
effects. Using analogues of gut hormones such as PP may allow the 
mimicking of the normal physiological process of satiation, and may thus be 
useful in maintaining a stable body weight, or treating obesity. 
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2.2 Hypothesis and Aims 
The breakdown of native human PP will be investigated using KBB 
membrane preparations and a number of purified recombinant degradative 
enzymes to establish which amino acid sites are targeted. Once these sites 
are established, PP analogues with amino acids rational substitutions at 
these sites will be tested for their ability to withstand enzymatic degradation 
in vitro.  
Hypothesis: The substitution of amino acids at key sites targeted by KBB 
membrane preparations, DPPIV, neprilysin and meprin beta will produce PP 
analogues resistant to enzymatic degradation.  
 
Aims: 
1. To determine the effects on native PP of incubation with KBB 
membrane, DPPIV, neprilysin and meprin beta using high 
performance liquid chromatography (HPLC) and matrix-
assisted laser desorption/ionization time of flight (MALDI-TOF) 
mass spectroscopy. 
2. To determine the effects of peripheral administration of PP in 
combination with enzyme specific inhibitors on acute food 
intake in C57/BL6 mice. 
3. To investigate the differences in between the enzymatic 
breakdown of PP and PP analogues using HPLC and MADLI-
TOF mass spectroscopy. 
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2.3 Materials and Methods 
Human PP was made by and purchased from Bachem (St. Helens, UK), 
divided into aliquots on arrival at Hammersmith and freeze dried. PP 
analogues were custom synthesised by Bachem bioscience INC. 
(Philadelphia, USA) or BIOMOL International LP (Exeter, UK). Peptides were 
synthesised using automated fluorenylmethoxycarbonyl (Fmoc) solid phase 
peptide synthesis (SPSS), with each amino acid added sequentially from the 
C to the N terminus. 
2.3.1 PP analogue synthesis 
Fmoc SPSS uses repeat cycles of coupling and deprotection to create 
custom made peptides of up to 100 amino acids. The starting block is a 
single amino acid joined by covalent bonds to a polyamide–rink resin. The N-
terminal amine of the resin embedded amino acid is deprotected by the 
addition of piperidine in dimethylformamide (DMF); the resin is then washed, 
removing all the Fmoc from the amine groups, which allows the next amino 
acid to be coupled to the embedded amino acid when it is added in excess. 
Each subsequent amino acid is then added in the same fashion. Each amino 
acid has the Fmoc to protect the reactive amine group, giving greater stability. 
Once the addition of amino acids is complete the peptide is cleaved from the 
resin.  All peptides were determined to be 90-100% pure by analytical HPLC. 
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2.3.2 Kidney brush border membrane (KBB) 
2.3.2.1 Preparation of KBB membrane 
Rat kidneys were placed in cold 0.5M sucrose solution, and the renal 
cortices dissected and removed. Cortex tissue was then cut into 0.25cm 
pieces and gently hand homogenised in a solution of 0.5M sucrose (6ml 
sucrose solution to 1 gram tissue). The tissue was then homogenised using 
a motorised homogeniser (Jencons) with a tight fitting Teflon coated pestle at 
1000rpm (Beckman J2-21, rotor JS-13.1). Following this, 1M MgCl2 was 
added to the homogenate to produce a final concentration of 10mM. This 
solution was then stirred in an ice bath for 15 minutes to remove sub cellular 
structures from the brush border cells. The sub cellular structures were then 
removed by centrifugation at 1500g (3000rpm,Beckman J2-21, rotor JS-13.1) 
at 4ºC for 20 minutes, and centrifugation of the resulting supernatant at 
15000g (10000rpm, Beckman J2-21, rotor JS-13.1) for 12 minutes at 4ºC. 
The supernatant was then discarded and the pellet resuspended in 100µl of 
300mM mannitol in 12mM Tris-HCL (pH 7.4) with 10mM MgCl2. The solution 
was then centrifuged for 12 minutes at 2200g (3700rpm, Beckman J2-21, 
rotor JS-13.1) at 4ºC and the pellet discarded. A further 500µl of buffer was 
added and the solution centrifuged for 12 minutes at 4ºC at 15000g 
(10000rpm, Beckman J2-21, rotor JS-13.1). The pellet was then 
resuspended in 10ml of 300mM mannitol in 12mM N- (2-hydroxyethyl) 
piperazine-N-(2-ethanesulfonicacid);4-(2-hydroxyethyl)-1 
piperazineethanesulfonic acid  (HEPES) (pH7.4) and protein concentration 
measured by biuret assay (Medeiros and Turner, 1994a). Subsequently, 
1.5mg aliquots of KBB membrane were aliquoted and stored at -80ºC, to be 
defrosted at room temperature when required. 
Biuret Test 
A biuret test was used to calculate protein content of KBB membrane. A 
standard solution of BSA at 10mg/ml was made, and increasing volumes of 
this solution added to tubes (0, 100, 200, 300, 400 and 500µl), corresponding 
to 0, 1, 2, 3, 4 and 5mg of protein. The BSA solution in the 5 tubes was then 
made up to 500µl with water. Twenty µl and 200µl of KBB membrane was 
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then added to a further 2 tubes and made up to 500µl with water. Three ml of 
biuret solution was added to each tube, mixed and then placed in a boiling 
water bath for 2 minutes. Each tube was then allowed to cool and 
absorbance was measured using a spectrophotometer (UV-160, Shimadzu) 
at A595nM. The protein content of the samples was interpolated from the 
BSA standard curve.  
2.3.2.2 PP and PP analogues incubation with KBB membrane 
A 5nmol vial of freeze dried PP was reconstituted in 250µl of 300mM 
mannitol in 12mM HEPES buffer (pH7.4). Freeze dried aliquots of peptide 
were used to ensure peptide concentration and activity was consistent.  One 
hundred µl (2nmol) of peptide solution was then added to 2 microtubes and 
either  ten µl of KBB buffer or ten µl (1.5mg) of KBB membrane added and 
mixed. The peptide was then incubated at 37ºC in a water bath for 0, 5, 15, 
30, 45, 60, 90 and 120 minutes. Five µl of 10% TFA was added to terminate 
the reactions following incubation. This decreased the pH of the solution to a 
level which prevented the enzymes from functioning. The solution was then 
centrifuged at 13,000g for 3 minutes. One hundred and ten µl of supernatant 
was then removed for analysis by HPLC. The time point where 50% 
breakdown occurred was identified and used for further experiments. 
A 30 minute incubation of 2nmol PP with 1.5mg of KBB membrane resulted 
in approximately 50% of the PP being broken down. Subsequent 
experiments were therefore incubated for 30 minutes. PP, GLP-1 and each 
PP analogue were incubated with KBB as described above in three separate 
experiments to allow an SEM to be calculated for % breakdown. 
2.3.2.3 MALDI-TOF MS analysis 
PP was incubated with KBB as described in section 2.3.2.2. Following 
centrifugation, 110µl of supernatant was dried down using a speed vac 
savant (Thermo, speed/vac concentrator, SPD 2010) at room temperature 
for 30 minutes until 5µl of supernatant remained. This was then frozen at -
20ºC and sent to Bachem for analysis by MALDI-TOF MS. At Bachem 100µl 
of 0.1%TFA was added to dilute the sample and mixed. Following sample 
dilution, 1µl of sample was mixed with 2µl of 10mg/ml matrix (10mg alpa-
70 
 
cyano-4-hydrcinnanic acid, 495µl ACN, 495µl ethanol and 10µl 0.1% TFA).  
One µl of sample/matrix was added to an MS plate, and the plate run on 
MALDI micro MX (Waters, Milford USA) using both linear and reflectron 
modes. Data was analysed using MassLynx mass spectroscopy software 
(Waters, Milford USA). 
2.3.2.4 Reverse phase HPLC analysis 
PP, PP analogues and GLP-1 were incubated with KBB as described in 
section 2.3.2.2. Following centrifugation 110µl of supernatant placed in a 
HPLC vial and injected onto the HPLC.  A linear gradient of 15 to 55% 
acentronitrile/water over 30 minutes (both containing 0.5% TFA) was used 
and absorbance measured at a wavelength of 214nM (Jasco HPLC system, 
solvent delivery system PU-2080 plus, autosampler AS-2057 plus, degasser 
DG2080-53, dynamic mixer 2080-32 UV detector uv-2075 using a 
Phenomenex Gemini C18 (5-m particles) 250 mm x 4.6 mm column).  
Percentage degradation was calculated by comparing area under peak in 
reactions with and without KBB membrane.  Percentage degradation values 
were calculated from a minimum of three experiments and a mean and SEM 
calculated. Chromatograms shown are representative examples. 
2.3.3 DPPIV  
2.3.3.1 PP and PP analogues incubation with DPPIV 
The effect of DPPIV on PP and PP analogues was investigated as described 
in section 2.3.2.2, but with porcine DPPIV enzyme purchased from Sigma-
Aldrich (Dorset, UK) used instead of KBB membrane. Previously published 
experiments on OXM determined that 10mU of DPPIV was effective at 
breaking down OXM (Druce et al., 2009; Liu et al., 2010). I therefore used 
this amount of DPPIV to examine its effects on PP. DPPIV was diluted with 
100mM TRIS-HCL buffer and divided into 10mU aliquots (10mU in 10µl). A 
5nmol vial of freeze dried PP was reconstituted in 250µl of 100mM Tris–HCl 
buffer (pH8). Two nmol of peptide solution in 100µl was then added to 2 
microtubes and either 10µl of buffer or 10µl (10mU) of DPPIV added and 
mixed.  
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A 120 minute incubation of 2 nmol PP with 10mU of DPPIV resulted in 
approximately 50% of PP being broken down when analysed by MALDI-TOF 
MS. The timeline was taken from previous experiments with OXM (Druce et 
al., 2009; Liu et al., 2010).  Subsequent experiments were therefore 
incubated for 120 minutes. PP and each PP analogue were incubated with 
DPPIV as described above in three separate experiments to allow an SEM to 
be calculated for % breakdown. 
2.3.3.2 MALDI-TOF MS analysis 
PP was incubated with DPPIV as described in section 2.3.3.1. Following 
centrifugation, 110µl of supernatant was dried down using a speed vac 
savant (Thermo, speed/vac concentrator, SPD 2010) at room temperature 
for 30 minutes until 5µl of supernatant remained. This was then frozen at -
20ºC and sent to Bachem for analysis by MALDI-TOF MS. 
2.3.3.3 Reverse phase HPLC analysis 
PP and PP analogues were incubated with DPPIV as described in section 
2.3.3.1. Following centrifugation 110µl of supernatant was added to a HPLC 
vial and injected onto the HPLC. HPLC was performed as described in 
section 2.3.2.4 but using a gradient of 31.5-32.5 acetonitrile/water (both 
containing 0.05% TFA) 15-40 min. No differences between PP incubated 
with DPPIV and with DPPIV buffer were detected using HPLC even using 
this relatively shallow gradient. Chromatograms shown are representative 
examples. Therefore all further analysis was done by MALDI-TOF MS. 
2.3.3.4 The effects of PP administration in combination with a DPPIV 
inhibitor on the food intake of C57/BL6 mice 
All animal procedures were approved by the British Home Office under the 
UK Animal (Scientific Procedures) Act 1986 (Project Licence 70/6402). 
Adult male C57/BL6J mice (Harlan) weighing 22-28g were maintained in 
individual cages, under controlled conditions with a 12 hours light  and 12 
hours dark.    All animals were allowed ad libitum access to water and RM1 
diet (Special Diet Services, Witham, UK) unless otherwise stated.  Animals 
were handled and received sham SC injections of saline on at least two 
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occasions prior to study days in order to acclimatise them to the 
experimental procedure. 
Feeding studies were carried out during the early light phase (0800-1000) in 
mice fasted from 1600 the preceding day. Mice following a fast have a 
greater food intake than their non-fasted counterparts, and are therefore 
more likely to demonstrate the anorectic effects of an agent.  Peptides were 
administered subcutaneously (SC) in a maximum volume of 0.1 ml of saline, 
with inhibitors administered intraperitoneally (IP) in a maximal volume of 
0.1ml. Animals were weighed and their body weight recorded before IP 
injection of either the DPPIV inhibitor valine pyrolidide (a gift from Prof. M 
Ghatei) (75mg/kg) or saline, which was, followed by a SC injection of either 
saline or PP at a dose of 50nmol/kg. The mice were then returned to their 
home cage with a known amount of food. Food was reweighed at 1, 2, 4, 8 
and 24 hours. Food was removed from the hopper, a visual inspection of the 
cage made to check for any food spillage/hoarding, and food weighed using 
balances accurate to 0.01 g.  Mouse body weight was measured 24 hours 
post-injection.  All mice feeding studies were completed in conditions where 
external stressors were minimised, as stress is known to influence feeding 
behaviour (Marti et al., 1994).  
2.3.4 NEP  
2.3.4.1 PP and PP analogues incubation with NEP 
The effect of NEP on PP and PP analogues was investigated as described in 
section 2.3.2.2, but with human recombinant NEP 24.11 enzyme purchased 
from R&D systems (Minneapolis, USA) used instead of KBB membrane. 
Previously published experiments on OXM determined that 200ng of NEP in 
10µl was effective at breaking down OXM (Druce et al., 2009; Liu et al., 
2010). I therefore used this amount of NEP to examine its effects on PP. 
NEP was diluted with  100mM TRIS-HCL buffer and divided into 200ng 
aliquots (200ng in 10µl). A 5nmol vial of freeze dried PP was reconstituted in 
300µl of 100mM Tris–HCl buffer (pH9). Two nmol of peptide solution in 100µl 
was then added to 2 microtubes and either 10µl of buffer or 10µl (200ng) of 
NEP added and mixed.  
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A 30 minute incubation of 2 nmol PP with 200ng NEP resulted in 
approximately 50% of PP being broken down. Subsequent experiments were 
therefore incubated for 30 minutes. PP and each PP analogue were 
incubated with NEP as described above in three separate experiments to 
allow an SEM to be calculated for % breakdown. 
2.3.4.2 MALDI-TOF MS analysis 
PP was incubated with NEP as described in section 2.3.4.1. Following 
centrifugation 110µl of supernatant was dried down using a speed vac 
savant (Thermo, speed/vac concentrator, SPD 2010) at room temperature 
for 30 minutes until 5µl of supernatant remained. This was then frozen at -
20ºC and sent to Bachem for analysis by MALDI-TOF MS. 
2.3.4.3 Reverse phase HPLC analysis 
PP, PP analogues and GLP-1 NEP incubations were analysed by reverse 
phase HPLC as described in section 2.3.2.4.  
2.3.4.4 The effects of PP administration in combination with inhibition 
of NEP on the food intake of C57/BL6 mice 
The effects of the inhibition of NEP on the reduction of food intake by PP was 
investigated as described in section 2.3.3.4, but with the NEP inhibitor 
phosphoramidon (R&D systems) administered IP at a dose of 1000mg/kg in 
a maximal volume of 0.1ml, and PP administered SC at a dose of 
150nmol/kg in a maximal volume of 0.1ml.   
2.3.4.5 The effects of inhibition of NEP on the plasma levels of PP in 
C57/BL6 mice following SC administration 
The effects of the inhibition NEP on the plasma levels of PP following SC 
administration of PP was investigated as described in section 2.3.3.4, with 
the following modifications. Mice were housed in groups of up to 5 animals. 
Animals were weighed and their tails marked, allowing for later identification. 
Mice were injected IP with either saline or the NEP inhibitor phosphoramidon 
at a dose of 30mg/kg in a maximal volume of 0.1ml. Immediately following 
the IP injection, mice were SC injected with either with 25nmol/kg of PP or 
saline and allowed to return to their cage of origin with free access to water. 
Animals were then culled at 45 or 90 minutes post injection by inhalation of 
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carbon dioxide (a schedule 1 method). Once the animals had been culled, 
cardiac puncture was performed by inserting a 27 gauge needle attached to 
1 ml syringe (heparinised using a 100 I.U/ml heparin solution) into the chest 
cavity and puncturing the heart muscle, and blood removed.  
Blood samples were dispensed into 1ml microtubes containing 20µl Trasylol 
(Nordic Pharma, UK). The tubes were then spun in a microcentrifuge for 10 
minutes at 3000g at room temperature. The plasma supernatant was 
collected and stored in microtubes at -80ºC until assay for PP. 
2.3.4.6 Radioimmunoassay (RIA) of PP plasma samples  
RIA relies on the competition between radioactively labelled ligand and non-
radioactively labelled ligand for a fixed number of specific antibody binding 
sites. The radioactive label used for the RIAs described in this thesis was 
iodine-125 (I125). In an RIA, the amount of labelled peptide and antibody are 
at a constant concentration in each tube. As the amount of unlabelled 
peptide in a tube is increased (from samples or standards), the amount of 
labelled peptide which binds to the antibody is reduced. Separation of 
unbound (free) and bound labelled peptide and counting the proportion of 
labelled peptide in each fraction in a gamma-counter enables differentiation 
of the percentage of labelled peptide that has bound to the antibody. A 
standard curve is established by using known concentrations of unlabelled 
peptide (standard) to calculate the percentage of labelled peptide bound for 
each concentration of unlabelled peptide. Concentrations of the peptide in 
samples can then be determined by interpolation.  
The method of separation used in the PP RIA was charcoal absorption. The 
charcoal was dextran coated to prevent the larger antibody-peptide 
complexes entering the pellet. Free labelled peptide is bound in the charcoal 
pellet and is separated from the antibody-bound labelled peptide by 
centrifugation. Tubes were centrifuged at 2500rpm at 4ºC for 20 minutes 
immediately following addition of dextran-coated charcoal (6mg/tube). The 
supernatant containing the antibody-peptide complex was aspirated and 
placed into an empty tube. Both pellet and supernatant were counted in a 
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gamma-counter (model NE1600, Thermo Electron Corporation) to determine 
percentage of labelled peptide bound to the antibody.  
PP plasma levels were measured using established methods (Adrian et al., 
1976). Anti-PP antibody was raised in rabbits against human PP and the 
radiolabelled PP was prepared by Professor Ghatei by the Bolton and Hunter 
Method. The RIAs were performed in 0.06M phosphate buffer (54mM 
Na2HPO4, 6mM KH2PO4, 10mM EDTA, 8mM NaN3, 0.1% (v/v) bovine serum 
albumin (BSA) pH7.4 ± 0.1) and were incubated for 3 days at 4˚C before 
separating using activated charcoal. 
2.3.5 Meprin beta  
2.3.5.1 PP and PP analogues incubation with meprin beta 
The effect of meprin beta on PP and PP analogues was investigated as 
described in section 2.3.2.2, but with human recombinant meprin beta 
enzyme purchased from R&D systems (Minneapolis, USA) used instead of 
KBB membrane. Previously published experiments on meprin beta 
determined that 200ng of meprin beta in 10µl may be effective at breaking 
down 2 nmol of peptide (Butler et al., 1987). I therefore used this amount of 
meprin beta to examine its effects on PP. Meprin beta was activated as 
directed by R&D system protocol and then subsequently diluted with 50mM 
TRIS-HCL buffer (pH 7.5) and divided into 200ng aliquots (200ng in 10µl). A 
5nmol vial of freeze dried PP was reconstituted in 300µl of 50mM Tris–HCl 
buffer (pH7.5). Two nmol of peptide solution in 120µl was then added to 2 
microtubes and either 10µl of buffer or 10µl (200ng) of meprin beta added 
and mixed.  
A 30 minute incubation of 2 nmol PP with 200ng meprin beta resulted in 
approximately 50% of PP being broken down. Subsequent experiments were 
therefore incubated for 30 minutes. PP and each PP analogue were 
incubated with meprin beta as described above in three separate 
experiments to allow an SEM to be calculated for % breakdown. 
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2.3.5.2 MALDI-TOF MS analysis 
PP was incubated with meprin beta as described in section 2.3.5.1. 
Following centrifugation, 110µl of supernatant was dried down using a speed 
vac savant (Thermo, speed/vac concentrator, SPD 2010) at room 
temperature for 30 minutes until 5µl of supernatant remained. This was then 
frozen at -20ºC and sent to Bachem for analysis by MALDI-TOF MS. 
2.3.5.3 Reverse phase HPLC analysis 
PP, PP analogues and GLP-1 meprin beta incubations were analysed by 
reverse phase HPLC as described in section 2.3.2.4.  
2.3.6 Statistical analysis 
The results from acute feeding and plasma breakdown studies were 
compared using a one-way ANOVA with post hoc Bonferroni test. The 
breakdown of PP and PP analogues was examined by comparing the area 
under the curve of the peptide with enzyme/membrane to the same 
incubation without enzyme/membrane. Enzymatic breakdown experiments 
were performed a minimum of three times for each peptide and the mean 
percentage breakdown and S.E.M calculated. An n of three was choosen to 
give an indication of breakdown, but it is understood that a larger n number 
would decrease the S.E.M and increase the reliability of the results.The 
significance compared to native PP was then calculated for each analogue 
using Student‟s T test. A p value of less than 0.05 was considered to be 
significant in all analyses. 
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2.4 Results 
2.4.1 The breakdown of native PP 
2.4.1.1 Breakdown of PP by KBB membrane 
Following the incubation of PP at 37ºC with KBB buffer alone for 30 minutes, 
a single peak with an identical elution time to that of freshly dissolved PP 
was detected. This single peak at a retention time of 26 minutes was also 
observed when PP was incubated with KBB membrane preparation for 
increasing amounts of time between 15 and 120 minutes (Figure 2.1). PP 
incubated with KBB for 15 minutes was broken down by 22%. At 45 minutes 
this had increased to 69% breakdown, and at 60 minutes to 88% (Figure2.1). 
By 120 minutes nearly all PP had been degraded (92%) (Figure 2.1). In 
addition to the reduction in size of the primary PP peak, a number of 
additional peaks with earlier retention times were observed. In total, twelve 
major UV-absorbing fractions could be resolved following incubation of PP 
with 1.5mg of KBB protein for 30 minutes. These fractions were observed at 
retention times of 9, 12, 13, 14, 15.5, 16, 17, 18, 21, 23, 24 and 25.5 minutes 
(Figure 2.1). Incubation of PP with KBB for 30 minutes produced 66 ±14% 
breakdown compared to PP incubated with reaction buffer under the same 
conditions. This time was subsequently used for PP analogue incubations.  
The NEP inhibitor phosphoramidon was added to a number of PP KBB 
incubations, to investigate what percentage of KBB breakdown of PP could 
be attributed to NEP. There was no difference in the HPLC elution profile 
between PP incubated with KBB in the presence of phosphoramidon or 
without phosphoramidon (Figure 2.2).  
Further analysis of PP incubated with KBB using MALDI-TOF MS indicated 
that there were a number of PP breakdown products detectable following a 
10 minute or 30 minute incubation with KBB.  A single peak with a mass to 
charge ratio of 4183M/Z was detected following incubation of PP with buffer 
for 0 minutes. This peak is consistent with the molecular weight of PP1-36. A 
number of additional peaks were observed after a 10 minute incubation of 
PP with KBB, shown in figure 2.3. The number of peaks detected by MALDI-
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TOF MS increased when the incubation time was increased to 30 minutes. 
At 10 minutes, peaks with mass to charge ratios of 2008, 2101, 4015 and 
4143M/Z were detected. These masses are consistent with PP and the PP 
fragments PP9-26, PP3-21, and PP3-36. At 30 minutes, peaks with mass to 
charge ratios of 1063, 2093, 2871, 4015 and 4143M/Z were detected. These 
masses are consistent with PP and the PP fragments PP18-26, PP23-36, PP3-21, 
PP3-27, and PP3-36 (Figure 2.3). 
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Figure 2.1 Representative HPLC chromatograms of 2nmols PP incubated with 1.5mg of KBB (black line) or with buffer (red line) at 
37ºC for A) 15 B) 30 C) 60 and D) 120 minutes.  Reactions were terminated with 5µl of 10%TFA and the supernatant injected onto 
HPLC with a Gemini C18 column and a gradient of 15- 55% ACN (green line) run over 30 minutes. 
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Figure 2.2 Representative HPLC chromatograms of 2nmols of PP incubated with 1.5mg of KBB (Black line) and an excess of 
phosphoramidon or with buffer (red line) at 37ºC for A) 15 B) 30 and C)120 minutes.  Reactions were terminated with 5µl of 
10%TFA and the supernatant injected onto HPLC with a Gemini C18 column and a gradient of 15-55% ACN (green line) run over 
30 minutes. 
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Figure 2.3 Representative MS chromatograms of PP incubated with 1.5mg of KBB for A) 10 minutes and B) 30 minutes at 37ºC.  
Reactions were terminated with 5µl 10%TFA and the supernatant concentrated using a speed vac concentrator and frozen and 
sent for MALDI-TOF MS analysis. The vertical axis represents percentage (%) and horizontal axis represents mass to charge ratio 
(M/Z). The arrows indicate the masses of possible PP fragments following breakdown by KKB membrane. 
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2.4.1.2 Breakdown of PP by DPPIV 
Following the incubation of PP at 37ºC with DPPIV buffer alone for 120 
minutes, a single peak with an HPLC elution time identical to that of freshly 
dissolved PP was detected (Figure 2.4). This single peak at a retention time 
of 29 minutes was also observed when PP was incubated with DPPIV 
enzyme for 120 minutes (Figure 2.4). Using HPLC there was no detectable 
difference between PP incubated with or without enzyme, and therefore no 
percentage breakdown could be calculated.  
Further analysis of PP incubated with DPPIV using MALDI-TOF MS 
indicated that the peptide eluting at the same position as native PP was not 
intact. A single peak was observed at a mass to charge ratio of 4183M/Z 
following incubation of PP with buffer. This peak is consistent with the 
molecular mass of PP1-36. The single peak detected by HPLC after a 120 
minute incubation of PP with DPPIV had a mass to charge ratio of 4014M/Z, 
as determined by MALDI-TOF (Figure 2.4). This mass is consistent with  
PP3-36. 
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Figure 2.4 Representative A) HPLC and B) MALDI-TOF MS chromatograms of PP incubated with 10mU of DPPIV enzyme at 37ºC 
for 120 minutes.  Reactions were terminated with 5µl of 10%TFA and the supernatant was either injected onto HPLC with a Gemini 
C18 column and a gradient of 31.5-33.5% ACN run over 35 minutes, or sent for analysis by MADLI-TOF MS. 
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2.4.1.3 Breakdown of PP by NEP 
Following the incubation of PP at 37ºC with NEP buffer alone for 30 minutes, 
a single peak with an elution time identical to that of freshly dissolved PP 
was detected. This single peak at a retention time of 25.5 minutes was also 
observed when PP was incubated with NEP enzyme for increasing amounts 
of time between 5-120 minutes (Figure 2.5). PP incubated with NEP for 5 
minutes was broken down by 27%. At 15 minutes this had increased to 35% 
breakdown, and at 45 minutes to 81%. By 120 minutes nearly all PP had 
been degraded (90%) (Figure 2.5). In addition, a number of additional peaks 
with earlier retention times were observed. In total, seven major UV-
absorbing fractions could be resolved following incubation of PP with 200ng 
of NEP enzyme for 30 minutes (Figure 2.5). These fractions were observed 
at retention times of 11, 13.5, 15.5, 17, 21, 22 and 24.5 minutes (Figure 2.5) 
Incubation of PP with NEP for 30 minutes produced 52±5.7% breakdown 
compared to PP incubated with reaction buffer under the same conditions. 
This time was subsequently used for PP analogue incubations.  
Under the standard conditions (30 minute incubation at 37ºC) the addition of 
the NEP inhibitor phosphoramidon in excess prevented any breakdown of 
PP by NEP (Figure 2.6). During an extended incubation of PP with NEP (120 
minute incubation at 37ºC) breakdown was reduced to 20% compared to    
90% without inhibitor (Figure 2.6).  
Further analysis of PP incubated with NEP using MALDI-TOF MS indicated 
that there were a number of breakdown products of PP detectable following 
a 15 or 45 minute incubation with NEP.  A single peak with a mass to charge 
ratio of 4183M/Z was detected following incubation of PP with buffer at both 
time points examined. This peak is consistent with the molecular weight of 
PP1-36.   
A number of additional peaks were observed after a 15 minute incubation of 
PP with NEP, shown in figure 2.7. The number of peaks detected by MALDI-
TOF MS increased when the incubation time was increased to 45 minutes. 
At 15 minutes, peaks with mass to charge ratios of 803, 1026 and 1324M/Z 
were detected. These masses are consistent with the PP fragments PP30-35, 
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PP20-27, and PP9-20. At 45 minutes, peaks with mass to charge ratios of 803, 
1026, 1049 and 1324M/Z were detected. These masses are consistent with 
PP and the PP fragments PP30-35, PP20-27, PP29-36 and PP9-20 (Figure 2.7).  
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Figure 2.5 Representative HPLC chromatograms of 2nmols PP incubated with 200ng NEP (black line) or buffer (red line) at 37ºC 
for A) 15 B) 30 C) 60 and D) 120 minutes.  Reactions were terminated with 5µl of 10%TFA and the supernatant injected onto HPLC 
with a Gemini C18 column and a gradient of 15-55% ACN (green line) run over 30 minutes. 
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Figure 2.6 Representative HPLC chromatograms of 2nmols PP incubated with 200ng NEP and an excess of phosphoramidon  
(black line) or with buffer (red line) at 37ºC for A) 15 B) 30 and C) 120 minutes.  Reactions were terminated with 5µl of 10%TFA and 
the supernatant injected onto HPLC with a Gemini C18 column and a gradient of 15-55% ACN (green line) run over 30 minutes. 
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Figure 2.7 Representative MS chromatograms of 2nmols of PP incubated with 200ng NEP for A) 15 minutes and B) 45 minutes at 
37ºC.  Reactions were terminated with 5µl 10%TFA and the supernatant concentrated using a speed vac concentrator and frozen 
and sent for MALDI-TOF MS analysis. Vertical axis represents percentage (%) and the horizontal axis represents mass to charge 
ratio (M/Z). The arrows indicate the masses of possible PP fragments following breakdown by NEP. 
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2.4.1.4 Breakdown of PP by Meprin Beta 
Following the incubation of PP at 37ºC with meprin beta buffer alone for 30 
minutes, a single peak with an elution time identical to that of PP freshly 
dissolved was detected. This single peak at a retention time of 25.5 minutes 
was also observed when PP was incubated with meprin beta enzyme for 
increasing amounts of time between 5-120 minutes (Figure 2.8). PP 
incubated with meprin beta for 5 minutes caused limited breakdown 0.9%. At 
15 minutes this had increased to 39% breakdown, and at 45 minutes this had 
further increased to 65% (Figure 2.8). By 120 minutes nearly all PP had been 
degraded (92%) (Figure 2.8). In addition, a number of additional peaks with 
earlier retention times were observed. In total 4 major UV-absorbing fractions 
could be resolved following incubation of PP with 200ng of meprin beta 
enzyme for 30 minutes (figure 2.8). These fractions were observed at 
retention times of 15, 15.5, 19.5, and 25 minutes. PP, when incubated with 
meprin beta for 30 minutes, produced 50 ±8.33% breakdown compared to 
PP incubated with reaction buffer under the same conditions. This time was 
subsequently used for PP analogue incubations.  
Further analysis of PP incubated with meprin beta using MALDI-TOF MS 
indicated that there were a number of breakdown products of PP detected 
following a 15 minute and 30 minute incubation with meprin beta.  A single 
peak was observed at a mass to charge ratio of 4183M/Z following 
incubation of PP with buffer at both time points examined. This peak is 
consistent with the molecular weight of PP1-36. A number of additional peaks 
were observed after a 15 minute incubation of PP with meprin beta, shown in 
figure 2.9. However, unlike PP incubations with NEP and KBB or DPPIV, 
incubation of meprin beta with buffer alone produced a number of peaks 
making the chromatograms of PP with meprin beta difficult to interpret 
(Figure 2.9). At 15 minutes peaks with mass to charge ratios of 1481, 1705, 
2093 and 3260M/Z were detected. These masses are consistent with the PP 
fragments PP26-36, PP23-35, PP3-21 and PP10-36. At 30 minutes, peaks with 
mass to charge ratios of 1704, and 3483M/Z were detected. These masses 
are consistent with the PP fragments PP23-35, and PP4-33 (Figure 2.9). 
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Figure 2.8 Representative HPLC chromatograms of 2nmols of PP incubated with 200ng meprin beta (black line) or with buffer (red 
line) at 37ºC for A) 15 B) 30 C) 60 and D) 120 minutes.  Reactions were terminated with 5µl of 10%TFA and the supernatant 
injected onto HPLC with a Gemini C18 column and a gradient of 15-55% ACN (green line) run over 30 minutes.  
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Figure 2.9 Representative MS chromatograms of 2nmols of PP incubated with 200ng meprin beta for A) 15 minutes and B) 45 
minutes at 37ºC.  Reactions were terminated with 5µl 10%TFA and the supernatant concentrated using a speed vac concentrator 
and frozen and sent for MALDI-TOF MS analysis. Vertical axis represents percentage (%) and the horizontal axis represents mass 
to charge ratio (M/Z). The arrows indicate the masses of possible PP fragments following breakdown by meprin beta.
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2.4.2 The prevention of PP breakdown in vivo  
2.4.2.1 The effects of PP administration in combination with inhibition 
of DPPIV on the food intake of C57/BL6 mice 
PP significantly reduced food intake compared to saline at 0-1 hour; the 
DPPIV inhibitor valine pyrolidide (VP) did not significantly affect food intake 
when given with saline compared to saline alone (Saline 1.0 ±0.02grams, PP 
0.55±0.04grams (p=≤0.001), VP 0.8±0.06grams). However, when PP was 
administered in combination with VP it significantly inhibited food intake 
when compared to saline control but significantly increased food intake when 
compared to PP alone (Saline 1.0 ±0.02grams, PP 0.55±0.04grams 
(p=≤0.001), PP+VP 0.75±0.03grams (p=≤0.01 and p=≤0.05)). There were no 
other significant effects on food intake at any other time-points where it was 
measured (Figure 2.10).  
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Figure 2.10 The effect of SC administration of PP (50nmol/kg) with the 
DPPIV inhibitor valine pyrolidide (VP) (75mg, IP), saline or VP alone on food 
intake in C57/BL6 mice fasted overnight A) 0-1 hour post injection, B) 1-2 
hours post injection, C) 4-8 hours post injection and D) 8-24 hours post 
injection. PP and PP with inhibitor compared to saline (black *) or compared 
to PP (red *) using one-way ANOVA with Bonferroni post hoc test *p≤0.05, 
**p≤0.01,or  *** p≤ 0.001 (n=8-10). 
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2.4.2.2 The effects of PP administration in combination with inhibition 
of NEP on the food intake of C57/BL6 mice 
PP significantly reduced food intake compared to saline at 0-1 hour; the NEP 
inhibitor phosphoramidon (P) did not significantly affect food intake when 
given with saline compared to saline alone (Saline 1.03 ±0.05grams, PP 
0.54±0.06grams (p=≤0.001), Phosphoramidon 0.92±0.07grams). When PP 
was administered in combination with P, it significantly inhibited food intake 
when compared to saline control (Saline 1.03 ±0.06grams and PP+P 
0.69±0.07grams (p=≤0.01)). There were no other significant effects on food 
intake at any other time-points where it was measured (Figure 2.11).  
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Figure 2.11 The effect of SC administration of PP (150nmol/kg) with the 
NEP inhibitor phosphoramidon (P) (1000mg, IP), saline or P alone on food 
intake in C57/BL6 mice fasted overnight A) 0-1 hour post injection, B) 1-2 
hours post injection, C) 4-8 hours post injection and D) 8-24 hours post 
injection. PP and PP with inhibitor compared to saline using one-way 
ANOVA with Bonferroni post hoc test **p≤0.01, *** p≤ 0.001 (n=8/10). 
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2.4.2.3. The effects of inhibition of NEP on the plasma levels of PP in 
C57/BL6 mice following SC administration 
Following a SC injection of PP in combination with an IP injection of either 
saline or the NEP inhibitor phosphoramidon plasma levels of PP were 
measured at 45 and 90 minutes post injection in C57/BL6 mice (Figure 2.12). 
At 45 minutes PP levels had risen to 11170±2237pmol/L in combination with 
saline and 30499±2801pmol/L in combination with phosphoramidon. The 
combination of PP with inhibitor significantly increased plasma PP levels 
compared to PP alone (p=≤0.01). At 90 minutes post injection, plasma PP 
levels had decreased from 45 minute levels to 5576±367pmol/L. Ninety 
minute plasma PP levels had also decreased from 45 minute levels when 
combined with a NEP inhibitor to 13938±668pmol/L. However plasma PP 
levels were still significantly higher in mice which received phosphoramidon 
than those which received saline (p=≤0.001) (Figure 2.12).  
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Figure 2.12 The plasma levels of PP following SC administration of PP 
(25nmol/kg) in combination with either saline or the NEP inhibitor 
phosphoramidon (30mg, IP) in male C57/BL6 mice.  Following SC injection 
of peptide and IP injection of saline or inhibitor, mice were returned to their 
cages and blood collected via cardiac puncture at A) 45 and B) 90 minutes. 
Plasma levels were compared using a one-way ANOVA with Bonferroni post 
hoc test (**=p≤0.01, ***=p≤0.001) (n=3). 
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2.4.3 The breakdown of PP analogues 
2.4.3.1 The breakdown of PP analogues by KBB 
Following the incubation of PP analogues at 37ºC with KBB buffer alone for 
30 minutes, a single peak with an identical elution time to that of each freshly 
dissolved PP analogue was detected. This single peak at a retention time of 
24 minutes was also observed when the PP analogues were incubated with 
KBB membrane preparation for 30 minutes (Figure 2.13). GLP-1 was used 
as a positive control as it is known to be susceptible to a number of 
degradative enzymes found in the KBB (Stephenson and Kenny, 1987b; 
Stephenson and Kenny, 1987a; Vanneste et al., 1988). The KBB broke down 
73±5.3% of GLP-1 (Figure 2.17). 
There was no significant difference between the percentage breakdown of 
PP and PP analogues Val 30 and Phe 30 and Asn 30 (PP, 66±14%, Val 30  
68±2% Phe 30 66±2.8 % and Asn 30 65±5%) (Figure 2.13, Table 2.1). The PP 
analogue Lys 30 was broken down by 85±5% when incubated with KBB 
(Figure 2.13). The PP analogues Glu 30 and Cys 30 had improved resistance 
to breakdown by KBB than PP. However, this effect did not reach statistical 
significance (Glu 30 30±7% and Cys 30 47±3.5%) (Figure 2.13). 
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Figure 2.13 Representative HPLC chromatograms of PP analogues A) Val 30 
B) Phe 30 C) Asn 30 D) Lys 30  E) Glu 30  and F) Cys 30 incubated with 1.5mg 
of KBB at 37ºC  for 30 minutes. PP analogues incubated with KBB are 
represented with a black line, and analogues incubated with buffer with a red 
line. Reactions were terminated with 5µl of 10%TFA and the supernatant 
injected onto HPLC with a Gemini C18 column and a gradient of 15-55% 
ACN (green line) run over 30 minutes.  
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2.4.3.2 The breakdown of PP analogues by DPPIV 
As PP could not be separated from PP3-36 using reverse phase HPLC, 
analysis of PP analogues, breakdown by DPPIV was investigated using 
MALDI-TOF MS. The two analogues investigated were PP Ala 0 and PP 2-36 
When PP Ala 0 and PP 2-36 were incubated with DPPIV for 120 minutes at 
37ºC the mass to charge ratios detected by MALDI-TOF MS were consistent 
with the full length PP analogues (PP Ala 0 4253M/Z and PP 2-36 4111KM/Z) 
(Figure 2.14).  
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Figure 2.14 Representative MALDI-TOF MS chromatograms of PP analogues A) Ala 0 and B) PP 2-36 incubated with 10mU of 
DPPIV enzyme at 37ºC for 120 minutes. Reactions were terminated with 5µl of 10%TFA and the supernatant sent or MALDI-TOF 
MS analysis. The arrows indicate the masses of uncleaved PP analogues Ala 0 and PP 2-36 following incubation with DPPIV. 
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2.4.3.3 The breakdown of PP analogues by NEP 
Following the 30 minute incubation of PP analogues at 37ºC with NEP buffer, 
a single peak with an elution time identical to that of each PP analogue 
freshly dissolved was detected. This single peak at a retention time of 24 
minutes was also observed when the PP analogues were incubated with 
NEP enzyme for 30 minutes (Figure 2.15). GLP-1 was used as a positive 
control as it is known to be susceptible to NEP (Hupe-Sodmann et al., 
1995a). NEP broke down 75±9% of GLP-1, higher than the percentage 
breakdown observed for PP (Figure 2.17). 
There was no significant difference between the percentage breakdown of 
PP and PP analogue Lys 30 (PP, 52±5.7%, and Lys 30 68±2%) (Figure 2.15, 
Table 2.1). The PP analogues Phe 30 and Cys 30 were less susceptible to 
breakdown by NEP than PP under the same conditions. However, this did 
not reach statistical significance (PP, 52±5.7%, Phe 30 36±3 % and Cys 30 
27±7.2%) (Figure 2.15). The PP analogues Val 30 Asn 30 and Glu 30  had 
statistically significant improvements in their resistance to breakdown by 
NEP when compared to PP (PP, 52±5.7%, Val 30 16±6% (p≤0.05), Asn 30 
32±0.6% (p≤0.05 and Glu 30 13±1.9% (p≤0.01))(Figure 2.15). 
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Figure 2.15 Representative HPLC chromatograms of PP analogues A) Val 
30 B) Phe 30 C) Asn 30 D) Lys 30  E) Glu 30  and F) Cys 30 incubated with 
200ng of NEP  at 37ºC  for 30 minutes. PP analogues incubated with NEP 
are represented with a black line, and analogues incubated with buffer with a 
red line. Reactions were terminated with 5µl of 10%TFA and the supernatant 
injected onto HPLC with a Gemini C18 column and a gradient of 15-55-% 
ACN (green line) run over 30 minutes. 
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2.4.3.4 The breakdown of PP analogues by Meprin beta 
Following the incubation of PP analogues at 37ºC with meprin beta buffer 
alone for 30 minutes, a single peak with an elution time identical to that of 
each PP analogue freshly dissolved was detected. This single peak at a 
retention time of 25 minutes was also observed when the PP analogues 
were incubated with meprin beta for 30 minutes (Figure 2.16). GLP-1 was 
used as a positive control as it is known to be unstable and susceptible to a 
number of degradative enzymes found in the kidney brush borders 
(Stephenson and Kenny, 1987b; Stephenson and Kenny, 1987a; Vanneste 
et al., 1988). Meprin beta broke down 44±13.2% of GLP-1, slightly lower than 
the percentage breakdown observed for PP (Figure 2.17). 
There was no significant difference between the percentage breakdown of 
PP and PP analogues Cys 30 and Asn 30 (PP, 52±5%, Cys 30 61±4.5% and 
Asn 30 42±10.2%) (Figure 2.16, Table 2.1). The PP analogues Lys 30 and Val 
30 had significantly decreased resistance to breakdown compared to PP 
when incubated with meprin beta (PP, 52±5%, Lys 30 73±5%, and Val 30 
72±2.8%,(p≤0.05)) (Figure 2.16). The PP analogues Glu 30 and Phe 30 had 
significantly improved resistance to breakdown by meprin beta than PP (PP, 
52±5%, Glu 30 32±3.7% and Phe 30 34±3.6%, (p≤0.01)) (Figure 2.16). 
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Figure 2.16 Representative HPLC chromatograms of PP analogues A) Val 
30 B) Phe 30 C) Asn 30 D) Lys 30  E) Glu 30  and F) Cys 30 incubated with 
200ng of meprin beta at 37ºC  for 30 minutes. PP analogues incubated with 
meprin beta are represented with a black line, and analogues incubated with 
buffer with a red line. Reactions were terminated with 5µl of 10%TFA and the 
supernatant injected onto HPLC with a Gemini C18 column and a gradient of 
15-55-% ACN (green line) run over 30 minutes. 
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Figure 2.17 Representative HPLC chromatograms of GLP-1 with A) KBB 
membrane B) 200ng NEP and C) 200ng Meprin beta at 37ºC for 30 minutes. 
GLP-1 incubated with enzyme or membrane is represented with a black line, 
and GLP-1 incubated with buffer with a red line. Reactions were terminated 
with 5µl of 10%TFA and the supernatant injected onto HPLC with a Gemini 
C18 column and a gradient of 15-55-% ACN run over 30 minutes. 
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Table 2.1 The percentage breakdown of PP analogues with amino acid substitutions at position 30 following incubation with KBB, 
NEP or meprin beta. Breakdown was calculated by comparing the area under the curve of peptide with and without enzyme/ 
membrane (n= 3). Red indicates percentage breakdown higher than PP, blue indicates breakdown lower than PP *p≤0.05, **p≤0.01 
compared to PP using Student‟s T test. 
 
PP/ 
Analogue 
KBB NEP Meprin beta 
 
% Breakdown 
 
SEM 
 
% Breakdown 
 
SEM 
 
% Breakdown 
 
SEM 
PP 66 14 52 5.7 52 5 
Val 30 68 2 16* 6 72 2.8 
Phe 30 66 2.8 36 3 34** 3.6 
Asn 30 65 5 32* 0.6 42 10.2 
Lys 30 85 5 68 2 73 5 
Glu 30 30 7 13** 1.9 32** 3.7 
Cys 30 47 3.5 27 7.2 61 4.5 
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2.5 Discussion 
2.5.1 The breakdown of PP 
The studies described in this chapter suggest that PP is a broken down via 
enzymes present on the KBB membrane. The specific KBB membrane 
enzymes investigated were DPPIV, NEP and meprin beta. These enzymes 
were chosen due to their involvement in the breakdown of other regulatory 
peptides, including other gut hormones (Medeiros and Turner, 1994a; 
Medeiros and Turner, 1994b; Mentlein et al., 1993a; Ahren et al., 2002; 
Drucker et al., 1997; Hupe-Sodmann et al., 1995; Kieffer et al., 1995; 
Mentlein, 1999). In particular, DPPIV, and NEP are known to have a role in 
the breakdown of PYY. PP and PYY are closely related; they differ by only 4 
amino acids and share the PP-fold structural motif (Medeiros and Turner, 
1994a; Medeiros and Turner, 1994b; Mentlein et al., 1993a; Cerda-Reverter 
and Larhammar, 2000; Larhammar, 1996a; Tatemoto et al., 1982; Nygaard 
et al., 2006). The results from section 2.3 suggest that PP is a substrate for 
all the enzymes investigated.  
The KBB membrane was used as the initial method of investigating PP 
breakdown due to the high number of degradative enzymes located there 
(Bond et al., 1986; Carmago et al., 2002; Oneda et al., 2008; Bai, 1993; 
Vanneste et al., 1988). Previous work indicated that PYY is broken down by 
NEP and DPPIV from the KBB (Vanneste et al., 1988; Mentlein et al., 1993a; 
Mentlein et al., 1993b; Medeiros and Turner, 1994a). PP was broken down 
by enzymes on the KBB: 22% of the PP was broken down following 15 
minute incubation with KBB membrane, and by 120 minutes there was 
almost complete breakdown of PP (98%).  
MALDI-TOF MS indicated that PP had been cleaved at a number of positions 
after 10 or 30 minutes incubation with KBB.  PP fragments 3-21 and 3-35 
(2101M/Z and 4015M/Z) are the fragments that might be expected if PP was 
broken down by DPPIV, which cleaves the first two amino acids of small 
peptides with an Ala or Pro at position P1 and a hydrophobic amino acid at 
position P2 (Mentlein, 1999; Durinx et al., 2000; Lambeir et al., 2003). PP 
meets these requirements and is therefore potentially a good substrate for 
109 
 
DPPIV. It is possible that the DPPIV enzyme cleaves at position 2-3 first as 
this part of the PP amino acid sequence is on the end of the amino acid 
chain and is therefore putatively more exposed than the rest of the sequence 
(Blundell et al., 1981; Glover et al., 1983). This initial cleavage will disrupt 
tertiary structure of PP; the hair pin structure (PP-fold) of PP is created by 
interactions between the side chains of the proline helix (amino acids 1-8) 
and the side chains of the amino acids of the alpha helix (amino acids 15-32) 
(Li et al., 1992; Blundell et al., 1981; Cerda-Reverter and Larhammar, 2000; 
Glover et al., 1983). Specifically, the residues Pro 2 and Tyr 27, Pro 5 and 
Leu 24, Pro 8 and Met 17 and Pro 8 and Tyr 20 interact to stabilise the 
structure of PP (Blundell et al., 1981; Glover et al., 1983). The removal of the 
Pro at position 2 would therefore likely weaken the tertiary structure and 
might make the molecule susceptible to breakdown by other enzymes.  
Figure 2.18 is a flowchart illustrating a putative sequence of KBB enzymatic 
breakdown of PP. Once the initial cleavage is made by DPPIV between 
amino acids 2 and 3, PP3-36 may then be cleaved by NEP, meprin beta or 
other, as yet unknown enzymes, to generate the fragments 3-21, 23-36, 3-27 
and 9-26.  Fragments 3-21 and 9-26 are detected after only 10 minutes 
incubation, and therefore are likely to be generated most rapidly after the 
initial cleavage, and may represent the major breakdown fragments of PP3-36. 
Fragment 18-26 is only observed following 30 minutes incubation with KBB 
and cannot be produced from cleavage at only 1 site. It is therefore likely to 
be a secondary or a tertiary breakdown fragment. It may be that PP18-26 is 
produced following cleavage by either NEP or meprin beta at position 17-18.  
Amino acid 17 is a hydrophobic Met and therefore a substrate for both 
enzymes.  
When PP was incubated with KBB in the presence of excess NEP inhibitor 
phosphoramidon there was no difference in the percentage breakdown 
compared to control incubations. This was unexpected, as fragments 
consistent with PP being cleaved by NEP were detected in the KBB PP 
incubations. This may be due to the inhibitor itself being broken down by the 
enzymes present on the KBB membrane, or perhaps due to other enzymes 
playing a larger role in PP breakdown if NEP is inhibited.  
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The use of KBB membrane proved useful in investigating PP breakdown. 
However, following PP KBB incubations it is difficult to assess which enzyme 
produced which breakdown fragment, and the sequence in which breakdown 
fragments are generated. It was therefore necessary to investigate specific 
enzymes, such as DPPIV and NEP, which are present in the KBB and which 
were hypothesised to generate these breakdown products in isolation.   
 
Figure 2.18 A flowchart for the hypothesised sequence of PP breakdown 
when incubated with 1.5mg KBB protein at 37ºC for 10 or 30 minutes. Purple 
text indicates primary cleavage, red text indicates a secondary cleavage and 
orange text indicates tertiary cleavage. Grey text indicates an unknown 
mechanism and timeframe.  
The incubation of PP with KBB produced breakdown fragments consistent 
with PP being cleaved by the DPPIV enzyme. However, when PP was 
incubated with DPPIV and analysed using reverse phase HPLC, PP1-36 could 
not be resolved from PP3-36, despite the use of a very shallow gradient (31.5-
33.5% ACN over 35 minutes).  Further analysis of DPPIV breakdown of PP 
was thus performed using MALDI-TOF MS. The column used in the HPLC 
analysis separates by hydrophobicity. This suggests that PP1-36 and PP3-36 
have very similar hydrophobicity. The amino acids shown to be removed 
using MALDI-TOF MS were Ala and a Pro. These amino acids are not large 
and do not have large side groups, which explains why there was no 
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difference in hydrophobicity. The addition or removal of large or hydrophobic 
residues would potential change the isoelectric point of the molecule and 
potentially change the ratio of hydrophobic to non hydrophobic residues 
within the molecule. This would change how well the molecule is retained by 
the HPLC column and thus its retention time. An increase in the number of 
hydrophobic residues would ultimately increase the retention time of the 
molecule on the HPLC column, whereas an increase in the number of polar 
residues would reduce the retention time.  PP1-36 has an isoelectric point of 7, 
and a ratio of hydrophobic to non hydrophobic residues of 33%. PP3-36 has 
the same isoelectric point and a slightly higher ratio of hydrophobic to non 
hydrophobic residues of 35%. This very small difference makes it difficult to 
separate the two molecules via reverse phase HPLC.  
As previously discussed, the production of PP3-36 following the incubation of 
PP with KBB was thought to be likely due to the actions of DPPIV (Stewart 
and Kenny, 1984). DPPIV is also known to breakdown PYY, a closely related 
hormone from the same family (Grandt et al., 1993; Unniappan et al., 2006). 
It is possible that DPPIV provides the initial breakdown step, and that 
preventing breakdown by DPPIV could increase the length of time PP 
remains intact in circulation. The prevention of PP breakdown by DPPIV on 
the longevity of the anorectic effects of PP was thus investigated in fasted 
male C57/BL6 mice. The DPPIV inhibitor VP significantly enhanced the 
inhibition of food intake by PP at 0-1 hours, and appeared to extend the 
anorectic effects of PP to 1-2 hours, though the effect at this time point was 
not statistically significant. These data suggest that the prevention of 
breakdown of PP by DPPIV may increase the effectiveness of PP at 
reducing food intake. 
NEP is another enzyme that may be responsible for the breakdown of PP.  
Following incubation with KBB, PP fragments 9-26, 3-21, and 18-26 were 
generated. These fragments are consistent with cleavage by NEP. These 
fragments must be secondary or tertiary fragments; they cannot be produced 
from a single cut in the amino acid sequence, and in accord with this, most 
were detected in longer incubations. When PP was incubated with NEP 
enzyme alone, a number of breakdown fragments were identified using 
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HPLC and MALDI-TOF MS. The fragments generated were different to those 
produced by incubation with KBB. This may be due to the combination of 
enzymes present in the KBB working together to produce different 
breakdown fragments.  
Positions 30 and 21 appear susceptible to cleavage by recombinant NEP. 
The presence of the breakdown fragments 20-27 and 9-20 suggest NEP cuts 
the amino side of the hydrophobic Ala at position 21. However, positions 20 
(Tyr) and 21 (Ala) help to stabilise the tertiary structure of PP by the 
interaction of their side chains with the Pro at position 8. This makes 
substitutions difficult, as they may disrupt the tertiary structure. Changes at 
position 30, which has a limited role within the tertiary structure, may be a 
more useful position at which to substitute amino acids to make enzymatic 
resistant PP analogues. 
The effect of inhibiting NEP on the anorectic effects of PP was also 
investigated. It was observed that the addition of the NEP inhibitor 
phosphoramidon significantly enhanced the inhibition of food intake by PP at 
0-1 hours and appeared to extend its anorectic effects to 1-2 hours, though 
this effect did not achieve statistical significance. Inhibition of NEP 
significantly increased the levels of PP detected by RIA at both 45 minutes 
and 90 minutes after PP injection. At 45 minutes, animals which received 
phosphoramidon had plasma PP levels nearly three times higher than those 
animals which received a saline control. By 90 minutes, levels of PP had 
begun to decline in both sets of animals. However, animals which received 
phosphoramidon still had plasma PP levels double those of controls. This 
suggests that PP is broken down via NEP in vivo and that the prevention of 
NEP breakdown can significantly increase the persistence of PP in the 
plasma. Phosphoramidon has been shown to be a specific NEP inhibitor and 
has been used previously to investigate NEP both in vivo and in vitro (Oefner 
et al., 2000). When phosphoramidon was given at a large dose (1000mg) to 
fasted male C57/BL6 mice, food intake was increased at 1-2 hours. A much 
lower dose of phosphoramidon was therefore used in the plasma PP 
experiment (30mg) following a dose finding study (data not shown due to 
small n number), to avoid the confounding effects of these high doses.   
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The studies described in this chapter suggest that the enzyme meprin beta 
breaks down PP, but that it is less important than DPPIV and NEP. When PP 
was incubated with KBB, the majority of the breakdown fragments detected 
by MALDI-TOF MS could be attributed to either DPPIV or NEP. PP 
incubated with meprin beta for 30 minutes produced 50% breakdown and 
four breakdown peaks, when examined using HPLC. PP incubated with NEP 
under the same conditions produced 52% breakdown but seven breakdown 
peaks.  This suggests that although meprin beta breaks down PP; PP is a 
better substrate for NEP than it is for meprin beta.  
The incubations with meprin beta produced unexpected peaks with 
molecular weights suggesting they were not products of PP breakdown. 
Meprin beta incubated alone in buffer for 15 or 30 minutes resulted in a large 
amount of background noise on the MS chromatogram. This may be due to 
enzyme instability. Meprin beta may have been broken down by the 
temperature of the incubations (37ºC) or by the 10% TFA acid used to 
terminate the reaction. Those masses which corresponded to PP fragments 
indicated that, as previously suggested (Bond et al., 1986; Butler et al., 1987), 
meprin beta cleaves at amino acids which are either hydrophobic or which 
are flanked by hydrophobic amino acids. More PP fragments were detected 
using the MALDI-TOF MS following 15 minutes incubation than following 30 
minutes incubation. This is again unexpected as when PP was incubated 
with 200ng meprin beta for 15 minutes, only 39% breakdown was detected 
using HPLC. This increased to 50% when incubated for 30 minutes. A single 
similar fragment of PP was detected when PP was incubated with KBB that 
was also detected when PP was incubated with meprin beta. However, these 
two fragments differ by an amino acid. PP when incubated with KBB 
generated PP26-35 and when incubated with meprin beta it generated PP26-36. 
This last amino acid may have been cleaved in the KBB incubation by 
another enzyme.  
The experiments detailed in section 2.4 suggest that PP is broken down by 
enzymes located on the kidney brush border membrane, specifically the 
enzymes DPPIV, NEP and meprin beta. In experiments where enzyme 
inhibitors were used in combination with PP, the effects of the inhibition on 
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food intake in fasted male C57/BL6 mice and the plasma levels of PP were 
enhanced up to 2 hours. This suggests that the inhibition of PP breakdown 
will increase the anorectic effects of PP. Analogues of PP which have had 
susceptible amino acids substituted may therefore have greater enzymatic 
resistance and thus greater efficacy at reducing food intake in vivo compared 
to unmodified PP.  
2.5.2 The breakdown of PP analogues 
Analogues of PP were designed with amino acid substitutions at the N-
terminus to prevent breakdown by the enzyme DPPIV.  
The PP analogues PP2-36 and Ala 0 were shown to be resistant to the 
enzyme DPPIV. The addition of an amino acid (Ala) or removal of the first 
amino acid, Ala changes the position of the susceptible Pro at position P1. 
The addition or removal of an amino acid at the N terminus of peptides has 
previously been shown to help prevent breakdown by DPPIV (Mentlein, 1999; 
Druce et al., 2009). The amino acid Pro at position 2 is essential for the 
correct binding of PP to the hY4 receptor (Gehlert et al., 1996). Therefore, 
the prevention of cleavage at amino acid 2/3 should aid biological function. 
This suggests that any PP analogues with either an amino acid addition or 
substitution at the N-terminus may be more resistant to breakdown by DPPIV 
and therefore possibly more effective than PP at reducing food intake.  
PP analogues with amino acid changes at position 30 were designed to 
prevent breakdown by NEP. As described in section 2.5.1, amino acids 20, 
21 and 30 are sites thought to be susceptible to breakdown via NEP. 
However, substitutions to amino acids 20 and 21 would be predicted to 
compromise the correct folding of PP‟s tertiary structure (Blundell et al., 1981; 
Glover et al., 1983), and thus the ability of the analogues to bind to the Y4 
receptor. 
PP analogues with amino acid substitutions at position 30 were designed. 
Two replaced the hydrophobic Met with polar uncharged amino acids (Cys or 
Asn). Another two analogues exchanged the hydrophobic Met for alternative 
hydrophobic amino acids (Phe or Val). This was done to assess whether 
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different hydrophobic amino acids were more or less susceptible to NEP. 
The remaining two PP analogues replaced the hydrophobic Met with either 
an acidic (Glu) or a basic (Lys) amino acid at position 30.  
Substituting Met at position 30 for the basic amino acid Lys increased the 
percentage breakdown detected in both KBB and meprin beta incubations, 
and had no effect on breakdown by NEP. Lys is not present in the native PP 
sequence and only appears once in the sequences of NPY and PYY, at 
position 4 (Cerda-Reverter and Larhammar, 2000; Larhammar, 1996a). This 
may be due to the fact that it disrupts the tertiary structure of this group of 
peptides. In theory the removal of a hydrophobic amino acid and its 
replacement with a non-hydrophobic amino acid should have increased 
resistance to breakdown by both NEP and meprin beta (Hupe-Sodmann et 
al., 1995; Medeiros and Turner, 1994a; Turner et al., 2001; Roques et al., 
1993). However, the addition of a Lys may have changed the packing of the 
amino acids surrounding amino acid 30. Amino acids 15 to 32 form an alpha 
helix, and the addition of a Lys at position 30 may have disrupted the packing, 
or increased or decreased the turn within the helix (Blundell et al., 1981; 
Glover et al., 1983). This may have exposed specific amino acids that under 
normal conditions would have been protected by the packing of the structure 
to meprin beta and other enzymes on the KBB, and thus caused the 
increased breakdown.   
Changing the hydrophobic amino acid to a charged Lys had a detrimental 
effect on breakdown. However, the substitution of the Met at position 30 with 
the acidic amino acid Glu, decreased breakdown of the Glu30 analogue 
compared to PP in all three preparations. This effect was statistically 
significant for NEP and meprin beta. Aside from the difference in charge, Lys 
and Glu are similar in size, though Lys is longer than Glu. This difference in 
length may mean that Glu does not disrupt the packing of the side chains as 
much as Lys, therefore conferring resistance to breakdown by degradative 
enzymes without impairing the tertiary structure.  
Substituting a Phe at position 30 conferred some resistance to breakdown by 
the enzymes NEP and meprin beta. This was surprising, as both NEP and 
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meprin beta requires hydrophobic residues as substrates (Bond et al., 1986; 
Butler et al., 1987). The replacement of the hydrophobic Met at position 30 
for another hydrophobic amino acid would therefore have been predicted to 
have little effect on enzyme resistance. The phenol side group of the Phe 
amino acid may have impaired both NEP and meprin beta cleavage at this 
point, despite its hydrophobicity. The replacement of Met at position 30 with 
another hydrophobic residue (Val) had a different effect to replacement with 
Phe. PP analogue Val 30 had increased breakdown with meprin beta, and 
decreased breakdown when incubated NEP, but showed no change in 
breakdown profile when incubated with KBB membrane. Val is a smaller 
amino acid than Met, and also lacks the sulphur containing side chain of Met. 
This may mean that it decreases the turn in the alpha helix around position 
30, protecting it from breakdown by NEP (Blundell et al., 1981; Glover et al., 
1983). Meprin beta has a larger number of potential substrates in the PP 
molecule; it can cleave at hydrophobic amino acids and at those amino acids 
flanked by hydrophobic amino acids (Bond et al., 1986; Butler et al., 1987). 
This may mean that despite preventing breakdown at position 30 with the 
substitution of Met for Val, overall breakdown by meprin is increased 
because other hydrophobic amino acids or amino acids flanking hydrophobic 
amino acids are exposed to its actions.  
The PP analogues Cys 30 and Asn 30 had increased resistance to breakdown 
by NEP compared to native PP. This was expected, as the potential 
substrate amino acid was replaced with an uncharged polar amino acid.  
However, Cys or Asn at position 30 had limited effects on breakdown by 
either meprin beta or by the enzymes on the KBB membrane. This may be 
because of the greater number of potential targets for meprin beta, and the 
large number of possible enzymes on the KBB membrane (Butler et al., 
1987). Substituting a single amino acid may therefore have little effect on 
meprin beta or KBB resistance.  
In summary, a number of the PP analogues investigated in this section were 
shown to have increased resistance to breakdown by the KBB membrane 
preparation and by the enzymes DPPIV, NEP and meprin beta. Further 
analogues of PP could also be developed by combining amino acid 
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substitutions. This may confer resistance to multiple enzymes.  However, it is 
not known if these small amino acid substitutions compromise biological 
function. The substitution of multiple amino acids is more likely to impair 
binding to the Y4 receptor. Further investigation is therefore required into the 
ability of these analogues to both bind to the Y4 receptor and inhibit food 
intake in vivo.  
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Chapter 3 
 
Pancreatic Polypeptide 
Analogues: hY4 
Receptor Binding 
Affinity And Acute 
Effects On Food Intake 
In Mice. 
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3.1 Introduction 
Resistance to degradation by proteolytic enzymes is not the only 
consideration for the development of a peptide hormone drug. It has 
previously been reported that amino acid substitutions at specific sites in the 
oxyntomodulin molecule can prevent degradation by the enzymes DPPIV 
and neprilysin 24.11 (Druce et al., 2009). For this series of studies on 
oxyntomodulin analogues, in addition to the amino acid substitutions 
designed to aid resistance to enzymatic degradation, additional modifications 
were made to improve the molecule‟s affinity for the GLP-1 receptor. Other 
groups have used primary sequence modifications both to promote 
degradative enzyme resistance and to improve drug pharmacokinetic profiles 
(Tomita et al., 2008). Peptide analogues have been used to investigate 
structure-activity relationships for peptide hormones, including growth 
hormone releasing hormone (GHRH), CCK and somatostatin (Danho et al., 
1992; Rosenthal et al., 1983; Tang et al., 2009). The studies described in the 
previous chapter demonstrated that individual amino acid changes in the PP 
primary structure can aid resistance to the breakdown caused by tissue 
membranes, such as the kidney brush border, and by purified enzymes, such 
as neprilysin 24.11. Additional modifications to improve affinity for the human 
hY4 receptor could increase the potential of PP based drugs as anti-obesity 
treatments. 
3.1.1 Analogue development to increase the longevity effect on peptide 
receptor interaction 
Short chain peptides are generally considered to be more susceptible to 
breakdown by circulating and membrane bound endopeptidases than larger 
peptide chains, which often posses more stable tertiary and/or quaternary 
structures (Hupe-Sodmann et al., 1995b). The addition of extra residues to 
either the C-or N terminus of a peptide may therefore aid its resistance to 
breakdown by such enzymes. The main disadvantage of this method is that 
these additional  residues  may disrupt the overall tertiary structure of the 
peptide and consequently impair its ability to activate its receptor (Pauling et 
al., 1949). In the previous chapter, it was described how substituting specific 
amino acids in the PP sequence could confer relative resistance to 
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enzymatic breakdown. However, the effects of these substitutions on the 
binding affinity of these molecules for the hY4 receptor were not investigated. 
Modifications to the amino acid sequence may enhance or impair the binding 
of PP to other Y receptors. Y1 and Y5 receptors are mainly located in the 
brain (Parker and Herzog, 1999). Given the inability of PP to cross the blood 
brain barrier (Whitcomb et al., 1990),  binding to the Y1 and Y5 receptors is 
unlikely to result in PP analogues having biological side effects. However, 
the Y2 receptor is found in similar regions to the Y4 receptor (Dumont et al., 
1993) where there is a incomplete blood brain barrier. Any modifications 
made to the structure of PP which increased affinity for the Y2 receptor might 
therefore cause side effects, particularly given that Y2 receptor agonist 
administration can cause nausea (Le Roux et al., 2008). This would make 
drug development difficult due to compliance issues. It is therefore necessary 
to determine the effects of modifications to PP structure on both hY4 
receptor and hY2 receptor binding.  
3.1.2 Analogue development to increase the longevity of the anorectic 
effect of PP on food intake in male C57/BL6 mice  
The amino acid modifications made to improve resistance to degradative 
enzymes and improve affinity for the hY4 receptor were initially investigated 
in vitro. It is necessary to determine the effect of these modifications on PP 
activity in vivo; this can be assessed by determining the effect of the 
analogues on food intake. Amino acid modifications have been used 
previously to improve the anorectic effect of a peptide hormone efficacy 
(Druce et al., 2009) and to investigate structure activity relationships 
(Caporale et al., 2009; Danho et al., 1992; Rosenthal et al., 1983). PP 
inhibits food intake in a dose dependent manner for up to 4 hours post IP 
injection in mice (Asakawa et al., 1999; Kojima et al., 2007; Taylor and 
Garcia, 1985; Nakajima et al., 1994; Liu et al., 2008), and for up to 24 hours 
post IV infusion in humans (Batterham et al., 2003; Jesudason et al., 2007). 
A PP based drug treatment for obesity administered daily or weekly, would 
be a relatively easy treatment regimen for patients to comply with, and would 
have a lower cost than more frequently administered peptides. Therefore, 
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developing a PP analogue which reduced food intake for a longer period 
than unmodified PP may identify a potentially more effective obesity 
treatment.  
3.1.3 The development of PP analogue XPP and its circulating half life 
in rodents 
PP analogue XPP is more resistant to enzymatic degradation (Appendix IV) 
than unmodified PP. Analogue XPP has a number of amino acid 
substitutions which aid its enzymatic resistance. Amino acid changes may 
also have increased its plasma half life and consequently the longevity of its 
inhibitory effect on food intake.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
122 
 
3.2 Hypothesis and Aims 
PP has a high affinity for the Y4 receptor, and a limited affinity for other Y 
receptors (Parker et al., 2002). Amino acid substitutions at key sites 
throughout the PP molecule could help to improve its binding to the hY4 
receptor, and ultimately improve the utility of PP as an obesity treatment. The 
subcutaneous administration of native PP has a well characterised inhibitory 
effect on food intake in fasted mice (Asakawa et al., 1999; Asakawa et al., 
2003; Nakajima et al., 1994).  Comparing the effects of PP analogues on 
food intake to that of native PP will determine whether specific amino acid 
changes improve or impair bioactivity.  
Hypothesis: I hypothesise that the substitution of amino acids at key sites in 
the PP molecule to increase resistance to enzymatic degradation, (section 
2.4), and will generate specific PP analogues with a higher affinity for the 
hY4 receptor and a greater inhibitory effect on food intake in mice than native 
PP.  
Aims: 
1. To investigate the effect of extending the PP sequence at the 
N-terminus by a single amino acid and the substitution of amino 
acids at positions 17, 19, 23 and 30 on the binding affinity of 
PP analogues for  the hY4  and hY2 receptors. 
2. To compare the effect of these PP analogues on food intake in 
mice compared to native PP.   
3. To determine the circulating levels of a specific PP analogue, 
XPP, achieved following subcutaneous administration in mice 
and rats.  
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3.3. Materials and Methods 
3.3.1 Preparation of membrane from cells over-expressing human Y4              
(hY4) receptors 
Membrane preparations were made from the HEK 293T cells over 
expressing the hY4 receptor. Cells were gifted by Dr J Minnion. Cell 
membrane preparations were made from cells between passage numbers 15 
and 35. 
HEK 293T cells were cultured in Dulbecco‟s modified medium (DMEM, 
Invitrogen LTD, Paisley UK) supplemented with 10% foetal bovine serum 
(FBS) (Invitrogen LTD, Paisley UK) and 1% antibiotic (Penicillin (100units/ml) 
and Streptomycin (100µg/ml), Invitrogen LTD, Paisley UK). Medium was 
changed every 2-3 days and the cells sub-cultured when 70% confluent 
using a non-enzymatic cell dissociation buffer (Sigma-Aldrich).  The medium 
was removed from the flask and 2 ml cell dissociation buffer (Invitrogen LTD, 
Paisley UK) added.  Cells were incubated at room temperature until they 
detached from the flask.  Five millilitres of fresh medium was added to each 
flask and cells recovered by centrifugation for 5 minutes at 100g.  The cells 
were resuspended in fresh medium and transferred to a new flask at a 
dilution of 1:5. 
A minimum of 30 confluent, 175cm2 flasks were used for each membrane 
preparation. The culture medium was removed and the cells detached from 
the flasks using ice cold 0.02 M phosphate buffered saline (PBS) (Sigma-
Aldrich) and scraping.  Cells were centrifuged at 2000g for 5 minutes at 4˚C, 
the supernatants discarded and the pellets put onto ice.  Pellets were then 
resuspended in 20 ml of ice-cold 1mM HEPES buffer containing the enzyme 
inhibitors aprotinin (100KIU/mL), pepstatin (0.5µg/mL), antipain (0.5µg/mL), 
leupeptin (0.5µg/mL), benzamidine (0.1µg/mL) and SBTI (10µg/mL), and 
cells homogenised for 1 minute with an Ultra Turrax.  Homogenates were 
further centrifuged at 100000g for 30 minutes at 4oC.  Supernatants were 
discarded and pellets resuspended in homogenisation buffer (0.1M PBS) 
without sucrose using a hand-held Teflon homogeniser (Potter, Elvehjem).  
Finally, pellets were resuspended at a final protein concentration of 1-2 
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mg/ml and stored at -70oC. Protein concentration was measured using 
Bradford assay. A standard curve was set up using known concentrations of 
bovine serum albumin protein (Sigma–Aldrich) (0, 0.25, 0.5, 1.0, 1.5 mg/ml) 
and 0.1 mL was added to 3 mL of Bradford reagent. The solution (0.1ml) of 
purified hY4 receptors was also added to 3ml of Bradford reagent. All 
solutions were incubated at room temperature for 45 minutes. The 
absorbance of each solution at 595nm was measured using a 
spectrophotometer (WPA Biotech Photometer, UV 1101). A standard curve 
was then constructed using the correlation of the known absorbance values, 
and the protein content of the unknown samples interpolated from the 
standard curve.  
3.3.1.1 Receptor binding assay 
Analogues of PP were tested for their binding affinity for the hY4 receptor. 
The amino acid sequences of the PP analogues are shown in table 3.1. 
Assays were carried out in siliconised eppendorfs in assay buffer containing 
HEPES (0.02M), CaCl2 (5mM), and MgCl2 (1mM). The total volume was 
500µl per tube. A standard curve was constructed using known values of 
unlabelled peptide (200, 10, 2, 0.25 0.1, 0.05, 0.01, 0.001, 0.0001pmol). 
Each tube contained 1000 counts per second of radiolabelled PP (see 
section 3.3.1.1.1) and 10µl of hY4 membrane (1.67mg/ml). Tubes were 
incubated for 90 minutes at room temperature. They were then spun in a 
microcentrifuge at 1500g for 3 minutes, and the supernatant discarded. 
Pellets were then resuspended in 500µl assay buffer, spun as above, and 
the supernatant once again discarded. The resulting pellets were counted in 
a NE 1600  counter (NE Technology Ltd, Reading) for 240 seconds. The 
inhibition coefficient (IC50) was then determined for PP and each PP 
analogue tested. This was done by reading off the competition binding curve 
the concentration of unlabelled peptide which displaced 50% of the specific 
radiolabelled peptide. All curves were performed with points in triplicate. IC50 
values were calculated using Prism (Version 4) (GraphPad Software Inc.) 
and values represented as +/- SEM of the IC50. 
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3.3.1.1.1 Preparation of I125 pancreatic polypeptide label 
Synthetic human PP (Bachem UK Ltd.)  was iodinated using the Bolton and 
Hunter method (Bolton and Hunter, 1973). Briefly, 5 nmol PP in 50μl 0.1 M 
borate buffer (pH 8.2) was added to 1 mCi dried Bolton and Hunter reagent 
(Amersham International, UK). The reaction was incubated at room 
temperature for 90 mins and the iodinated peptide separated by reversed 
phase HPLC on a C18 (Waters, Milford, USA.) column using a 10-40% 
gradient of acetonitrile (AcN)/water/ (vol/vol) acidified with 0.1% trifloroacteic 
acid (TFA) over 90 minute. Purified fractions which bound with high affinity 
to PP antibodies with low non specific binding (NSB) were selected for use 
in the assays.  
3.3.2 Animal studies  
All animal procedures were approved by the British Home Office under the 
UK Animal (Scientific Procedures) Act 1986 (Project Licence 70/6402). 
Adult male C57/BL6 mice (Harlan) weighing 22-28g were maintained either 
in individual cages (feeding studies), or group housed in cages of up to 5 
animals (pharmacokinetics studies) under controlled temperature (21-23ºC) 
and lights (12:12 hour light dark cycle lights on at 0700). Adult male Wistar 
rats (Charles River) weighing 130-180g were maintained in group houses in 
cages of 5 animals under the same controlled conditions.   All animals were 
allowed ad libitum access to water and RM1 diet (Special Diet Services, 
Witham, UK) unless otherwise stated.  Animals were handled and received 
sham SC injections of saline on at least two occasions prior to study days in 
order to acclimatise them to the injection procedure. 
3.3.2.1 Acute feeding studies in mice 
Feeding studies were carried out during the early light phase (0800-1000) in 
mice fasted from 1600 the preceding day. Mice following a fast have a 
greater food intake than their non-fasted counterparts, and are therefore 
more likely to demonstrate an anorectic effect.  Peptides were administered 
subcutaneously (SC) in a maximum volume of 0.1 ml of saline. Animals were 
weighed and their body weight recorded before injection. After injection the 
mice were returned to their home cage with a known amount of food. Food 
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was reweighed at 1, 2, 4, 8 and 24 hours. Food was removed from the 
hopper, a visual inspection of the cage made to check for any food 
spillage/hoarding, and food weighed using balances accurate to 0.01 g.  
Mouse body weight was measured 24 hours post-injection.  All mice feeding 
studies were completed in conditions where external stressors were 
minimised, as stress is known to influence feeding behaviour (Marti et al., 
1994). A dose of 25nmol/kg was chosen as the starting dose for PP and its 
analogues as it has been shown to be effective at inhibiting food intake in 
previous studies (Asakawa et al., 1999; Liu et al., 2008). If 25nmol/kg of PP 
analogue was ineffective at reducing food intake the dose was increased 
until food intake was significantly inhibited, up to 500nmol/kg. The amino acid 
sequences of the PP analogues can be found in table 3.1. 
3.3.2.2 Pharmacokinetic studies (PK) 
Animals were injected with a maximal volume of 0.1ml SC using a 1ml 
syringe with a 30G needle (Insulin syringe) (Termuo, Elkton, USA). The 
volume injected was adjusted depending upon the weight of the animal so 
that each received 50nmol/kg. This dose was used as it has been shown to 
inhibit food intake in mice (Asakawa et al., 1999; Liu et al., 2008) and should 
enable plasma levels of PP or its analogues to be detected via 
radioimmunoassay (RIA) at all time points. 
3.3.2.2.1 Pharmacokinetics in mice 
Mice were housed in groups of up to 5 animals. Animals were weighed and 
their tails marked, allowing for later identification.  
Mice were injected SC with either 50nmol/kg of PP or the PP analogue XPP 
and allowed to return to their cage of origin with free access to food and 
water. Animals were then culled at 0, 5, 10, 20, 30 45, 90, 120 and 180 
minutes post injection by inhalation of carbon dioxide (a schedule 1 method). 
Once the animals had been culled, cardiac puncture was performed by 
inserting a 27 gauge needle attached to 1 ml syringe (heparinised using a 
100 I.U/ml heparin solution) into the chest cavity and puncturing the heart 
muscle, and blood removed. These time points were concentrated before 45 
minutes due to PP‟s short circulating half life of around 7 minutes (Adrian et 
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al., 1978) and to establish the peak plasma concentration of PP or its 
analogue following SC administration. Once a peak plasma level was 
detected the later time points (90, 120 and 180 minutes) were used to give 
an indication of the time taken for clearance from the plasma.  
Blood samples were dispensed into 1ml eppendorf tubes containing 20µl 
Trasylol (Nordic Pharma, UK). The tubes were then spun in a centrifuge (3-
18K SciQuip, Sigma, USA) for 10 minutes at 3000g at room temperature. 
The plasma supernatant was collected and stored in an eppendorf at -80ºC 
until assay. 
3.3.2.2.2 Pharmacokinetics in rats 
Male Wistar rats were anaesthetised with an intraperitoneal (IP) injection of 
Hypnorm/Hypnovel at a dose of 2.7ml/kg (0.315mg Fentanyl with 10mg 
fluanisone/5mg/ml midazolam). Animals were monitored regularly throughout 
the procedure to ensure the correct level of anaesthesia was maintained.  
Cannula tubing was prepared before the start of the cannulation. Portex 
tubing (internal diameter (ID) 0.86mm, outside diameter (OD) 1.27mm) was 
cut to 10 cm length. One end had a 1ml syringe with a 27 gauge needle 
attached to it. A 1ml syringe was filled with heparinised saline (100 I.U/ml) 
and attached to the needle. The other end of the tube was cut with a scalpel 
blade to create a bevelled edge.  
Once animals were anesthetised they were placed on a heat mat covered 
with a drape. The animal was orientated with its back on the mat and its 
head facing the person performing the cannulation. The skin from the neck to 
the paw on the right side was removed using scissors. Any peripheral fat was 
removed by blunt dissection. Blunt dissection was then used to clean the 
right jugular vein of fat and excess tissue until the vein was easily visible. 
The salivary gland was held out of the area of the vein using hemostats (Fine 
Science Tools, Heidelberg, Germany) and forceps (Fine Science Tools, 
Heidelberg, Germany) passed under the vein to remove any remaining 
connective tissue.  
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Ideally a 1cm section of vein was visible. A doubled up piece of cotton thread 
was passed under the vein, and cut to provide 2 threads. One of these 
threads was moved to the rostral end of the vein and tied tightly to 
completely occlude the vein. The other thread was moved caudally towards 
the heart and a loose knot made. The vein was put under slight tension by 
pulling the thread occluding the vein and a small cut was made in the vein 
between the 2 pieces of thread. The pre-prepared tubing was inserted into 
the cut, and the loosely knotted thread tightened to hold the cannula in place. 
The needle was gentle drawn back to allow approximately 100µl of blood to 
fill the tube and then 100µl of heparinised saline injected to ensure that the 
vein had been correctly cannulated. 
When blood samples were taken, the saline filled syringe was replaced with 
an empty 1ml syringe. This was gently drawn back to remove 200ul of blood. 
Once this was collected the saline filled syringe was reattached, ensuring 
there were no air bubbles in the tubing, and 50µl of heparinised saline was 
then injected to help prevent blood clotting within the cannula. Once the time 
zero blood sample was taken animals were SC injected with 50nmol/kg or 
PP or analogue XPP, and blood samples taken at  10, 20, 30, 45, 60, 120 
and 180 minutes. 
Blood samples were dispensed into 1ml eppendorf tubes as described in 
section 2.3.3.2.1. The plasma supernatant was collected and stored in an 
eppendorf at -80ºC until assay. 
Once all the necessary samples had been collected the animals were 
terminally anesthetised using 1ml (IP) of 30mg/kg Pentobarbitone (Animal 
Care Ltd).  
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2.3.4 Statistical Analysis 
The results from acute feeding studies were compared using a one-way 
ANOVA with post hoc Bonferroni test. Plasma pharmacokinetic studies were 
analysed using the two-way ANOVA with Bonferroni post hoc test comparing 
the two treatments groups at each time point. A repeated measures one-way 
ANOVA with post hoc Bonferroni test was also used to compare time points 
within the same treatment group. Receptor binding studies were completed a 
minimum of 3 times for each peptide and the mean and S.E.M IC50 
calculated, and significance compared to native PP calculated using 
Student‟s T test. A p value of less than 0.05 was considered to be significant 
in all analyses. 
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PP/PP Analogue 
 
Amino acid sequence 
PP   A-P-L-E-P-V-Y-P-G-D-N-A-T-P-E-Q-M-A-Q-Y-A-A-D-L-R-R-Y-I-N-M-L-T-R-P-R-Y 
Phe 30   A-P-L-E-P-V-Y-P-G-D-N-A-T-P-E-Q-M-A-Q-Y-A-A-D-L-R-R-Y-I-N-F-L-T-R-P-R-Y 
Val 30   A-P-L-E-P-V-Y-P-G-D-N-A-T-P-E-Q-M-A-Q-Y-A-A-D-L-R-R-Y-I-N-V-L-T-R-P-R-Y 
Asn 30   A-P-L-E-P-V-Y-P-G-D-N-A-T-P-E-Q-M-A-Q-Y-A-A-D-L-R-R-Y-I-N-N-L-T-R-P-R-Y 
Cys 30   A-P-L-E-P-V-Y-P-G-D-N-A-T-P-E-Q-M-A-Q-Y-A-A-D-L-R-R-Y-I-N-C-L-T-R-P-R-Y 
Lys 30   A-P-L-E-P-V-Y-P-G-D-N-A-T-P-E-Q-M-A-Q-Y-A-A-D-L-R-R-Y-I-N-K-L-T-R-P-R-Y 
Glu 30   A-P-L-E-P-V-Y-P-G-D-N-A-T-P-E-Q-M-A-Q-Y-A-A-D-L-R-R-Y-I-N-E-L-T-R-P-R-Y 
Pro 0, Leu 30 P-A-P-L-E-P-V-Y-P-G-D-N-A-T-P-E-Q-M-A-Q-Y-A-A-D-L-R-R-Y-I-N-L-L-T-R-P-R-Y 
Pro 0, Lys 30 P-A-P-L-E-P-V-Y-P-G-D-N-A-T-P-E-Q-M-A-Q-Y-A-A-D-L-R-R-Y-I-N-K-L-T-R-P-R-Y 
Ala 0, Leu 30 A-A-P-L-E-P-V-Y-P-G-D-N-A-T-P-E-Q-M-A-Q-Y-A-A-D-L-R-R-Y-I-N-L-L-T-R-P-R-Y 
Ala 0, Thr 30 A-A-P-L-E-P-V-Y-P-G-D-N-A-T-P-E-Q-M-A-Q-Y-A-A-D-L-R-R-Y-I-N-T-L-T-R-P-R-Y 
Ala 0, Leu 17, Leu 30 A-A-P-L-E-P-V-Y-P-G-D-N-A-T-P-E-Q-L-A-Q-Y-A-A-D-L-R-R-Y-I-N-L-L-T-R-P-R-Y 
Ala 0, Ile 17, Cys 30 A-A-P-L-E-P-V-Y-P-G-D-N-A-T-P-E-Q-I-A-Q-Y-A-A-D-L-R-R-Y-I-N-C-L-T-R-P-R-Y 
 
Table 3.1 The amino acid sequences of PP and its analogues. Amino acid additions and substitutions are highlighted in red. The 
amino acid structure of XPP is detailed in appendix IV.
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3.4 Results 
3.4.1 The effect of amino acid substitutions on binding affinity to the     
hY4 receptor  
3.4.1.1 The effect of amino acid substitutions at position 30 on binding 
affinity to the hY4 receptor  
In hY4 competition receptor binding assays, native human pancreatic 
polypeptide displaced PP I125 with nanomolar affinity (IC50 0.230 ± 0.03nM) 
(Figure 3.4).  
The native sequence of human PP contains the amino acid methionine 
(Met/M) at position 30. Substituting a Phenylalanine (Phe/P) or a Glutamic 
acid (Glu/E), at this position (Figure 3.1) significantly impaired binding to the 
hY4 receptor compared to PP (Phe 30 IC50 0.66 ±0.013nM (p≤0.01)), Glu 30 
IC50 0.36 ±0.02nM (p≤0.01)). Substitution with Cysteine (Cys/C) or 
Asparagine (Asn/N) at position 30 (Figure 3.1) had no effect on the 
analogue‟s affinity for the hY4 receptor (Cys 30 IC50 0.23 ±0.01nM, Asn 30 
IC50 0.23 ±0.02nM) (Figure 3.1). Substitution with either a Lysine (Lys/K) or 
Valine (Val/V) at position 30 (Figure 3.1) improved the analogue‟s affinity for 
the hY4 receptor (Lys 30 IC50 0.12 ±0.02nM, (p≤0.01), and Val 30 IC50 0.10 
±0.04nM, (p≤0.5)) (Figure 3.1). 
3.4.1.2 The effect of amino acid substitutions at positions 0 and 30 on 
binding affinity to the hY4 receptor  
The addition of Alanine (Ala/A) at the 0 position in combination with a 
Threonine (Thr, T), at position 30 (Figure 3.2) improved binding affinity to the 
hY4 receptor (Ala 0, Thr 30 IC50 0.15 ± 0.01nM, (p≤0.01)). The combination 
of an Alanine (Ala/A) extension at the N terminus with a Leucine (Leu/L), at 
position 30 (Figure 3.2) had no effect on binding affinity to the hY4 receptor 
(Ala 0, Leu 30 IC50 0.27 ±0.05nM). The combination of a Pro at position 0 of 
PP with a Leu at position 30 had no effect on binding affinity to the hY4 
receptor (Pro 0, Leu 30 IC50 0.27 ±0.03nM) (Figure 3.2). The combination of 
a Pro at position 0 with a Lysine (Lys, K) at position 30 improved binding 
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affinity to the hY4 receptor (Pro 0, Lys 30 IC50 0.10 ±0.001nM (p≤0.05)) 
(Figure 3.2). 
3.4.1.3 The effect of amino acid substitutions at positions 0, 17 and 30 
on binding affinity to the hY4 receptor   
The substitution of amino acid Met at position 17 for a Leu, in addition to the 
addition of Ala at position 0 and the substitution of Met for Leu at position 30 
had no affect on the binding of the analogue Ala 0, Leu17, Leu 30 to the hY4 
receptor compared to native PP (IC50 0.23 ±0.003nM) (Figure 3.3). However, 
the substitution of Met 17 for an Isoleucine (Ile, I) in addition to Ala at position 
0 and Cys at position 30, significantly improved binding to the hY4 receptor 
(IC50 0.13 ±0.001nM, (p≤0.001)) (Figure 3.3). 
3.4.1.4 The effect of amino acid substitutions at multiple positions on 
binding affinity to the hY4 receptor   
See appendix IV for XPP hY4 receptor binding information (Figure 3.4).  
3.4.2 The effect of amino acid substitution on binding affinity to the hY2 
receptor  
In displacement human Y2 (hY2) receptor binding assays, native human PP 
displaced PP I125 with nanomolar affinity (IC50 0.12 ±0.06nM) (Figure 3.5). 
However, PP only displaced PYY3-36 
I125 with micromolar affinity (IC50 218 
±63nM). Analogue XPP (amino acid changes detailed in appendix IV) has a 
similar binding affinity for the hY2 receptor (IC50 0.036 ±0.1nM). 
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Figure 3.1 Representative competition binding affinity curves of PP 
analogues A) Asn 30, B) Cys 30, C) Glu 30, D) Lys 30, E) Val 30 and F) Phe 
30 to the hY4 receptor. Radiolabelled PP I125 was used to compete with 
unlabelled peptide for hY4 receptor binding sites. Cell membranes of HEK 
293T cells over expressing the cloned hY4 receptor were the source of hY4 
receptors. Fifty percent specific binding is represented by the dotted line. IC50 
values were calculated as mean ±SEM of three separate experiments (Table 
3.2). 
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Figure 3.2 Representative competition binding affinity curves of PP 
analogues A) Ala 0, Leu 30 B) Ala 0, Thr 30 C) Pro 0, Leu 30 D) Pro 0, Lys 
30 to the hY4 receptor. Radiolabelled PP I125 was used to compete with 
unlabelled peptide for hY4 receptor binding sites. Cell membranes of HEK 
293T cells over expressing the cloned hY4 receptor were the source of hY4 
receptors. Fifty percent specific binding is represented by the dotted line. IC50 
values were calculated as mean ±SEM of three separate experiments (Table 
3.2). 
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Figure 3.3 Representative competition binding affinity curves of PP analogue 
A) Ala 0, Ile 17, Cys 30 and B) Ala 0, Leu 17, Leu 30 to the hY4 receptor. 
Radiolabelled PP I125 was used to compete with unlabelled peptide for hY4 
receptor binding sites. Cell membranes of HEK 293T cells over expressing 
the cloned hY4 receptor were the source of hY4 receptors. Fifty percent 
specific binding is represented by the dotted line. IC50 values were 
calculated as mean ±SEM of three separate experiments (Table 3.2). 
 
Figure 3.4 Representative competition binding affinity curves of A) native PP 
B) PP analogue XPP to the hY4 receptor. Radiolabelled PP I125 was used to 
compete with unlabelled peptide for hY4 receptor binding sites. Cell 
membranes of HEK 293T cells over expressing the cloned hY4 receptor 
were the source of receptors. Fifty percent specific binding is represented by 
the dotted line. IC50 values were calculated as mean ±SEM of three 
separate experiments (Table 3.2). 
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Figure 3.5 Representative competition binding affinity curves of A) native PP 
B) PP analogue XPP to the hY2 receptor. Radiolabelled PP I125 was used to 
compete with unlabelled peptide for hY2 receptor binding sites. Cell 
membranes of HEK 293T cells over expressing the cloned hY2 receptor or 
hY2 receptor were the source of receptors. Fifty percent specific binding is 
represented by the dotted line. IC50 values were calculated as mean ±SEM of 
three separate experiments. 
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PP/PP 
Analogue 
 
Average binding to the hY4 Receptor (nM) 
 
hY4 
IC50 
 
SEM Statistical significance compared to PP 
binding to the hY4 receptor 
PP 0.23 0.03 - 
Phe 30 0.66 0.13 p≤0.01 
Val 30 0.10 0.04 p≤0.05 
Asn 30 0.23 0.02 Not Significant 
Cys 30 0.23 0.01 Not Significant 
Lys 30 0.12 0.02 p≤0.01 
Glu 30 0.36 0.02 p≤0.01 
Pro 0, Leu 30 0.21 0.03 Not Significant 
Pro 0, Lys 30 0.10 0.001 p≤0.05 
Ala 0, Leu 30 0.27 0.05 Not Significant 
Ala 0, Thr 30 0.15 0.01 p≤0.01 
Ala 0, Leu 17, 
Leu 30 
0.23 0.03 Not Significant 
Ala 0, Ile 17, 
Cys 30 
0.13 0.01 p≤0.001 
 XPP 0.10 0.008 p≤0.001 
 
Table 3.2 The binding affinities of PP and PP analogues for the hY4 receptor 
in vitro. The IC50 values of the PP analogues were compared to that of native 
PP IC50 using Student‟s T test, p≤0.05 was considered to be significant. 
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3.4.3 The effect of acute peripheral administration of PP and PP 
analogues on food intake in fasted male C57/BL6 mice  
3.4.3.1 The effect of PP and PP analogues with substitutions at amino 
acid position 30 on food intake in fasted male C57/BL6 mice 
PP and PP analogues with the substitution of the Met at position 30 in the PP 
sequence substituted with: Asn, Cys, Lys, Val, or Glu significantly reduced 
food intake compared with saline control at 0-1 hour (Saline, 1.1g 
±0.01grams, Asn 30, 0.55g ±0.01grams (p=≤0.001), Val 30, 0.49g 
±0.01grams (p=≤0.01), Lys 30, 0.49g ±0.01grams (p=≤0.001), Glu 30, 0.46g 
±0.01grams (p=≤0.001), and Cys 30, 0.78g ±0.01grams (p=≤0.05)). At 0-1 
hours PP analogue Asn 30 significantly reduced food intake compared to PP 
(PP 0.87g ±0.01grams and Asn 30, 0.55g ±0.01grams (p=≤0.001)). PP 
analogue Phe 30 reduced food intake compared to saline at 0-1 hour, but 
this effect did not reach statistical significance (0.75g, ±0.01grams) (Figures 
3.6 to 3.11).  
PP analogue Lys 30 significantly reduced food intake compared to saline 
control at 1-2 hours (Saline 0.46g ±0.01grams, 0.11g ±0.01grams, 
(p=≤0.001)). PP analogue Glu 30 increased food intake at 1-2 hours. 
However, this effect did not reach statistical significance (Saline    
0.24g±0.01grams, Glu 30, 0.28g ±0.01grams).  
PP analogue Lys 30 significantly reduced food intake compared to PP at 4-8 
hours (Saline 0.69g±0.01grams, PP 0.78g ±0.01grams, and Lys 30 0.47g 
±0.01grams p=≤0.05)). There were no statistically significant effects of PP 
analogues at any other time points examined (Table 3.3). 
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Figure 3.6 The effect of subcutaneous administration of PP (25nmol/kg) or 
PP analogue Phe 30 (25nmol/kg) on food intake in C57/BL6 mice fasted 
overnight A) 0-1 hour post injection, B) 1-2 hours post injection, C) 4-8 hours 
post injection and D) 8-24 hours post injection. PP and PP analogue 
compared to saline using one-way ANOVA with Bonferroni post hoc test 
(n=8/10). 
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Figure 3.7 The effect of subcutaneous administration of PP (25nmol/kg) or 
PP analogue Val 30 (25nmol/kg) on food intake in C57/BL6 mice fasted 
overnight A) 0-1 hour post injection, B) 1-2 hours post injection, C) 4-8 hours 
post injection and D) 8-24 hours post injection. **p=≤0.01 compared to saline 
using one-way ANOVA with Bonferroni post hoc test (n=8/10). 
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Figure 3.8 The effect of subcutaneous administration of PP (25nmol/kg) or 
PP analogue Asn 30 (25nmol/kg) on food intake in C57/BL6 mice fasted 
overnight A) 0-1 hour post injection, B) 1-2 hours post injection, C) 4-8 hours 
post injection and D) 8-24 hours post injection. ***p=≤0.001 compared to 
saline using one-way ANOVA with Bonferroni post hoc test (n=8/10). 
142 
 
 
Figure 3.9 The effect of subcutaneous administration of PP (25nmol/kg) or 
PP analogue Cys 30 (25nmol/kg) on food intake in C57/BL6 mice fasted 
overnight A) 0-1 hour post injection, B) 1-2 hours post injection, C) 4-8 hours 
post injection and D) 8-24 hours post injection. *p=≤0.05 compared to saline 
using one-way ANOVA with Bonferroni post hoc test (n=8/10). 
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Figure 3.10 The effect of subcutaneous administration of PP (25nmol/kg) or 
PP analogue Lys 30 (25nmol/kg) on food intake in C57/BL6 mice fasted 
overnight A) 0-1 hour post injection, B) 1-2 hours post injection, C) 4-8 hours 
post injection and D) 8-24 hours post injection. **p=≤0.01, ***p=≤0.001 
compared to saline using one-way ANOVA with Bonferroni post hoc test 
(n=8/10). 
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Figure 3.11 The effect of subcutaneous administration of PP (25nmol/kg) or 
PP analogue Glu 30 (25nmol/kg) on food intake in C57/BL6 mice fasted 
overnight A) 0-1 hour post injection, B) 1-2 hours post injection, C) 4-8 hours 
post injection and D) 8-24 hours post injection. *p=≤0.05, ***p=≤0.001 
compared to saline using one-way ANOVA with Bonferroni post hoc test 
(n=8/10). 
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3.4.3.2 The effect of PP and PP analogues with an amino acid addition 
at the N-terminus and position 30 substitutions on food intake in fasted 
C57/BL6 male mice  
3.4.3.2.1 Proline N-terminus extension 
PP and PP analogues with a Pro N-terminus extension and the substitution 
of Met 30 for either Lys or Leu reduced food intake compared to saline 
control at 0-1 hour  (Saline 1.12g ±0.01grams, Pro 0, Lys 30, 0.52g 
±0.01grams, (p=≥0.001) and Saline 0.76g ±0.01grams, Pro 0, Leu 30, 0.71g 
±0.01grams) (Figures 3.12 and 3.13). At 1-2 hours both analogues reduced 
food intake compared to saline (Saline 0.16g ±0.01grams, Pro 0, Leu 30, 
0.007g ±0.01grams (p=≥0.001), and Saline 0.19g ±0.01grams, Pro 0, Lys 30, 
0.13g ±0.01grams). PP analogue Pro 0 Lys 30 significantly reduced food 
intake compared to saline at 8-24 hours (Saline 4.34g ±0.01grams and Pro 0, 
Lys 30, 3.47g ±0.01grams (p=≥0.01)). PP analogue Pro 0 Leu 30 
significantly reduced food intake compared to PP at 4-8 hours (Pro 0, Leu 30 
0.57g ±0.01grams and PP 0.81g ±0.01grams (p=≥0.01)), (Table 3.3). 
3.4.3.2.2 Alanine N-terminus extension 
PP and PP analogues with an Ala N-terminus extension and the substitution 
of Met 30 for Leu at position 30 significantly reduced food intake compared to 
saline control at 0-1 hour (Saline 0.98g ±0.01grams, Ala 0, Leu 30, 0.71g 
±0.01grams (p=≥0.05), and Saline 0.96g ±0.01grams, Ala 0, Thr 30, 0.736g 
±0.01grams) (Figures 3.14 and 3.15). At a dose of 25nmol/kg, PP analogue 
Ala 0, Thr 30 failed to reduce food intake. The dose was therefore increased 
to 300nmol/kg, which reduced food intake compared to saline control at 0-1 
hour. There was no significant difference between saline control and PP or 
PP analogues at any further time points (Table 3.3). 
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Figure 3.12 The effect of subcutaneous administration of PP (25nmol/kg) or 
PP analogue Pro 0, Leu 30 (25nmol/kg) on food intake in C57/BL6 mice 
fasted overnight A) 0-1 hour post injection, B) 1-2 hours post injection, C) 4-8 
hours post injection and D) 8-24 hours post injection. **p=≤0.01, ***p=≤0.001 
compared to saline using one-way ANOVA with Bonferroni post hoc test 
(n=8/10). 
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Figure 3.13 The effect of subcutaneous administration of PP (25nmol/kg) or 
PP analogue Pro 0, Lys 30 (25nmol/kg) on food intake in C57/BL6 mice 
fasted overnight A) 0-1 hour post injection, B) 1-2 hours post injection, C) 4-8 
hours post injection and D) 8-24 hours post injection. **p=≤0.01, ***p=≤0.001 
compared to saline using one-way ANOVA with Bonferroni post hoc test 
(n=8/10). 
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Figure 3.14 The effect of subcutaneous administration of PP (25nmol/kg) or 
PP analogue Ala 0, Leu 30 (25nmol/kg) on food intake in C57/BL6 mice 
fasted overnight A) 0-1 hour post injection, B) 1-2 hours post injection, C) 4-8 
hours post injection and D) 8-24 hours post injection. *p=≤0.05 compared to 
saline using one-way ANOVA with Bonferroni post hoc test (n=8/10). 
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Figure 3.15 The effect of subcutaneous administration of PP (300nmol/kg) or 
PP analogue Ala 0, Thr 30 (300nmol/kg) on food intake in C57/BL6 mice 
fasted overnight A) 0-1 hour post injection, B) 1-2 hours post injection, C) 4-8 
hours post injection and D) 8-24 hours post injection. ***p=≤0.001 compared 
to saline using one-way ANOVA with Bonferroni post hoc test (n=8/10). 
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3.4.3.3 The effect of PP and PP analogues with an Alanine N-terminus 
extension, and amino acid substitutions at positions 17 and 30 on food 
intake in fasted male C57/BL6 mice 
3.4.3.3.1 PP analogue: Alanine 0, Isoleucine 17, Cysteine 30 
PP and PP analogue Ala 0, Ile 17, Cys 30 reduced food intake compared to 
saline control at 0-1 hour (Saline 0.83g ±0.01grams, Ala 0, Ile 17, Cys 30, 
0.59g ±0.01grams) (Figure 3.16). There was no significant difference in food 
intake of PP analogue Ala 0, Ile 17, Cys 30 and either saline or PP at any 
time point examined (Table 3.3).  
3.4.3.3.2 PP analogue: Alanine 0, Leucine 17, Leucine 30 
PP and PP analogue Ala 0, Leu 17, Leu 30 reduced food intake compared to 
saline control at 0-1 hour (Saline 0.97g ±0.01grams and Ala 0, Leu 17, Leu 
30,  0.78g ±0.01grams) (Figure 3.17). At 1-2 hours PP analogue Ala 0, Leu 
17, Leu 30 significantly reduced food intake compared to saline (Saline 0.36g 
±0.01grams and Ala 0, Leu 17, Leu 30, 0.02g ±0.01grams (***p=≤0.001)). 
There was no significant difference in food intake between PP analogue Ala 
0 Leu 17 Leu 30 and saline at any further time points. There was also no 
significant differences in food intake between PP analogue Ala 0, Leu 17, 
Leu 30 and PP at any other time point examined (Table 3.3).  
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Figure 3.16 The effect of subcutaneous administration of PP (25nmol/kg) or 
PP analogue Ala 0, Ile 17, Cys 30 (25nmol/kg) on food intake in C57/BL6 
mice fasted overnight A) 0-1 hour post injection, B) 1-2 hours post injection, 
C) 4-8 hours post injection and D) 8-24 hours post injection. Compared to 
saline using one-way ANOVA with Bonferroni post hoc test (n=8/10). 
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Figure 3.17 The effect of subcutaneous administration of PP (25nmol/kg) or 
PP analogue Ala 0, Leu 17, Leu 30 (25nmol/kg) on food intake in C57/BL6 
mice fasted overnight A) 0-1 hour post injection, B) 1-2 hours post injection, 
C) 4-8 hours post injection and D) 8-24 hours post injection. **p=≤0.01, 
***p=≤0.001 compared to saline using one-way ANOVA with Bonferroni post 
hoc test (n=8/10). 
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3.4.4 The effect of increasing doses of PP and PP analogue XPP on 
food intake in fasted male C57/BL6 mice 
PP and PP analogue XPP significantly reduced food intake at 0-1 hour 
compared to saline control (Saline 0.75g ±0.01grams and 100nmol/kg PP 
0.432g ±0.01grams (*p=≤0.05) and XPP at 20nmol/kg, 0.397g ±0.01grams 
(**p=≤0.01) and 50nmol/kg 0.44g ±0.01grams, (*p=≤0.05)) (Figure 3.18).  At 
1-2 hours 100nmol/kg PP significantly reduced food intake compared to 
saline control (Saline 0.25g±0.01grams, 100nmol/kg PP 0.03g ±0.01grams 
(**p=≤0.01)). At 1-2 hours, 50nmol/kg of XPP significantly reduced food 
intake compared to 5nmo/kg PP (5nmol/kg PP, 0.571g ±0.01grams and 
50nmol/kg XPP, 0.44g ±0.01grams (**p=≤0.01)). There was no significant 
difference in food intake between saline control and PP or analogue XPP at 
any further time points. There were also no significant differences in food 
intake between PP and analogue XPP at any further time points examined 
(Table 3.3).  
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Figure 3.18 The effect of subcutaneous administration of PP (5, 20 and 
100nmol/kg) or PP analogue XPP (5, 20 and 50nmol/kg) on food intake in 
C57/BL6 mice fasted overnight A) 0-1 hour post injection, B) 1-2 hours post 
injection, C) 4-8 hours post injection and D) 8-24 hours post injection. 
*p=≤0.05, **p=≤0.01, compared to saline using one-way ANOVA with 
Bonferroni post hoc test (n=8/10) 
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Analogue Significance of anorectic dose of PP or analogue 
compared to saline control (*=p<0.05,**=p<0.01, 
***=p<0.001) 
Significance of anorectic dose of analogue 
compared to equivalent dose of PP 
(**=p<0.01 and  ***=p<0.001) 
 Dose 
(nmol/kg) 
0-1 
hours 
1-2 
hours 
4-8 
hours 
8-24 
hours 
0-1 
hours 
1-2 
hours 
4-8 
hours 
8-24 
hours 
PP 25 - - - - - - - - 
Phe 30 25 - - - - - - - - 
Val 30 25 * - - - - - - - 
Asn 30 25 *** - - - *** - - - 
Cys 30 25 * - * - - - - - 
Lys 30 25 *** *** - - - - - - 
Glu 30 25 *** - - - ** - - - 
Pro 0, Leu 30 25 - ** - - - - ** - 
Pro 0, Lys 30 25 *** - - ** - - - - 
Ala 0, Leu 30 25 * - - - - - - - 
Ala 0, Thr 30 300 * - - - - - - - 
Ala 0, Leu 17, Leu 30 25 - ** - - - - - - 
Ala 0, Ile 17, Cys 30 25 - - - - - - - - 
XPP 5-50 ** - - - - ** - - 
Table 3.3 PP analogues acute feeding study summary
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3.4.5 Plasma levels of PP and PP analogue XPP following acute 
peripheral administration in rodent models 
 
3.4.5.1 Plasma levels of PP and analogue XPP following SC injection in 
male C57/BL6 mice 
Following a SC injection of either PP or PP analogue XPP (50nmol/kg), 
plasma levels of PP or analogue XPP in C57/BL6 mice were measured at 0, 
5, 10, 20, 30, 45, 90, 120 and 180 minutes post injection using PP and XPP 
specific RIAs (Figure 3.19).  Plasma levels of PP rose to an average maximal 
plasma concentration at 10 minutes post injection (15397 nmol/ml ±1100 
nmol/ml) from undetectable levels at time point zero. Levels of PP were 
lower 30 minutes after injection (9925 nmol/ml ±1681 nmol/ml at 30 minutes 
post injection). At 120 minutes post injection levels of PP had continued to 
decrease (300 nmol/ml ±50 nmol/ml at 120 minutes) and at 180 minutes 
were at the lower limit of detection by RIA (4nmol/l). The PP RIA used is 
unable to detect rodent PP. Plasma levels of XPP rose to an average 
maximal plasma concentration at 20 minutes post injection (23728 nmol/ml 
±2183 nmol/ml). The levels of XPP detected by specific XPP RIA fell after 45 
minutes (15732 nmol/ml ± 1164 nmol/ml). Plasma levels of XPP were 
significantly higher than those of PP at 5 (p≤0.01), 10, 20, 30 and 45 minutes 
(p≤0.001) following administration. There was no significant difference 
between the maximal plasma levels (10 minutes) of PP and the plasma 
levels at 20 minutes using a repeated measures one-way ANOVA with 
Bonferroni post hoc test. However, comparing the remaining time points to 
the maximal plasma levels, there was a significant difference between 10 
minutes and 5 minutes (p≤0.01), 30 minutes (p≤0.01), 45, 90, 120 and 180 
minutes (p≤0.001). There was no significant difference between the maximal 
plasma levels (30 minutes) of XPP and the plasma levels at 5, 10, and 30 
minutes using a repeated measures one-way ANOVA with Bonferroni post 
hoc test. However, comparing the remaining time points to the maximal 
plasma levels there was a significant difference between 20 minutes and 45 
minutes (p≤0.05), 90, 120 and 180 minutes (p≤0.001).  
157 
 
3.4.5.2 Plasma levels of PP and analogue XPP following SC injection in 
male wistar rats 
Following a SC injection of either PP or PP analogue XPP (50nmol/kg), 
plasma levels of PP or analogue XPP in lean male wistar rats were 
measured at 0, 10, 20, 30, 45, 60, 120 and 180 minutes post injection 
(Figure 3.20).  Plasma levels of PP rose to an average maximal plasma 
concentration at 20 minutes post injection (2077nmol/ml± 359 nmol/ml), and 
fell after 45 minutes. At 120 minutes post injection levels of PP had 
decreased and had reached the lower limit of detection by RIA (4nmol/L). 
Plasma levels of XPP rose to an average maximal plasma concentration at 
60 minutes post injection (9369 nmol/ml ±547 nmol/ml). The levels of XPP 
detected by specific XPP RIA fell after 60 minutes. The XPP RIA is unable to 
detect rodent PP or native human PP and has a lower limit of detection of 
0.3nmol/L. However, average plasma levels of XPP were still higher than 
those of PP at 180 minutes (XPP 95.4 nmol/ml ±12.5 nmol/ml and PP 37.7 
±1.12nmol/ml). Plasma levels of XPP were significantly higher than those of 
PP at 20 (p≥0.01), 30, 45, 60 (p=≤0.001) and 120 minutes (p=≤0.01) 
following administration. There was no significant difference between the 
maximal plasma levels (10 minutes) of PP and the plasma levels at 20, 30, 
45 and 60 minutes using a repeated measures one-way ANOVA with 
Bonferroni post hoc test. However, comparing the remaining time points to 
the maximal plasma levels, there was a significant difference between 10 
minutes and 120, and 180 minutes (p≤0.001). There was no significant 
difference between the maximal plasma levels (60 minutes) of XPP and the 
plasma levels at 20, 30, and 45 minutes using a repeated measures one-way 
ANOVA with Bonferroni post hoc test. However, comparing the remaining 
time points to the maximal plasma levels there was a significant difference 
between 60 minutes and 10 minutes (p≤0.05), 120 and 180 minutes 
(p≤0.001).  
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Figure 3.19 The plasma levels of PP or XPP following subcutaneous 
administration in male C57/BL6 mice (50nmol/kg).  Following SC injection of 
peptide, mice were returned to their cages and blood collected via cardiac 
puncture at 0, 5, 10, 20, 30, 45, 90,120 and 180 minutes. **=p≤0.01, 
***=p≤0.001 plasma levels were compared at each time point using a two-
way ANOVA with Bonferroni post hoc test (n=4-7). 
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Figure 3.20 The plasma levels of PP or XPP following subcutaneous 
administration in male wistar rats (50nmol/kg).  Following anaesthesia, rats 
were given SC injection of PP or XPP, blood collected via jugular vein 
cannula at 0, 10, 20, 30, 45, 60, 120 and 180 minutes. **=p≤0.01, 
***=p≤0.001 plasma levels were compared between groups at each time 
point using a two-way ANOVA with Bonferroni post hoc test (n=3). 
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3.5 Discussion 
The experiments described in section 2.3 demonstrated that specific amino 
acid substitutions can increase the resistance of PP to enzymatic breakdown 
in vitro. PP, unlike other small peptides, has a tertiary structure (Blundell et 
al., 1981; Gellman and Woolfson, 2002), which results in the “PP-fold” 
characteristic of PP, PYY and NPY. The tertiary structure of PP is reliant 
upon the primary amino acid sequence to form correctly in vivo. Small 
changes to the amino acid sequence of a peptide such as PP can therefore 
effect receptor interaction and bioefficacy. I hypothesised that the amino acid 
changes made to the structure of PP would increase the ability of the 
analogues to bind to the hY4 receptor and inhibit food intake. This would be 
likely due to increased bioavailability, as less peptide would be broken down 
by enzymatic cleavage, increasing the amount of peptide available to interact 
with the receptor, and might also reflect the altered structure of the molecule 
binding more efficaciously to the receptor. These alterations would hopefully 
ultimately result in a PP analogue which circulates for longer in plasma than 
native PP, in a form which interacts more effectively with the hY4 receptor, 
therefore inhibiting food intake for longer. 
I investigated the effect of single and multiple amino acid substitutions to the 
PP sequence on hY4 receptor binding, using competition binding assays, 
and on in vivo bio-efficacy, using acute food intake studies in lean male mice.  
3.5.1 The effect of changes to the PP molecule on binding affinity for 
the hY4 receptor. 
The enzymes NEP and DPPIV were found to be important in the breakdown 
of PP. Amino acids were subsequently substituted to prevent degradation by 
both these enzymes and to stabilise the tertiary structure of PP. These 
analogues were then examined to ensure that bioefficacy was maintained or 
improved.  
A number of amino acids have previously been found to be essential for 
receptor interaction and activation. The amidated tyrosine at position 36 of 
PP is essential for hY4 receptor binding (Schwartz et al., 1990; Walker et al., 
1997; Gingerich et al., 1991; Gehlert et al., 1996).  The whole PP molecule is 
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necessary for high affinity binding to the hY4 receptor; small sections of PP 
have been shown to have impaired hY4 receptor binding compared to full 
length PP (Gingerich et al., 1991; Gehlert et al., 1996; Walker et al., 1997).  
The studies described in section 3.4.1 demonstrated that amino acid 
changes at position 30 affected the ability of PP to displace radiolabelled PP 
in binding assays. It has been shown previously that oxidation of the native 
Met improved the ability of the analogue to bind to the hY4 receptor 
(Gingerich et al., 1991). It was suggested that this was due to increased Van 
de Waals forces between the oxidised Met and the amino acid side chains of 
other amino acids in the alpha helix. Amino acid 30 (Met), as well as being a 
key site for enzymatic cleavage by NEP 24.11, is also likely to play a role in 
the stability of the tertiary structure. Therefore Met 30 needs to be substituted 
carefully to allow better enzymatic resistance whilst maintaining structural 
stability.  
Replacing Met at position 30 with Asn, Cys, Lys, or Val improved binding to 
the hY4 receptor compared to native PP. The substitution of Met for these 
amino acids improved resistance to breakdown by NEP, with limited effect on 
KBB or meprin beta breakdown (Section 2.4). In avian PP, position 30 is 
occupied by a Val and has been shown to cause Van de Waal interactions 
between Val 30 and Pro 2, providing extra cross links between the alpha 
helix and the proline helix side chains, and thus helping to maintain the hair 
pin bend shape (Blundell et al., 1981). Amino acids Asn and Cys are both 
similar in size to Met in relative molecular mass (Asn 132, Cys 121 and Met 
149) and, despite being polar molecules, are unlikely to disrupt the tertiary 
structure. Conversely, the addition of a Glu at position 30 impaired binding to 
the hY4 receptor, despite significantly improving resistance to breakdown by 
both NEP and meprin beta and the KBB membrane (Section 2.4). This may 
be due to the change in charge from a neutral Met to a negative Glu. A 
change in charge may have disrupted the packing of the proline helix 
hydrophobic side chains, altering overall tertiary structure. Alternatively, it 
may have impaired the degree of turn in the amphipathic alpha helix. If the 
degree of the alpha helix turn is changed this could cause the uncoiling of 
the entire alpha helix, as hydrophobic residues may no longer be facing into 
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the hair pin bend. The tertiary structure of the molecule would then have 
been destroyed. A further theory is that a charge at this position may 
somehow effect the interaction of the substrate for the receptor, therefore 
impairing binding. Substituting a Phe at position 30 also increased the IC50 
compared to native PP. This may be due to the phenol group side chain 
disrupting the side chain interactions which play a major role in the 
secondary structure of PP (Schwartz et al., 1990). A Phe at position 30, 
however, improved resistance to the degradative enzymes examined 
(Section 2.4). PP analogues Glu 30 and Phe 30 are examples of analogues 
which despite improved enzymatic resistance have impaired biological 
function.  
The Pro at position 2 has also been described as critical for the binding of PP 
to the hY4 receptor (Gehlert et al., 1996). This Pro is cleaved by the enzyme 
DPPIV, as shown in section 2.4. DPPIV cleaves between the Pro at position 
2 and the Leu at position 3 to generate PP3-36. It was shown in section 2.4 
that the addition of another amino acid at position 0 inhibited cleavage of PP 
by DPPIV. It was also shown in section 2.3 that the addition of Ala at the N-
terminus of PP slightly inhibited binding to the hY4 receptor compared to 
native PP. In section 3.4.1.1, competition binding assays demonstrated that 
the addition of Ala at position 0 of the PP in combination with either Leu or 
Thr at position 30 did not inhibit binding to the hY4 receptor, as these 
analogues have an IC50 lower than or equal to that of unmodified PP. 
The hair-pin bend in the „PP-fold‟ family of peptides is highly conserved in all 
species and throughout all the „PP-fold‟ peptides (Blomqvist et al., 1992; 
Cerda-Reverter and Larhammar, 2000; Larhammar, 1996a). This indicates 
that the hair pin bend is necessary for the PP family of peptides to correctly 
bind to the Y family of receptors. The hair pin bend is created by the beta 
turn (amino acids 9-14). However, without the interactions of the poly-proline 
helix side chains (amino acids 1-8) with the amphipathic alpha helix (amino 
acids 15-31), this bend would not be maintained (Blundell et al., 1981). This 
suggests that both the C and the N terminus of the peptide are required for 
receptor interaction. This is further supported by the limited affinity of PP 
fragments for the hY4 receptor (Gingerich et al., 1991; Gehlert et al., 1996; 
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Walker et al., 1997). The stabilisation of the hair pin structure may therefore 
improve receptor binding affinity.  
Alanine N-terminus extensions in combination with position 30 changes were 
investigated with the addition of either a Leu or an Ile at position 17. These 
two additional amino acids changes were chosen to putatively stabilise the 
alpha helix which runs from amino acids 14 to 31 (Blundell et al., 1981; 
Glover et al., 1983). Isoleucine and leucine are both hydrophobic, and thus 
may stabilise the alpha helix by positioning themselves inside the helix. The 
stabilisation of the alpha helix may also mean that the analogue is less likely 
to be degraded by circulating and membrane bound enzymes. Circulating 
plasma levels might therefore remain higher for longer after administration, 
possibly leading to a greater anorectic effect. Having a more stable structure 
may also enable a greater number of analogue molecules to be in the correct 
form to bind to the hY4 receptor at any specific moment, creating more 
receptor substrate interactions in a shorter period of time.   
Most amino acid changes at position 30 significantly improved hY4 receptor 
binding affinity. However, substituting Met at position 30 with Phe or Glu 
significantly impaired hY4 receptor binding.  The combination of an N-
terminus extension and changes at position 30 had a range of affects on 
affinity for the hY4 receptor. Lys at position 30 and a Pro N-terminus 
extension significantly decreased the IC50 compared to native PP.  Using the 
amino acid Ala to extend the N-terminus had a different effect, in 
combination with a Leu 30 or a Thr 30 on hY4 receptor binding. Ala 0, Thr 30 
significantly increased affinity for the hY4 receptor compared to PP, whereas 
Ala 0, Leu 30 had only slightly improved binding to the hY4 receptor. The 
combination of an Ala extension with an Ile at position 17 and a Cys at 
position 30 significantly improved hY4 receptor binding, whereas an 
analogue with the substitutions Ala 0, Leu 17, Leu 30 had slightly, and non-
significantly, impaired hY4 receptor binding. Overall, displacement assays 
suggest that an N terminus extension can aid hY4 receptor binding and that 
specific amino acid substitutions of the Met at positions 17 and 30 can either 
impair or enhance binding to the hY4 receptor compared to native 
unmodified PP.  
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3.5.2 The effect of changes to the PP molecule on food intake in 
overnight fasted male C57/BL6 mice. 
Displacement assays indicate how well a peptide binds to the receptor. 
However, they do not indicate the bioefficacy of a peptide. PP binding to the 
hY4 receptor has been shown previously to inhibit intracellular cyclic AMP 
levels (Kojima et al., 2007; Hosoda et al., 2000; Dumont et al., 2005; Dumont 
et al., 1993). This secondary messenger system could therefore be used to 
measure the level of receptor activation by each analogue compared to PP.  
However, the need to stimulate cyclic AMP levels in order to observe the 
suppressant effects of PP and PP analogues can lead to high variation 
between studies. Analogues which do not bind well to the hY4 receptor or act 
as antagonists will not inhibit food intake in mice as effectively as native PP.  
Measuring the effect of PP and PP analogues on food intake in fasted 
C57/BL6 mice is a simple and effective measure of bioefficacy. Fasted mice 
were used as PP analogues were predicted to have an anorectic effect. Mice 
following a fast would be expected to have a greater food intake than their 
non-fasted counterparts, and therefore to more clearly demonstrate the 
anorectic effect of a test agent. 
PP has a well characterised inhibitory effect on food intake when 
administered peripherally to mice (Asakawa et al., 1999; Katsuura et al., 
2002; Kojima et al., 2007; Liu et al., 2008; Ueno et al., 1999). In a number of 
the experiments detailed in section 3.4.3 native PP did not significantly inhibit 
food intake as had been demonstrated in previous studies. In previous 
studies a dose of between 25nmol/kg and 30nmol/kg had been shown to be 
effective at inhibiting food intake in fasted male mice (Asakawa et al., 1999; 
Liu et al., 2008; Ueno et al., 1999).  There was no apparent reason for the 
differences in PP‟s ability to inhibit food intake. The experiments were carried 
out under the same conditions in the same mice. The PP used in all the 
studies was from a single batch freeze dried prior to the studies and 
reconstituted before each experiment. The body weights within each of the 
groups were matched, and randomised for each experiment therefore the 
mice in each group had all received different peptides/saline in the previous 
experiments. All mice had a minimum of a 24 hour wash out period between 
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once experiment and the next. However, it is possible that mice which had in 
the previous experiment received an anorectic peptide had too little body 
weight to lose in the subsequent experiment. Thus, making food intake 
inhibition by PP harder to achieve, possibly causing PP to be less effective in 
some experiments.  
 To ensure that analogues maintained or improved upon the bioefficacy of 
PP, the ability of PP analogue to inhibit food intake in fasted lean C57/BL6 
male mice was investigated. The results of these studies suggest that some 
of the changes made to the PP structure had little or no effect on the ability 
of PP analogues to inhibit food intake. Examples of analogues which had 
improved receptor binding affinity but were no better than native PP at 
inhibiting food intake in fasted mice included PP analogue Ala 0, Leu 30 and 
PP analogue Ala 0, Thr 30.  
The inhibitory effect of PP analogues on food intake did not always reflect 
their hY4 receptor affinity. PP analogue Glu 30 would be expected to have a 
limited effect in vivo due to the significant decrease in binding affinity for the 
hY4 receptor. However, at 0-1 hours Glu 30 significantly inhibited food intake 
compared to saline control. This was unexpected and may be due its 
improved enzymatic resistance enabling more Glu 30 to remain intact in the 
circulation, allowing more analogue molecules to interact with the hY4 
receptor, and thus compensating for its relatively low affinity (Section 2.4).  
Alternatively it may be that Glu 30 has improved binding to the mouse Y4 
receptor, but not the hY4 receptor. This could be checked by developing a 
binding assay which uses a membrane which over-expresses mY4 receptor, 
rather than hY4 receptors. This may indicate why PP analogues which do not 
bind well to the hY4 receptor in vitro and would not be expected to inhibit 
food intake greatly in vivo, achieve a significant inhibition of food intake in 
fasted male mice. However, the similarities between the human and mouse 
Y4 receptor and human and mouse PP suggest this is unlikely. Conversely 
PP analogue Ala 0, Thr 30 had significantly improved affinity for the hY4 
receptor and yet when it was administered SC, a dose of 300nmol/kg had to 
be given before a significant food intake inhibition was observed at 0-1 hours. 
This analogue may for example, be binding tightly to plasma proteins such 
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as albumin which would then prevent it from interacting with the receptor as it 
is trapped in the circulation (Gokara et al., 2010; Ghuman et al., 2005).  
The majority of analogues investigated did not inhibit food intake in fasted 
male mice as effectively as would be expected from their binding to the hY4 
receptor in vitro. The food intake results suggest that despite improved 
affinity for the hY4 receptor, some PP analogues do not have improved 
abilities to inhibit food intake in fasted male mice. This may be due to the 
differences between the human and mouse Y4 receptor; human PP 
analogues may reduce food intake more effectively in human studies, but it is 
unfortunately impractical to test a large number of such analogues in humans. 
However, other unknown factors may also be impairing the actions of PP 
analogues in vivo, including their ability to enter the circulation from the SC 
depot. This could be impaired by analogues  binding to plasma proteins such 
as albumin (Ghuman et al., 2005). All of these factors would impair biological 
functioning, despite improved affinity for the hY4 receptor in vitro.  
3.5.3 PP analogue XPP: hY4 and hY2 receptor affinity, food intake 
inhibition and circulating plasma levels. 
XPP amino acid sequence details, Appendix IV. 
Analogue XPP required a 50% lower dose than native PP to inhibit food 
intake in fasted mice.  This may reflect its greater affinity for the Y4 receptor, 
or a combination of improved affinity and improved resistance to enzymatic 
breakdown. Food intake inhibition by XPP was significantly greater than PP 
(5nmol/kg) at 1-2 hours (p≥0.01); this may be due to the higher circulating 
plasma levels of XPP at this time. At 0-1 hours PP significantly inhibited food 
intake at a dose of 100nmol/kg (p≤0.5). However, XPP significantly inhibited 
food intake at the same time point at both 20 and 50nmol/kg (p≤0.01 and 
p≤0.5). At 4-8 hours, animals receiving XPP at doses of 20 and 50nmol/kg 
had lower food intakes than animals receiving saline or PP (5 and 
20nmol/kg), but this effect did not achieve statistical significance. These 
details suggest that XPP has a longer effect on food intake than unmodified 
PP. This may be due to the combination of increased enzymatic resistance, 
improved affinity for the hY4 receptor and maintenance of a low affinity for 
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the hY2 receptor. In addition to the increased time in circulation, it would 
appear that XPP levels take longer to reach the maximum plasma 
concentration than native PP following SC administration. Both a longer 
circulation time and a delay in reaching maximal plasma concentrations 
could help to explain why XPP inhibits food intake for longer, and at a lower 
dose than unmodified PP.  
Interestingly, XPP levels peaked at 60 minutes in rats and 30 minutes in 
mice. These differences may be explained by the differences in experimental 
procedure, with rats being anaesthetised and mice being returned to home 
cages following SC administration.  During anaesthesia, basal metabolic rate 
slows, which may explain why both XPP and PP levels detected were higher 
in mice which remained conscious  following SC injection (Choi et al., 2002). 
In addition, the body temperature of the anaesthetised rats may have 
dropped (despite being on a heat mat) which may have reduced circulation 
to the skin, reducing the uptake of both PP and XPP from the SC depot. In 
addition, rats and mice have different metabolic rates, which is likely to 
influence drug metabolism. However, the time when maximal levels of PP 
were detected in the circulation was the same in both rats and mice (10 
minutes).  
It is possible that analogue XPP exerts its effects on food intake via other Y 
receptors, for example, the Y2 receptor. This was shown to be unlikely as 
XPP has a lower affinity for the Y2 receptor than native PP. However, XPP 
might potentially exert its effects via an Y1 or Y5 receptor mediated 
mechanism.  The Y1 receptor has the highest binding affinity for NPY 
(Kanatani et al., 2000; Dumont et al., 1993; Parker and Herzog, 1999), which 
is orexigenic. If XPP acts as an antagonist for the Y1 receptor, this could 
decrease food intake. However, as the Y1 receptor is found only in the brain 
and PP is not thought at present to be able to cross the blood brain barrier 
this is also an unlikely mechanism (Whitcomb et al., 1990; Allen et al., 1983; 
Flynn et al., 1999; Trinh et al., 1996; Parker and Herzog, 1999). Further 
studies are required to determine whether XPP can access the brain from 
the circulation, and whether it binds to and inhibits the Y1 and/or Y5 receptor.  
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3.5.4 Conclusions 
PP analogue XPP was chosen as the lead analogue for further studies. XPP 
has improved affinity for the hY4 receptor and unaltered affinity for the Y2 
receptor compared to PP. It remained at higher levels in circulating plasma 
following peripheral administration than unmodified PP in both rats and mice.  
XPP reached its peak plasma concentration later than native PP following 
SC administration. XPP also inhibited food intake in fasted male mice at half 
the dose required of PP. The experiments described in this chapter only 
investigated the acute effects of XPP on food intake. I therefore investigated 
the effects of XPP on energy homeostasis following chronic administration in 
different models of obesity, as described in the following chapter. 
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Chapter 4 
 
The Effect Of Chronic 
Administration Of A 
Pancreatic Polypeptide 
Analogue On Energy 
Homeostasis In Mice. 
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4.1 Introduction 
The studies described in chapters 2 and 3 demonstrated that small changes 
to the amino acid sequence of PP alter the resistance of PP to degradative 
enzymes and the affinity of PP analogues to the hY4 receptor. These studies 
resulted in the development of PP analogue XPP. PP analogue XPP has 
improved enzyme resistance and improved affinity for the hY4 receptor 
binding, without increased affinity for the hY2 receptor. These changes are 
thought to be responsible for the more potent and longer acting anorectic 
effects of XPP compared to PP, following acute peripheral administration.   
It is necessary to demonstrate that potential obesity treatments are effective 
at chronically reducing food intake and body weight. The effectiveness of 
chronic daily administration of the candidate treatment at reducing food 
intake and body weight in animal models of obesity gives a valuable 
indication of how likely a treatment is to be effective in obese humans. Two 
well established models of obesity in rodents are the leptin knockout mouse 
(Ob/Ob mouse) (Moriya et al., 2009; Vrang et al., 2006; Ravinet et al., 2003; 
Pocai et al., 2009), and the diet induced obese mouse (DIO mouse) (Vrang 
et al., 2006).  
The leptin deficient Ob/Ob mouse is hyperphagic and obese (Zhang et al., 
1994; Drel et al., 2006; Ingalls et al., 1950), and was first observed in the 
1950‟s following a chance mutation in the leptin gene (Ingalls et al., 1950). 
The Ob mutation is also associated with a number of other hormonal and 
metabolic alterations, including poor temperature regulation, poor fertility, 
decreased expression of β3 adrenergic receptors and lower oxygen 
consumption in comparison with heterozygous litter mates (Breslow et al., 
1999; Zhang et al., 1994; Kaplan and Leveille, 1974). In humans, leptin 
deficiency has been observed in a small number of obese adults and 
children (Montague et al., 1997; Strobel et al., 1998). Ob/Ob mice gain 
weight quickly and are often used as a model of obesity. The Ob/Ob mouse 
has previously been used to elucidate the role of NPY in obesity (Erickson et 
al., 1996; Beck, 2006; Hollopeter et al., 1998). The Ob/Ob mouse has also 
been used to investigate the effects of chronic administration of gut 
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hormones, including PYY, DPPIV resistant GLP-1 analogues, and PP (Neary 
et al., 2005; Irwin et al., 2007; Asakawa et al., 2003), on food intake and 
body weight.   
However, animals lacking a particular gene may undergo adaptive changes 
to overcome the loss of this gene. For example, embryonic knockout of NPY 
or AgRP has little effect, but adult animals with knockdown of NPY or 
knockout of the NPY/AgRP neurons are hypophagic, demonstrating the 
ability of the hypothalamus to compensate for the loss of specific signals 
within specific temporal windows (Lin et al., 2004; Challis et al., 2004; 
Thorsell and Heilig, 2002; Yang et al., 2009; Bi et al., 2007; Bewick et al., 
2005b). The Ob/Ob mouse lacks an operational form of the gene which 
controls the production of leptin, and although it is obviously unable to 
completely compensate for the lack of leptin, it may have developmental or 
adaptive changes secondary to the loss of leptin. Therefore, although the 
Ob/Ob mouse is a useful model, it does not mimic the pathophysiological 
mechanisms responsible for the majority of human obesity, and may have 
altered energy homeostasis-regulating systems which do not reflect normal 
physiology.   
The diet induced obese (DIO) mouse model is usually used on a C57/BL6 
background. DIO mice are fed high fat diet, typically with 40-60% of their 
calories derived from fat from an early age, for between 8-16 weeks (Harlan 
Laboratories, 2010). The obese phenotype is typically observed after a 
month of feeding with a high fat diet. After 16 weeks of feeding on a high fat 
diet, mouse body weight gain begins to slow and they are considered to be 
relatively weight stable. DIO mice are often used as a non leptin deficient 
model of obesity, as DIO mice have a 93% increase in fat mass compared to 
control diet fed mice at 16 weeks (Surwit et al., 1995; Reuter, 2007). DIO 
mice have a similar obesity phenotype to humans, including visceral 
adiposity, insulin resistance, hyperinsulinemia, hyperleptinemia, and leptin 
resistance (Petro et al., 2004; Rossmeisl et al., 2003; Van et al., 1997; Surwit 
et al., 1995). Numerous studies have used the DIO model of obesity to 
examine novel therapeutic interventions for the treatment of obesity, 
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including the CB1 receptor antagonist Rimonabant (Reuter, 2007; Ahren et 
al., 2000; Hildebrandt et al., 2003). 
Currently available obesity treatments have limited efficacy, as detailed in 
section 1.3.1. Initially, leptin was investigated as a potential drug target 
(Zhang et al., 1994; Campfield et al., 1995). However, subsequent studies 
suggested that obesity leads to leptin resistance, and thus that any 
exogenous administration of leptin would have little effect on weight loss 
(Bjorbaek, 2009; Scarpace and Zhang, 2009; Heymsfield et al., 1999). In 
recent years, a number of gut hormones have been proposed as potential 
treatments for obesity,  including Oxyntomodulin, GLP-1, CCK, PYY3-36 and 
PP (Druce and Bloom, 2006; Field et al., 2008; Neary and Batterham, 2009; 
Small and Bloom, 2005). All of these gut hormones reduce food intake 
following peripheral administration in animal models and in healthy human 
volunteers (Cohen et al., 2003; Dakin et al., 2002; McMahon and Wellman, 
1998; Scott and Moran, 2007; Vrang et al., 2006; Batterham et al., 2003).  
Gut hormones have potential as obesity treatments as they often act via 
discrete receptors or neuronal systems accessible from the periphery, 
reducing the potential for adverse effects. They also mimic the physiological 
appetite-regulating system, again limiting the possibility of harmful side 
effects. It has recently been suggested that the administration of gut 
hormones may also mimic the bariatric post operative state, (currently the 
most effective treatment for obesity) (Le Roux et al., 2007; Karra et al., 2009; 
Morinigo et al., 2006; Morinigo et al., 2008; Holdstock et al., 2008). Bariatric 
surgery achieves on average a 13% loss of excess weight over a 6 month 
period (Adams et al., 2007; Christou and Efthimiou, 2009; Kolotkin et al., 
2009). It was originally assumed that malabsorption of nutrients drives the 
weight loss following bariatric surgery. However, it has now been shown that 
this malabsorption lasts only a few weeks (Holdstock et al., 2008). The 
longer lasting effects of bariatric surgery may result from changes in 
circulating gut hormones, with surgery associated with increased levels of 
the anorexigenic gut hormones PYY3-36 and GLP-1 and reduced levels of the 
orexigenic gastric hormone ghrelin (Karamanakos et al., 2008; Kolotkin et al., 
2009; Neary and Batterham, 2009). Mimicking the post-surgery gut hormone 
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profile may therefore have potential as an obesity treatment. Such drug 
treatment poses less risk to the patient than invasive bariatric surgery, and 
removes the time and costs associated with surgical recovery (Pories, 2008). 
There are, however, a number of limiting factors, including half life and route 
of administration, which make gut hormones difficult to develop as obesity 
treatments (Bays and Dujovne, 2002). If the short half life of gut hormones 
could be overcome allowing a once daily or weekly preparation to be used, 
gut hormones may have clinical utility as obesity treatments.  
PP has potential to improve on currently available treatments for obesity as it 
has previously been shown to be well tolerated in acute infusion studies 
(Jesudason et al., 2007; Batterham et al., 2003). It has a specific receptor 
target and limited affinity for any other receptors or systems (Dumont et al., 
1998; Berglund et al., 2001), therefore limiting potential side effects. High 
circulating levels of PP in patients with PPomas are reasonably well tolerated 
(Adrian, 1986). Currently, two analogues of PP are being developed by 7TM 
Pharma for the treatment of obesity, each targeting different receptor 
systems. These are obinepitide (targeting Y2 and Y4 receptors) and 
TM30339 (targeting Y4 receptors alone). A recent phase I/II double blind 
placebo controlled study evaluating obinepitide has found that there is 
effective inhibition of food intake in obese subjects, and a phase II study is 
being carried out at present (7TM Pharma, 2007). If PP analogues were to 
be developed as a treatment for obesity, an IV infusion (as used by acute 
studies to date (Batterham et al., 2003; Jesudason et al., 2007)) would not 
be suitable and an alternative route of administration would need to be 
established.  
PP, however, has a short half life of around 7.5 minutes (Adrian et al., 1978) 
which limits its utility as an obesity treatment in its endogenous form. In 
breakdown studies (Appendix IV), PP analogue XPP had greatly improved 
resistance to a number of enzymes thought to play a role in the breakdown 
and deactivation of PP. In studies investigating circulating plasma 
pharmacokinetics, plasma levels of XPP were maintained at higher 
concentrations for longer than the same dose of unmodified PP in both 
mouse and rat models (Section 3.4.5). In acute studies, XPP inhibited food 
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intake by around 50% at 2 hours (Section 3.4). If this effect was maintained 
over an extended period it would result in significant weight loss, possibly 
greater than that achieved using Orlistat (Hogan et al., 1987; Ackroff and 
Sclafani, 1996). The studies undertaken in this section investigate the effect 
of chronic SC administration of XPP on food intake and body weight in 
animal models. 
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4.2 Hypothesis and aims 
PP acutely inhibits food intake and causes weight loss when administered 
peripherally (IP). An acute IP injection of PP at 30 nmol/kg has been shown 
to decrease food intake for up to 6 hours, with increasing doses decreasing 
food intake for up to two days in mice (Liu et al., 2008; Asakawa et al., 2003; 
Katsuura et al., 2002; Kojima et al., 2007; Lin et al., 2009).  
If this treatment could be adapted to cause greater food intake inhibition 
following a single daily subcutaneous injection it could provide a putative new 
treatment for obesity with greater efficacy, and fewer side effects then 
current therapies.  
Hypothesis: I hypothesise that chronic daily administration of PP analogue 
XPP will reduce food intake and body weight in DIO and Ob/Ob mice. 
Aims: 
1. To investigate the effect of chronic daily SC injection of XPP on 
food intake and body weight in male Ob/Ob mice. 
2. To investigate the effect of chronic daily SC injection of XPP on 
food intake and body weight in two different sets of male DIO 
mice. 
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4.3 Materials and Methods 
4.3.1 Custom designed analogues and peptide 
PP analogue XPP was custom synthesised, purified and purchased and as 
described in section 2.3.1. 
4.3.2 Animals 
All animal procedures were approved by the British Home Office under the 
UK Animal (Scientific Procedures) Act 1986 (Project Licence 70/6402). 
Three sets of mice were used for these experiments: male Ob/Ob mice, male 
DIO C57/BL6 mice fed on a medium fat diet (study 2) and male DIO C57/BL6 
mice fed on a high fat diet (study 3). Animals were maintained as described 
in 3.3.2. All animals were allowed ad libitum access to water and ad libitum 
access to RM1 diet (Special Diet Services, Witham, UK) unless otherwise 
stated.  Animals were handled and received sham SC injections of saline on 
at least two occasions prior to study days in order to acclimatise the animals 
to the injection procedure. All mice feeding studies were completed in 
conditions where external stressors were minimised as stress is known to 
influence feeding behaviour in rodents (Marti et al., 1994).  
4.3.3 Chronic administration of XPP in ob/ob mice. 
4.3.3.1 Study/Injection procedure 
Male Ob/Ob (Harlan, USA) mice were randomised into weight controlled 
groups (average weight 43.2 grams, (n=4/5)). Mice were SC injected during 
the early dark phase (1800-1900), in a maximum volume of 0.1 ml of saline. 
Before an animal was injected it was weighed and body weight recorded. 
After each injection, mice were returned to their home cages with a known 
amount of food. Food was reweighed at the same time each day at the point 
of injection.  Food was removed from the hopper, a visual inspection of the 
cage made to check for any food spillage/hoarding and food weighed using 
balances accurate to 0.01 g. Acute food intake was measured on day one at 
4 hours post injection. This was done to observe any initial acute effect on 
food intake. 
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4.3.3.2 Dosage 
Animals received daily SC injections of either saline or XPP at 50nmol/kg or 
150nmol/kg for 7 days. In a dose finding study 40nmol/kg of XPP was the 
most effective and highest dose used. Therefore 50 nmol/kg of XPP a dose 
slightly higher than the dose which was the most effective was used to try 
and ensure that a reduction in food intake was observed. 150nmol/kg was 
also used as 3 times the predicted lowest effective dose to establish the 
maximal effective dose. 
4.3.4 Chronic administration of XPP in diet induced obese mice 
DIO models of two different levels of obesity were used. Mice of an average 
weight of around 46grams were considered morbidly obese and leptin 
insensitive (Study 2). Mice used in the subsequent study had an average 
weight of around 36grams and were characterised as mildly obese (Study 3). 
These two groups of mice were used to help represent the broad spectrum of 
obesity in the human population.  
4.3.4.1 High fat diet induced obesity- Study 2 
4.3.4.2 Diet 
C57/BL6 mice were group housed in cages of 10 and fed on a high fat diet 
containing 45% energy as fat from seven weeks of age and were maintained 
on this diet throughout the study (% energy content: 30% Carbohydrate, 25% 
Protein and 45% Fat) (Research Diets, USA). Mice were maintained as 
described in section 3.3.2. At week 11, mice were transferred from group 
housing to individually ventilated cages, and then given 2 weeks to 
acclimatise to the new cages before the start of the study.  
4.3.4.3 Study/Injection procedure 
Male DIO (Harlan, USA) mice were randomised into weight controlled groups 
(average weight 46.45 grams, (n=7/8). Mice were SC injected during the 
early dark phase (1800-1900) in a maximum volume of 0.1 ml of saline. 
Before an animal was injected it was weighed and body weight recorded. 
After each injection, mice were returned to their home cages with a known 
amount of food. Food was reweighed at the same time each day at the point 
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of injection.  Food was removed from the hopper, a visual inspection of the 
cage made to check for any food spillage/hoarding and food weighed using 
balances accurate to 0.01 g. Acute food intake was measure on day 1, and 
day 27 at 4, hours post injection. This was done to observe any initial acute 
food intake effect and to establish if an acute food intake effect was still 
observed following around 4 weeks of daily administration. 
4.3.4.4 Dosage 
Animals received daily SC injections of either saline or XPP at 66nmol/kg or 
200nmol/kg of peptide for 62 days. These doses were used as they are 
higher than those used in the previous study which proved ineffective at 
reducing food intake. 
4.3.4.5 Glucose tolerance testing (GTT) 
Glucose tolerance tests were performed on day 63 of the study to assess if 
treatment with XPP influenced glucose tolerance. Mice were fasted overnight 
from 1600 on day 62.  At 0900 on day 63, mice were removed from their 
cages and 10µl of blood was collected via venopuncture of the tail vein, and 
a baseline glucose measurement taken via a glucose metre and glucose 
strips (Acc-check, Roche, Switzerland). After a baseline glucose level was 
established, mice received a 10ml/kg IP dose of 20% dextrose solution 
(glucose challenge) and were returned to their home cages. Blood samples 
were then taken via the initial venous puncture at 15, 30, 45, 60, 90 and 120 
minutes post dextrose injection. Blood glucose levels were plotted and area 
under the curve, between 0 to 120 minutes was calculated for each mouse. 
4.3.5 High fat diet induced obesity- Study 3 
4.3.5.1 Diet 
C57/BL6 mice were group housed in cages of 10 and fed on a high fat diet 
containing 60% of its energy as fat for 13 weeks prior to the study (% energy 
content: 20% Carbohydrate, 20% Protein and 60% Fat) (Research Diets, 
USA). Mice were maintained as described in section 3.3.2. At week 13, mice 
were transferred from group housing to individually ventilated cages, and 
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then given 2 weeks to acclimatise to the new cages before the start of the 
study. 
4.3.5.2 Study/Injection procedure 
Male DIO (Harlan, USA) mice were randomised into weight controlled groups 
(average weight 37.15 grams, n=8/10). Mice were SC injected during the 
early dark phase (1800-1900), in a maximum volume of 0.1 ml of saline.  
Before an animal was injected it was weighed and body weight recorded. 
After each injection mice were returned to their home cages with a known 
amount of food. Food was reweighed at the same time each day at the point 
of XPP injection.  Food was removed from the hopper, a visual inspection of 
the cage made to check for any food spillage/hoarding and food weighed 
using balances accurate to 0.01 g. Acute food intake was measured on days 
1 and 30 at 4 hours post injection. This was done to observe any initial acute 
food intake effect and to establish if an acute food intake effect was still 
observed following around 4 weeks of daily administration. 
4.3.5.3 Dosage 
Animals received daily SC injections of either saline or XPP for 32 days. Due 
to the large dose being administered the doses were ramped; on day 1-9 
animals received either 200nmol/kg or 1000nmol/kg, from day 10 onwards 
doses were trebled, with animals receiving 600nmol/kg or 3000nmol/kg for 
the remaining 22 days. These higher doses of XPP were used as previous 
doses of 200nmol/kg were not effective at either reducing body weight or 
food intake. Dose ramping or escalating doses have been used previously 
within the laboratory. In previous work on exendin-4, dose escalation helped 
to prevent dose related side effects  This hopefully gave the mice time to 
acclimatize to each dose step before the final largest dose was given, 
therefore providing protection against the problems previously observed with 
administration of large doses of anorexigenic agents (Fineman et al., 2004; 
Gentilella et al., 2009).  
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4.3.6 Statistical analysis 
The results from acute feeding studies were compared using a one-way 
ANOVA with post hoc Bonferroni test. Chronic body weight and food intake 
data was compared using the general estimating equation (GEE). If the GEE 
indicated a significant difference between a treatment group and saline, a 
Mann Whitney U test was used to assess the time point at which significance 
was reached. The glucose tolerance tests results were analysed using a 
one-way ANOVA with repeated measures. A p value of less than 0.05 was 
considered to be significant in all analyses.  
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4.4 Results 
4.4.1 Study 1: The effect of daily SC injections of analogue XPP in male 
Ob/Ob mice. 
4.4.1.1 Body weight and food intake 
Daily administration of 50nmol/kg and 150nmol/kg of PP analogue XPP to 
Ob/Ob mice did not significantly reduce body weight compared to saline 
controls (Figure 4.1). However, daily doses of XPP at 150nmol/kg 
significantly reduced cumulative food intake over 7 days compared to saline 
control (Day 1 to day 5 p=0.02, day 5 to day 7 p=0.0087). XPP at a lower 
dose of 50nmol/kg reduced food intake compared to saline control over 7 
days. However, this effect did not reach statistical significance.  
4.4.1.2 Acute food intake 
XPP at both 50nmol/kg and 150nmol/kg did not significantly reduce acute 
food intake compared to saline control at 4 hours on day 1 (Saline 0.46+/-
0.073grams, 50nmolkg XPP 0.371 +/- 0.06grams, 150nmol/kg XPP 0.353 +/-
0.04grams) (Figure 4.2).  
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Figure 4.1 The effect of daily SC administration of PP analogue XPP at 
50nmol/kg, and 150nmol/kg on A) body weight and B) cumulative food intake 
in Ob/Ob mice over 7 days. (n=4/5, *p ≤0.05 and **p ≤0.01 (treatment group 
Vs saline control)).  
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Figure 4.2: The acute effect of SC administration of XPP at 50nmol/kg and 
150nmol/kg on 4 hour food intake on day 1 in Ob/Ob mice (n=7/8).  
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4.4.2 Study 2: The effect of daily SC injections of XPP in male diet 
induced obese C57/BL6 mice.  
4.4.2.1 Body weight and food intake 
Daily administration of 66nmol/kg and 200nmol/kg of PP analogue XPP to 
male DIO mice did not significantly reduce body weight or food intake over 
62 days (Figure 4.3). 
4.4.2.2 Acute food intake 
At 4 hours post injection, on days 1 and 27, 66nmol/kg of XPP and 
200nmol/kg did not significantly reduce acute food intake compared to saline 
control (Day 1, Saline 0.68 +/-0.09grams, XPP 66nmol/kg 0.59 +/-0.08grams, 
and 200nmol/kg 0.59 +/-0.06grams. Day 27, Saline 1.34 +/-0.1grams, XPP 
66nmol/kg 1.68 +/-0.1grams, XPP 200nmol/kg 1.12 +/-0.1grams). (Figure 4.4)  
4.4.2.3 Glucose tolerance tests 
There was no significant difference in glucose tolerance between saline 
control group and the two treatments (66nmol/kg group, 908.6mmol/L and 
200nmol/kg, 970.07mmol/L) (Figure 4.5).  
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Figure 4.3: The effect of daily SC administration of XPP at 66nmol/kg and 
200nmol/kg on A) body weight and B) cumulative food intake in DIO 
C57/BL6 mice over 62 days. (n= 7/8). 
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Figure 4.4: The acute effect of SC administration of XPP at 66nmol/kg and 
200nmol/kg on 4 hour food intake on A) day 1, and B) day 27 in DIO 
C57/BL6 mice (n= 7/8). 
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Figure 4.5: Glucose tolerance tests in DIO C57/BL6 mice following 62 days 
of daily administration of 66nmol/kg XPP or 200nmol/kg XPP on A) blood 
glucose levels at 0 to 120 minutes B) incremental area under curve for blood 
glucose values (n= 7/8).  
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4.4.3 Study 3: The effect of daily subcutaneous injections of analogue 
XPP in male diet induced obese C57/BL6 mice.  
4.4.3.1 Body weight and food intake 
Daily administration of 600nmol/kg and 3000nmol/kg of PP analogue XPP to 
DIO mice reduced body weight over 32 days (600nmol/kg, average body 
weight decreased by 2.77grams, and 3000nmol/kg average body weight 
decreased by 1.88grams). However, this effect did not reach statistical 
significance. There was no statistically significant reduction in food intake in 
either of the two treatment groups compare to saline control (Figure 4.6). 
4.4.3.2 Acute food intake 
On day 1 there was no significant acute food intake reduction in either 
treatment group compared to saline control at 4 hours (Saline 0.48 +/-
0.05grams, XPP 600nmol/kg 0.36 +/-0.06grams, and 3000nmol/kg 0.48 +/-
0.04grams). On day 30 there was a significant increase in acute food intake 
at 4 hours in both treatment groups compared to saline control (Saline 0.33 
+/-0.04grams, 600nmol/kg, 0.65+/-0.05grams, and 3000nmol/kg 0.88 +/-
0.05grams, ***p=<0.001) (Figure 4.7).   
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Figure 4.6: The effect of daily SC administration of XPP at 200/1000nmol/kg 
day 0 to 8 and 600/3000nmol/kg day 9 to 32 on A) body weight and B) 
cumulative food intake in DIO C57/BL6 mice over 32 days. (n= 8/10 per 
group).  
190 
 
 
Figure 4.7: The acute effect of SC administration of XPP at 
200/1000nmol/kg day 0 to 8 and 600/3000nmol/kg day 9 to 32 on 4 hour 
food intake on A) day 1, and B) day 30 in DIO C57/BL6 mice (n= 8/10, 
***p<0.001). 
 
191 
 
4.5 Discussion 
The studies described in this chapter were carried out to assess the effect of 
chronic peripheral administration of PP analogue XPP on body weight and 
food intake in two different models of obesity. In chapter 3 the acute effects 
of increasing doses of XPP were examined compared to PP in lean C57/BL6 
mice. It was shown that XPP significantly reduced food intake at 2 hours 
post-injection at 50nmol/kg whereas 100nmol/kg of PP significantly reduced 
food intake at the same time point. This suggested that XPP may be useful 
as an obesity treatment if given over a longer period of time and at a higher 
dose. Daily administration of XPP was used to investigate the effectiveness 
of XPP at reducing food intake and body weight over periods of 7 to 62 days.  
The daily administration of PP or the PP analogue XPP has not been 
investigated previously.  However, PP‟s acute effects on food intake have 
been demonstrated in a number of studies (Nakajima et al., 1994; Ueno et al., 
1999; Asakawa et al., 1999; Asakawa et al., 2006), with PP reported to 
reduce food intake for over 24 hours. A number of mechanisms have been 
suggested to mediate the effects of PP on food intake. It has been proposed 
that PP acts via Y4 receptors to activate POMC neurons and GABAergic 
neurons in the ARC of the hypothalamus, stimulating an increase in alpha 
MSH release by removal of GABAergic inhibition, and by a direct increase in 
POMC neuronal activity. An increase in POMC activity in the ARC leads to 
an increase in activation of MC4 receptors by the agonist alpha MSH (Lin et 
al., 2009). It has also been suggested that PP acts on the Y4 receptor to 
modulate an orexin pathway in the LHA and a BDNF pathway in the VMH to 
reduce food intake (Sainsbury et al., 2010). As yet it is unclear how PP 
exerts these effects as it is unable to cross the blood brain barrier (Pieribone 
et al., 1992). Repeated peripheral injection of PP over 24 hours reduces 
hypothalamic NPY and orexin mRNA expression (Asakawa et al., 2003), 
again suggesting a central mechanism of action.  The minimal amino acid 
changes and improved Y4 receptor affinity of XPP suggest its mechanism of 
action is likely similar to that of unmodified PP.   
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Daily SC administration of XPP at various doses reduced body weight in 2 
different models of obesity, though these effects did not reach statistical 
significance in all studies. However, in all 3 chronic studies there was an 
initial trend of reduced body weight followed by a small body weight regain, 
and a period of weight stability. Interestingly, in the 2 DIO studies the level of 
body weight lost does not appear to correlate with a decrease in food intake. 
In study 2 and 3, acute food intake post day 10 is higher in the animals 
receiving treatment compared to saline treated animals. This may not be an 
accurate assessment as it was only the food intake up to 4 hours post 
injection, and the animal‟s receiving XPP treatment may be eating less than 
saline treated controls later on in the dark period. However, cumulatively 
there is little difference in food intake between the saline animals and those 
animals in the treatment groups. It is possible that desensitisation to the 
effects of XPP at anorectic receptors reveals milder agonistic effects of XPP 
at orexigenic Y receptors Whatever the mechanism, the lack of obvious 
anorectic effects suggests that XPP may be increasing energy expenditure, 
most likely by increasing locomotor activity as PP is reported to (Liu et al., 
2008). It has been suggested previously that lean individuals have a higher 
rate of spontaneous physical activity (SPA) compared to overweight 
individuals (Teske et al., 2008). XPP or PP may promote an increase in 
locomotor activity leading to an increase in SPA, allowing the animals to lose 
weight without a reduction in food intake.  
In the Ob/Ob study, the animals in the treatment groups significantly reduced 
their food intake compared to the saline treated animals. This suggests that 
perhaps these animals have different mechanisms with regard to weight 
control and food intake than animals used in studies 2 and 3 with a 
functioning leptin system.  This could be due to the genetic differences 
between the two groups of animals. Ob/Ob mice lack to Ob gene which 
codes for leptin therefore they are leptin deficient from birth (Ingalls et al., 
1950). Conversely the DIO mice have a functioning leptin system, but are 
obese due to overfeeding. The DIO model may be considered to be a more 
physiological model, as few humans have a leptin deficiency, whereas many 
humans over eat and become obese.  
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In both DIO studies, XPP reduced body weight up to 10 days. The body 
weights of the animals in the treatment groups then plateaued for around 10 
days, and subsequently increased from day 35 in study 3. In study 3, body 
weight again plateaued from day 10 to day 20. The acute food intake 
measured on day 30 (study 3) and day 27 (study 2) showed that XPP does 
not have a profound effect on the acute food intake following SC 
administration. This was unexpected as, in acute studies using smaller doses, 
XPP significantly reduced food intake over 24 hours. The overall body weight 
regain observed after days 10 in studies 2 and 3 in the XPP treatment 
groups may be due to tachyphylaxis, that is, the mice in these treatment 
groups become desensitised to XPP. Receptor internalisation may be one of 
the mechanisms by which the mice are adapting to high levels of XPP. 
However, previous studies using chinese hamster ovary (CHO) cells over-
expressing human Y4 receptors have shown the receptor internalisation 
does not occur when cells are exposed to high concentrations of PP in vitro  
(Parker et al., 2007).    
Conversely another hormonal mechanism may be compensating for the high 
levels of XPP, preventing further weight loss. The plateau observed in these 
studies may be the point where the counter acting mechanism is beginning 
to work, and the subsequent weight gain is the body attempting to return to 
its set point. It has been shown previously that daily administration of PYY3-36, 
has a delayed orexigenic action (Parkinson et al., 2008), that study  
suggested that an increase in hypothalamic NPY and AgRP mRNA may be 
the cause. A similar mechanism may act to balance the overall actions of 
both PP and PYY due to their close evolutionary background (Larhammar, 
1996a; Blomqvist et al., 1992; Cerda-Reverter and Larhammar, 2000). As 
detailed previously, α-MSH containing neurons within the POMC are 
activated following acute peripheral PP, as they are by PYY (Lin et al., 2009). 
However, as yet there is no mechanism showing neuronal activation 
following chronic administration of PP. It may be that chronic administration 
somehow changes the neurons activated by PP with the POMC or other 
areas of the brain, therefore preventing long term weight loss. 
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At present the most effective treatment for obesity is bariatric surgery. For a 
new drug treatment to be classed as an effective alternative to bariatric 
surgery or to Orlistat (the only available pharmacological obesity treatment 
licensed in Europe) it would need to be as effective with reduced side effects 
or risks, or significantly more effective. Treatment of DIO mice with XPP at 
either 200nmol/kg or 3000nmol/kg resulted in a 30% reduction in excess 
weight for a period of time during each study (based on average weight of a 
mouse being 25 grams, the mice in study 2 were 22 grams overweight and 
the mice in study 3 were 12 grams overweight). However, this weight loss 
was not sustained, and the average body weight of the mice gradually rose, 
perhaps reflecting the mice becoming less sensitive to XPP.  
The initial weight loss achieved by XPP in each of the studies which used 
DIO mice indicates that XPP may have potential as an obesity treatment but 
that either the treatment regime or the formula needs to be modified to allow 
XPP to cause maximal weight loss. Dose ramping is a mechanism used 
previously to help prevent desensitisation and overcome any initial nausea 
problems (Fineman et al., 2004; Gentilella et al., 2009). This strategy 
appears to have prevented the mice from feeling unwell. The animals were 
observed daily and particularly after each dose ramp, and showed no signs 
of ill health. However, as weight loss plateaued in all 3 studies it would 
suggest that dose ramping does not prevent desensitisation to XPP.  A slow 
release preparation of XPP, which allows the minimum activation of the Y4 
receptors to cause food intake inhibition or an increase in locomotor activity 
without causing desensitisation of the system, might prove more effective 
than XPP dissolved in saline.  
The use of slow release preparations of insulin have allowed once daily 
administration to be used in the control of blood glucose in both type I and 
type II diabetes (Kato et al., 2010; Meneghini et al., 2010). The methods 
used to develop long lasting slow release preparations could be adapted to 
develop XPP into a once daily preparation which maintains low circulating 
levels without causing desensitisation of the Y4 receptors. Insulin glargine 
uses amino acid substitutions to allow insulin to precipitate once injected SC, 
allowing it to be released slowly throughout the day (True, 2010; Kato et al., 
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2010). Further amino acids could be substituted into XPP to allow 
precipitation once in the SC depot. However, there is potential for further 
amino acid substitutions to have a detrimental effect on binding to the Y4 
receptor and the biological effects of any such structural changes would 
therefore need to be examined carefully. Another option would be the 
addition of a fatty acid to the XPP sequence. The insulin analogue Levemir 
has a myristic fatty acid attached to the Lysine at the B29 position which 
allows it to bind to serum albumin (Russell-Jones et al., 2009; Russell-Jones 
et al., 2009). This Levemir-albumin complex then disassociates slowly over a 
long period of time, elevating Levemir levels over 24 hour profile. Addition of 
a similar fatty acid to the XPP molecule might allow the long term 
maintenance of a low circulating concentration of XPP, possible preventing 
desensitisation of the Y4 receptor.  
In summary, daily XPP administration at doses of 200nmol/kg to 
3000nmol/kg (SC) reduces body weight in DIO mice and a dose of 
150nmol/kg significantly reduces food intake in Ob/Ob mice. Unfortunately, 
this reduction in body weight is not sustained when treatment is continued up 
to 62 days. Due to its ability to inhibit food intake acutely, and the initial body 
weight reduction observed in the DIO mice, XPP may have some utility as an 
obesity treatment if it a slow release preparation could be developed.  
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Chapter 5 
 
Final Discussion 
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The number of people in the UK categorised by the world health organisation 
(WHO) as obese (BMI 25-30) is rising. The NHS predicts that the number of 
people classed as either overweight or obese is likely to increase to 60% of 
men and 50% of women by 2050 (World Health Organisation, 2006). This 
will ultimately put the health service under pressure due to the cost of obesity 
treatment, and the treatment of obesity associated conditions such as T2DM 
(Avenell et al., 2004). As mentioned in section 1.3.1, the medicinal 
treatments currently available to treat obesity are limited (Neovius and 
Narbro, 2008). The surgical strategy for treating obesity is contentious due to 
the cost and risk benefit profiles, and is impractical to use it to treat the 
increasing numbers of obese patients (Christou and Efthimiou, 2009; Garb et 
al., 2009; Martins et al., 2010). This suggests that new, more effective 
treatments for obesity are necessary (Field et al., 2009; Pournaras and Le 
Roux, 2009; Neovius and Narbro, 2008; Clapham et al., 2001; Butland B, 
2007; Bourne J, 2001; Bays and Dujovne, 2002). Gut hormones such as PP, 
PYY, and OXM have potential as obesity pharmacotherapies, due to their 
physiological actions on food intake, and a number are currently in 
development (Bays and Dujovne, 2002; Clapham et al., 2001; Cooke and 
Bloom, 2006; Druce et al., 2004; Druce and Bloom, 2006; Field et al., 2008; 
Vivus Pharmaceuticals, 2009; Wynne et al., 2005a).  
PP has been shown in mouse models and in humans with a normal BMI to 
reduce food intake after acute administration over a period of up to 24 hours 
(Asakawa et al., 1999; Asakawa et al., 2006; Batterham et al., 2003; 
Jesudason et al., 2007; Katsuura et al., 2002; Kojima et al., 2007; Liu et al., 
2008). PP acts via the Y4 GPCR to inhibit cyclic AMP production (Dumont et 
al., 2007; Dumont et al., 2005; Kojima et al., 2007). The Y4 receptor is 
located in a number of locations within the brain (area postrema and DVC) 
and the peripheral nervous system (vagus nerve) (McTigue et al., 1993; 
Larsen and Kristensen, 1997; Parker and Herzog, 1999). Studies using 
transgenic PP over-expressing mice have indicated that PP levels 20 times 
higher than those levels detected in their wild type litter mates can be well 
tolerated, with the transgenic mice eating significantly less than wild type 
mice, but otherwise behaving healthily (Ueno et al., 1999). In human infusion 
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studies, healthy volunteers have been shown to eat up to 22% less than 
saline control over 24 hours (PP 10pmol/kg/min) (Batterham et al., 2003). 
These studies suggest that PP may have potential as an obesity treatment. 
Unmodified PP, however, has little clinical utility due to its short circulating 
half life of around 6 minutes (Adrian et al., 1978). 
I have demonstrated that the substitution of enzyme sensitive amino acids 
within the PP sequence can increase resistance to certain enzymes and 
tissue preparations. These modifications in combination with modifications 
thought to increase affinity for the hY4 receptor produced an analogue of PP 
with increased resistance to enzyme and tissue degradation and increased 
affinity for the hY4 receptor in vitro.  The ability of PP analogue XPP to inhibit 
food intake was investigated in two different models of obesity and indicated 
potential to decrease food intake and ultimately reduce body weight over the 
long term.  
5.1 PP analogue XPP as a potential treatment for obesity. 
PP analogue XPP is resistant to all the enzymes and tissue preparations 
examined in this thesis (<5% breakdown, appendix IV). It has been shown to 
have significantly improved affinity for the hY4 receptor (section 3.4). XPP 
also inhibited food intake compared to PP in acute feeding studies (section 
3.4). It has been shown previously that peripheral administration of PP 
reduces food intake and body weight over 48 hours (Liu et al., 2008). 
Chronic studies investigating food intake and body weight in Ob/Ob mice 
receiving daily SC injections of XPP showed that XPP significantly inhibited 
food intake over 8 days but that this food intake inhibition did not correspond 
with a body weight reduction. It was observed that despite the food intake 
reduction detected in Ob/Ob mice, the average body weight within all the 
groups increased. It was decided that Ob/Ob mice with their genetic lack of 
leptin, may have disturbed weight reduction mechanisms, and  that  these 
mice were therefore not an ideal model of obesity for studies in this thesis 
(Pelleymounter et al., 1995).  
The DIO mouse is considered to be a more reflective model of human 
obesity, and therefore was used for the longer term chronic studies detailed 
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in this thesis. These studies showed that body weight was reduced in all 
animals which received daily SC injections of XPP. The food intake and body 
weight of mice receiving XPP did not differ significantly from those animals 
receiving saline treatment. Despite this, mice receiving 66nmol/kg of XPP 
over 45 days lost approximately 6 grams of body weight (starting weight of 
47g to end weight of 40.8g). The average weight of a C57/BL6 mouse is 25 
grams therefore a 6 gram weight loss is approximately 28% excess weight 
lost. In the same study, mice receiving saline also lost weight and on day 45 
had lost 5 grams (approximately 23% of excess weight). Therefore overall on 
day 45 XPP has enabled an extra 5% of excess weight to be lost compared 
to saline. Further studies are required to examine whether this is real 
biological effect that could be demonstrated statistically using, for example, 
larger group sizes.  
5.2 Proposed mechanism of action of XPP. 
XPP in both DIO chronic studies reduced food intake for a short period of 
time. XPP also decreased body weight up to day 30. However, after this 
point body weight was observed to be slowly returning to baseline levels. 
This may be explained by a change in NPY levels within the hypothalamus, 
which previous studies suggested should occur following PP administration 
(Sainsbury et al., 2010; Asakawa et al., 2003). A decrease in NPY mRNA 
levels in the ARC of the hypothalamus would allow for an increase in 
activation of the MC4R (Cone et al., 2001). Previous studies have linked the 
MC4R system with the BDNF system within the hypothalamus (Sainsbury et 
al., 2010). Animals which lack BDNF are obese and hyperphagic, and mimic 
the phenotype observed when the MC4R is knocked out (Rios et al., 2001; 
Bariohay et al., 2005). Increased MC4R activation could potentially increase 
BDNF mRNA, which may subsequently decrease food intake and increase 
energy expenditure (Xu et al., 2003; Wang et al., 2010; Xu et al., 2003; 
Bariohay et al., 2005; Wang et al., 2010).  
Further investigation is required to decipher the mechanism by which XPP 
causes a reduction in body weight. The use of the comprehensive laboratory 
animal monitoring system (CLAMS) system would enable the energy 
200 
 
expenditure part of the proposed mechanism to be investigated. The use of a 
conditional knock-out animal model would also be a useful tool to investigate, 
for example, whether animals which lack BDNF in the hypothalamus lose 
weight following chronic administration of XPP.  
5.3 Future formulation modifications to XPP 
In the two long term chronic studies using DIO mice it was observed that the 
mice body weights plateaued and then rose again. As mentioned in section 
4.5, this may be due to receptor down regulation. Receptor down regulation 
is thought to occur when receptors are over exposed to stimuli and the 
number of receptors is reduced as part of a negative feedback mechanism. 
SC administration has been shown to cause a rapid increase in circulating 
levels of substance administered. For XPP, this rapid increase in 
combination with the reduced breakdown (shown in section 2.4) may mean 
that there is a large sustained spike in plasma XPP levels following injection 
which over stimulates the Y4 receptor system and leads to receptor down 
regulation. To overcome this, a constant low level of receptor activation could 
be maintained using, for example, a SC pump or a slow release form of XPP. 
These two different methods would enable more consistent plasma levels to 
be established compared to the sharply peaking levels commonly observed 
following SC injection.  Long lasting slow release formulations of insulin are 
currently available and have been shown to more effective at controlling 
blood glucose levels and HbA1C levels in the long term than shorter acting 
counterparts (Heinemann et al., 2000; Heise et al., 2011; Swinnen et al., 
2010; Hollander et al., 2008). The process by which insulin was manipulated 
to create a longer lasting form is similar to the process by which I have 
created a longer lasting analogue of PP, i.e. modifications to the primary 
amino acid sequence. Amino acids were modified in insulin to change the 
isoelectric point from 5.4 to 6.7. This made insulin more soluble at a slightly 
acidic pH, and less soluble at a physiological pH. These changes to insulin, 
in combination with a zinc based formulation, enabled insulin glargine to be 
soluble at pH 4, therefore enabling it to be injected.  After entering the SC 
depot the surrounding pH changes from 4 to nearer pH 7, causing the 
precipitation of the insulin. This allows the insulin to be stored at the depot 
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and released slowly, and thus for basal blood insulin levels to be maintained 
for a period of up to 24 hours (Raslova, 2010; Heinemann et al., 2000). If this 
formulation could be utilised for XPP, constant levels of XPP at doses low 
enough to activate the receptor and cause weight loss,  could potentially be 
achieved, whilst avoiding the over stimulation and subsequent down 
regulation of the system putatively caused by a bolus SC injection.  
Insulin can also be administered via SC dwelling pumps which allow for 
longer term control of blood glucose without the need for daily injections. 
However, it is unknown whether PP or XPP would be stable enough to be 
administered via this method.  
An alternative method to the two currently used for insulin is PEGylation 
(Veronese and Mero, 2008). This is a process by which a polymer of poly 
ethylene glycol is attached to a molecule. This method prevents elimination 
from the body by the kidneys and liver and thus often increases the biological 
half life of the resulting molecule (Kang et al., 2009). A poly ethylene glycol 
polymer can be added to the molecule by targeting an amino acid within the 
peptide, or by the addition of a His tag which already has the PEG attached  
at either end of the peptide. In the case of XPP, the His tag could be added 
instead of the Gly at position -1, perhaps also inhibiting cleavage by DPPIV.  
At present there are a number of products utilising PEG technology including 
hepatitis, and haemophilia treatments (Mei et al., 2010; Rasenack et al., 
2003). For example, PEGASY is a version of interferon alpha used in the 
treatment of chronic hepatitis A and B. Studies have shown that PEGASY is 
longer lasting, and therefore more effective, then unmodified interferon alpha 
(Rasenack et al., 2003). 
Modifications which allowed XPP to be administered less frequently would 
improve treatment compliance, and might help prevent maladministration or 
over use. It may also reduce the cost of treatment.  
The effect of XPP on the food intake and body weight of human volunteers 
needs to be investigated in the future. The in vitro work carried out in this 
thesis investigated the affinity for the hY4 receptor, whilst the animal models 
used examined the effects in vivo. The mouse version of the Y4 receptor 
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differs by only a few amino acids to the human form (Berglund et al., 2001). 
However, these small differences could mean that XPP given chronically is 
more effective in humans than in mouse models. 
5.4 The use of analogues as investigative tools 
Analogues of hormones and peptides have been used previously to 
investigate structure activity relationships. An example is oxyntomodulin, 
where analogues were used to investigate the parts of the molecule 
necessary to bind to either the GLP-1 receptor or the glucagon receptor 
(Druce et al., 2009; Estall and Drucker, 2006; Pocai et al., 2009), and for its 
biological activity (Pocai et al., 2009; Druce et al., 2009; Wynne et al., 2006). 
Analogues have been developed previously to overcome biological 
constraints which make the native hormone or peptide ineffective as a 
potential treatment. Useful analogues mimic the biological function of the 
native hormone but lack its limitations, such as rapid breakdown or short half 
life. Analogues can also provide information regarding both receptor binding 
requirements and the substrate requirements for degradative enzymes 
(Hupe-Sodmann et al., 1995a; Matsas et al., 1984). 
In this thesis I have used analogues to improve the resistance of PP to 
certain degradative enzymes and tissue preparations whilst improving affinity 
for the hY4 receptor. These experiments have highlighted the complicated 
structure activity relationship between PP and the hY4 receptor and overall 
biological function. For example, PP analogue Lys 30 has improved hY4 
receptor affinity compared to PP, but is more susceptible to breakdown by 
KBB membrane and meprin beta, which would suggest that it might not be 
as effective as PP at inhibiting food intake in vivo. However, in fasted male 
C57/BL6 mice Lys 30 significantly inhibited food intake at both 0-1 and 1-2 
hours. This suggests that although enzyme resistance is an important factor 
in overall biological function, other factors such as receptor affinity may be 
more important.  Conversely, analogue Ala 0, Thr 30 has improved affinity for 
the hY4 receptor compared to native PP, which suggested that it would have 
greater anorectic effects in vivo. On investigation this was found not to be the 
case; analogue Ala 0, Thr 30 required a dose of 300nmol/kg to inhibit food 
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intake whereas previously PP has been shown to inhibit food intake at 25 
nmol/kg.  
Amino acid substitutions have also suggested enzyme substrate preferences. 
For example, the enzyme NEP is known to require hydrophobic residues as 
its substrates (Erdos and Skidgel, 1989; Kenny, 1986a; Medeiros and Turner, 
1994b) . However, when I replaced the hydrophobic Met 30 residue of PP 
with Val another hydrophobic residue it resulted in a statistically significant 
improvement in breakdown by NEP. This suggests that there may be a 
hierarchy of substrate preferences for enzymes such as NEP. However, 
when the hydrophobic Met 30 was replaced by the basic amino acid Lys, 
which should have provided enzyme resistance at this site, it increased 
enzymatic breakdown. This highlights the complexity of the tertiary structure 
of PP, and that the use of analogues can identify which amino acids are 
necessary for biological function and which are needed to maintain tertiary 
structure.  
In conclusion, this thesis has developed an analogue of PP with improved 
enzyme resistance, and improved affinity for the hY4 receptor. In vivo 
experiments have indicated that XPP inhibits food intake acutely. Chronic 
administration experiments suggest that modifications may be needed to the 
formulation of XPP to develop it into a useful obesity treatment.  During the 
development of XPP, a number of PP analogues were generated which were 
useful in elucidating the complex structure activity relationship between PP 
and the hY4 receptor. Finally, further development of XPP may provide a 
new obesity treatment with greater utility than those currently on the market.  
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Confidentiality: 
THE FOLLOWING INFORMATION IS RESTRICTED, CONFIDENTIAL AND 
LEGALLY PROTECTED. The information detailed in the following 
appendices will not be in the publically available document for 5 years. 
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Appendix I – Development of XPP RIA 
XPP was conjugated to BSA by the gluteraldehyde method and lyophilized 
by freeze drying overnight. Sheep were immunised with the XPP conjugate 
which had been made up in water and complete Freund‟s adjuvant (Sigma-
Aldrich, USA). Sheep were given a primary injection SC, followed by a 
booster every 2 months after injection. One week after each injection the 
sheep were bled to test the antibody titre. Blood was centrifuged at 1600g at 
4ºC for 15 minutes and the plasma separated and stored at -20ºC. Serial 
dilutions were used to determine a suitable antibody titre for RIA. These 
antibodies were used to develop the RIA used in section 3.4.  
XPP label was iodinated using the Bolton and Hunter method, as previously 
detailed in section 3.3.  
The standard procedure for all XPP assays: 
Tubes (3mls) were labelled in specific RIA racks holding up to 128 tubes. 
The first 34 tubes in all assays were NSB, 1/2 x label, 2x label, Zeros x 2, 
standard curve x 10, zeros x2 all in duplicate. All samples were assayed in 
duplicate, separated by 2 zeros in duplicate at least every 50 samples. 
Additional standard curves, flanked by 2 zeros in duplicate were inserted 
every 400 tubes and at the end of the assay. Assays were carried out in 
0.06M phosphate buffer (pH 7.2) (appendix II), containing 0.3% BSA. Each 
tube was buffered with 500µl of this assay buffer, and the volume was 
adjusted for further additions. 
The standard concentration for all XPP assays was 0.25pmol/ml, achieved 
by adding 4mls to a 1pmol standard vial. The volume of buffer in the 
standard curve tubes was adjusted to allow the addition of 1µl, 2µl, 3µl, 5µl, 
10µl, 15µl, 20µl, 30µl, 50µl, and 100µl of standard solution in duplicate.  
The antibody was diluted in buffer to the correct titres for 100µl additions to 
every tube apart from the NSB. The excess tube received 600µl. The 
radioactive label was diluted in assay buffer to give 250 counts/ 10 seconds/ 
100µl after subtraction the background radiation for 100µl addition to every 
tube except the ½ x and the 2x which received 50 and 100 respectively. The 
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assays were then incubated for 3 days at -4ºC. After the 3 days the free 
bound antibody was separated from the label bound antibody by charcoal 
separation as detailed in section 3.3. After separation, the supernatant tubes 
were wax sealed and counted in 16 well gamma counters as detailed in 
section 3.3. 
 
Tube Buffer (µl) Label (µl) Ab (µl) Standard/sample 
(µl) 
NSB 600 100 - - 
½ x Label 550 50 100 - 
2x Label 400 200 100 - 
Zero 500 100 100 - 
Standard 
1-20µl 
500 100 100 1-20 
Standard 
30µl 
470 100 100 30 
Standard 
50µl 
450 100 100 50 
Standard 
100µl 
400 100 100 100 
Sample 500- X 100 100 X 
Excess Ab - 100 600 - 
 
Table A1: Contents of XPP RIA assay tubes 
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Appendix II – Solutions used in this thesis 
Dextran coated charcoal: 
Add 2.4g charcoal and 0.24g dextran to 100ml phosphate buffer with gelatine 
and mix for 20 minutes at 20ºC. 
DPPIV assay buffer: 
1.2g of Tris-HcL in 50mls GDW, confirm pH to be 8±0.1 and store at 4ºC. 
1M HEPES: 
Add 35.75g HEPES to 150mls of GDW, confirm pH 7.4±0.1 and store at 4ºC. 
HPLC buffers: 
Add 1.25ml of trifloroacteic acid to 1.25L GDW. 
Add 1.25ml of trifloroacteic acid to 1.25L acetonitrile 
KBB assay buffer: 
0.546g mannitol, and 0.038g HEPES in 10mls GDW, confirm pH to be 
7.4±0.1 and store at 4ºC. 
Meprin beta assay buffer: 
0.3g Tris-HcL in 50mls GDW, confirm pH to be 8±0.1 and store at 4ºC. 
Neprilysin assay buffer: 
0.3g Tris-HcL in 50mls GDW, confirm pH to be 7.5±0.1 and store at 4ºC. 
Phosphate buffer (RIA buffer): 
Dissolve 48g of Na2HPO4.2H2O, 4.13g KH2PO4, 18.61g 
C10H14H2O8Na2.2H2O, 2.5g NaN3 in 5L GDW, which had been boiled and 
allowed to cool, confirm pH to be 7.6±0.1 and store at 4ºC. 
Phosphate buffer with gelatine: 
Dissolve 12.5g gelatine in boiling GDW, allow to cool before addition of the 
other ingredients.  
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10% Trifloroacteic acid solution: 
Add 1ml of Trifluroacetic acid to 9mls of GDW, store at room temperature. 
Receptor binding assay buffer: 
Add 0.736g CaCl2, 0.204g MgCl2, 20mls of 1M HEPES to 980mls of GDW, 
store at 4ºC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
210 
 
Appendix III – Amino Acid codes 
Amino Acid          Codes 
     Three Letter   Single Letter 
Glycine     Gly    G 
Proline     Pro    P 
Alanine     Ala    A 
Valine      Val    V 
Leucine     Leu    L 
Isoleucine     Ile    I 
Methionine     Met    M 
Cysteine     Cys    C 
Phenylalanine    Phe    F 
Tyrosine     Tyr    Y 
Tryptophan     Trp    W 
Histidine     His    H 
Lysine      Lys    K 
Arginine     Arg    R 
Glutamine     Gln    Q 
Asparagine     Asn    N 
Glutamic Acid    Glu    E 
Aspartic Acid     Asp    D 
Serine      Ser    S 
Threonine     Thr    T 
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Appendix IV – XPP structure and supporting information  
 
Figure A1: Representative HPLC chromatograms of 2nmols XPP incubated 
with A) 1.5mg of KBB, B) 200ng NEP and C) 200ng meprin beta at 37ºC for 
30 minutes. The black line represent XPP with enzyme/tissue preparation 
and the red line represents XPP with buffer. Reactions were terminated with 
5µl of 10%TFA and the supernatant injected onto HPLC with a Gemini C18 
column and a gradient of 15- 55% ACN (green line) run over 30 minutes. All 
incubations showed less than 5% breakdown compared to buffer control. 
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The amino acid sequence of PP analogue XPP: 
 
For the amino acid sequence of XPP or details of its structure affinity 
relationship, please contact Prof. Steve Bloom at: 
Section of Investigative Medicine,  
Division of Diabetes, Endocrinolgy and Metabolism,  
Department of Medicine,  
Imperial College London. 
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Appendix V – List of Suppliers 
Bachem Ltd, Merseyside, UK 
Beckman Coulter, High Wycombe, Buckinghamshire, UK 
BIOMOL International L.P., Exeter, UK 
Charles River laboratories INC, Wilmington, USA 
Du Pont Ltd., Cambridgeshire, UK 
Fine Science Tools, Heidelberg, Germany 
GraphPad Software Inc., San Diego, USA 
Harlan, Oxon, UK 
Invitrogen, Paisely, Scotoland 
Jencons, East Grinstead, West Sussex, UK 
Jasco, Essex, UK 
Millipore, Milford, MA, USA 
NE Technology Ltd., Reading, Berkshire, UK 
Nordic Pharma, UK 
Phenomenex, Macclesfield, Cheshire, UK 
R&D Systems Europe Ltd., Abingdon, UK 
Research Diets Inc. New Brunswick, USA 
Sigma Aldrich, Poole, Dorset, UK 
Special Diet Services Ltd, Witham, Essex, UK. 
Thermo Scientific INC, Waltham, USA 
Termuo, Elkton, USA 
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